<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Nicotine receptor partial agonists for smoking cessation - Livingstone-Banks, J - 2023 | Cochrane Library</title> <meta content="Nicotine receptor partial agonists for smoking cessation - Livingstone-Banks, J - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006103.pub9/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Nicotine receptor partial agonists for smoking cessation - Livingstone-Banks, J - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006103.pub9/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006103.pub9" name="dc.identifier" scheme="DOI"/> <meta content="Nicotine receptor partial agonists for smoking cessation" name="citation_title"/> <meta content="Jonathan Livingstone-Banks" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="jonathan.livingstone-banks@phc.ox.ac.uk" name="citation_author_email"/> <meta content="Thomas R Fanshawe" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Kyla H Thomas" name="citation_author"/> <meta content="University of Bristol" name="citation_author_institution"/> <meta content="Annika Theodoulou" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Anisa Hajizadeh" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Lilian Hartman" name="citation_author"/> <meta content="John Radcliffe Hospital" name="citation_author_institution"/> <meta content="Nicola Lindson" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD006103.pub9" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/06/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006103.pub9/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006103.pub9/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006103.pub9/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Alkaloids [adverse effects]; Bupropion [adverse effects]; *Electronic Nicotine Delivery Systems; Nicotine [adverse effects]; Nicotinic Agonists [adverse effects]; *Smoking Cessation [methods]; Tobacco Use Cessation Devices; Varenicline [adverse effects]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006103.pub9&amp;doi=10.1002/14651858.CD006103.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="jxlIh5Me";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006103\x2epub9\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006103\x2epub9\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","pt","ms","hr","fr","hu","zh_HANS","zh_HANT","th","ja","fa","pl"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD006103.pub9",title:"Nicotine receptor partial agonists for smoking cessation",firstPublishedDate:"Jun 28, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Tobacco Addiction Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006103.pub9&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006103.pub9';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006103.pub9/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006103.pub9/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006103.pub9%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006103.PUB9" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006103.pub9/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006103.PUB9" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006103.pub9/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006103.pub9/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6561 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006103.pub9" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-sec-0121"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-sec-0013"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-sec-0014"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-sec-0037"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-sec-0115"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/appendices#CD006103-sec-0126"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/supinfo/CD006103-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/supinfo/CD006103-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Nicotine receptor partial agonists for smoking cessation</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/information#CD006103-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Jonathan Livingstone-Banks</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/information#CD006103-cr-0005">Thomas R Fanshawe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/information#CD006103-cr-0006">Kyla H Thomas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/information#CD006103-cr-0007">Annika Theodoulou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/information#CD006103-cr-0008">Anisa Hajizadeh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/information#CD006103-cr-0009">Lilian Hartman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006103.pub9/information#CD006103-cr-0010">Nicola Lindson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/information/en#CD006103-sec-0132">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 June 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006103.pub9">https://doi.org/10.1002/14651858.CD006103.pub9</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006103-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006103-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006103-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006103-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006103-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD006103-abs-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006103-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006103-abs-0001" lang="en"> <section id="CD006103-sec-0001"> <h3 class="title" id="CD006103-sec-0001">Background</h3> <p>Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). This is an update of a Cochrane Review first published in 2007. </p> </section> <section id="CD006103-sec-0002"> <h3 class="title" id="CD006103-sec-0002">Objectives</h3> <p>To assess the effectiveness of nicotine receptor partial agonists, including varenicline and cytisine, for smoking cessation. </p> </section> <section id="CD006103-sec-0003"> <h3 class="title" id="CD006103-sec-0003">Search methods</h3> <p>We searched the Cochrane Tobacco Addiction Group's Specialised Register in April 2022 for trials, using relevant terms in the title or abstract, or as keywords. The register is compiled from searches of CENTRAL, MEDLINE, Embase, and PsycINFO. </p> </section> <section id="CD006103-sec-0004"> <h3 class="title" id="CD006103-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials that compared the treatment drug with placebo, another smoking cessation drug, e‐cigarettes, or no medication. We excluded trials that did not report a minimum follow‐up period of six months from baseline. </p> </section> <section id="CD006103-sec-0005"> <h3 class="title" id="CD006103-sec-0005">Data collection and analysis</h3> <p>We followed standard Cochrane methods. Our main outcome was abstinence from smoking at longest follow‐up using the most rigorous definition of abstinence, preferring biochemically validated rates where reported. We pooled risk ratios (RRs), using the Mantel‐Haenszel fixed‐effect model. We also reported the number of people reporting serious adverse events (SAEs). </p> </section> <section id="CD006103-sec-0006"> <h3 class="title" id="CD006103-sec-0006">Main results</h3> <p>We included 75 trials of 45,049 people; 45 were new for this update. We rated 22 at low risk of bias, 18 at high risk, and 35 at unclear risk. </p> <p>We found moderate‐certainty evidence (limited by heterogeneity) that cytisine helps more people to quit smoking than placebo (RR 1.30, 95% confidence interval (CI) 1.15 to 1.47; I<sup>2</sup> = 83%; 4 studies, 4623 participants), and no evidence of a difference in the number reporting SAEs (RR 1.04, 95% CI 0.78 to 1.37; I<sup>2</sup> = 0%; 3 studies, 3781 participants; low‐certainty evidence). SAE evidence was limited by imprecision. We found no data on neuropsychiatric or cardiac SAEs. </p> <p>We found high‐certainty evidence that varenicline helps more people to quit than placebo (RR 2.32, 95% CI 2.15 to 2.51; I<sup>2</sup> = 60%, 41 studies, 17,395 participants), and moderate‐certainty evidence that people taking varenicline are more likely to report SAEs than those not taking it (RR 1.23, 95% CI 1.01 to 1.48; I<sup>2</sup> = 0%; 26 studies, 14,356 participants). While point estimates suggested increased risk of cardiac SAEs (RR 1.20, 95% CI 0.79 to 1.84; I<sup>2</sup> = 0%; 18 studies, 7151 participants; low‐certainty evidence), and decreased risk of neuropsychiatric SAEs (RR 0.89, 95% CI 0.61 to 1.29; I<sup>2</sup> = 0%; 22 studies, 7846 participants; low‐certainty evidence), in both cases evidence was limited by imprecision, and confidence intervals were compatible with both benefit and harm. </p> <p>Pooled results from studies that randomised people to receive cytisine or varenicline found no clear evidence of difference in quit rates (RR 1.00, 95% CI 0.79 to 1.26; I<sup>2</sup> = 65%; 2 studies, 2131 participants; low‐certainty evidence) and reported SAEs (RR 0.67, 95% CI 0.44 to 1.03; I<sup>2</sup> = 45%; 2 studies, 2017 participants; low‐certainty evidence). However, the evidence was limited by imprecision, and confidence intervals incorporated the potential for benefit from either cytisine or varenicline. We found no data on neuropsychiatric or cardiac SAEs. </p> <p>We found high‐certainty evidence that varenicline helps more people to quit than bupropion (RR 1.36, 95% CI 1.25 to 1.49; I<sup>2</sup> = 0%; 9 studies, 7560 participants), and no clear evidence of difference in rates of SAEs (RR 0.89, 95% CI 0.61 to 1.31; I<sup>2</sup> = 0%; 5 studies, 5317 participants), neuropsychiatric SAEs (RR 1.05, 95% CI 0.16 to 7.04; I<sup>2</sup> = 10%; 2 studies, 866 participants), or cardiac SAEs (RR 3.17, 95% CI 0.33 to 30.18; I<sup>2</sup> = 0%; 2 studies, 866 participants). Evidence of harms was of low certainty, limited by imprecision. </p> <p>We found high‐certainty evidence that varenicline helps more people to quit than a single form of nicotine replacement therapy (NRT) (RR 1.25, 95% CI 1.14 to 1.37; I<sup>2</sup> = 28%; 11 studies, 7572 participants), and low‐certainty evidence, limited by imprecision, of fewer reported SAEs (RR 0.70, 95% CI 0.50 to 0.99; I<sup>2</sup> = 24%; 6 studies, 6535 participants). We found no data on neuropsychiatric or cardiac SAEs. </p> <p>We found no clear evidence of a difference in quit rates between varenicline and dual‐form NRT (RR 1.02, 95% CI 0.87 to 1.20; I<sup>2</sup> = 0%; 5 studies, 2344 participants; low‐certainty evidence, downgraded because of imprecision). While pooled point estimates suggested increased risk of SAEs (RR 2.15, 95% CI 0.49 to 9.46; I<sup>2</sup> = 0%; 4 studies, 1852 participants) and neuropsychiatric SAEs (RR 4.69, 95% CI 0.23 to 96.50; I<sup>2</sup> not estimable as events only in 1 study; 2 studies, 764 participants), and reduced risk of cardiac SAEs (RR 0.32, 95% CI 0.01 to 7.88; I<sup>2</sup> not estimable as events only in 1 study; 2 studies, 819 participants), in all three cases evidence was of low certainty and confidence intervals were very wide, encompassing both substantial harm and benefit. </p> </section> <section id="CD006103-sec-0007"> <h3 class="title" id="CD006103-sec-0007">Authors' conclusions</h3> <p>Cytisine and varenicline both help more people to quit smoking than placebo or no medication. Varenicline is more effective at helping people to quit smoking than bupropion, or a single form of NRT, and may be as or more effective than dual‐form NRT. People taking varenicline are probably more likely to experience SAEs than those not taking it, and while there may be increased risk of cardiac SAEs and decreased risk of neuropsychiatric SAEs, evidence was compatible with both benefit and harm. Cytisine may lead to fewer people reporting SAEs than varenicline. Based on studies that directly compared cytisine and varenicline, there may be no difference or a benefit from either medication for quitting smoking. </p> <p>Future trials should test the effectiveness and safety of cytisine compared with varenicline and other pharmacotherapies, and should also test variations in dose and duration. There is limited benefit to be gained from more trials testing the effect of standard‐dose varenicline compared with placebo for smoking cessation. Further trials on varenicline should test variations in dose and duration, and compare varenicline with e‐cigarettes for smoking cessation. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006103-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006103-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD006103-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD006103-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006103-abs-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006103-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006103-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD006103-abs-0010">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ja#CD006103-abs-0018">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006103-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD006103-abs-0021">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD006103-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006103-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD006103-abs-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006103-abs-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD006103-abs-0015">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006103-abs-0002" lang="en"> <h3>Can medications like varenicline and cytisine (nicotine receptor partial agonists) help people to stop smoking and do they cause unwanted effects? </h3> <p><b>Key messages</b> </p> <p>· Varenicline can help people to stop smoking for at least 6 months. Evidence shows it works better than bupropion and using only one type of nicotine replacement therapy (e.g. only patches). Quit rates might be similar to using more than one type of nicotine replacement therapy at the same time (e.g. patches and gum together). </p> <p>· Cytisine can help people to stop smoking for at least 6 months. It may work as well as varenicline, but future evidence may show that while it helps, it is not quite as helpful as varenicline. </p> <p>· Future studies should test the effectiveness and safety of cytisine compared with varenicline and other stop‐smoking medications, and should also investigate giving cytisine or varenicline at different doses and for different lengths of time. </p> <p><b>What are 'nicotine receptor partial agonists'?</b> </p> <p>Smoking tobacco is extremely bad for people’s health. For people who smoke, quitting is the best thing they can do to improve their health. Many people find it difficult to quit smoking. Nicotine receptor partial agonists (NRPAs) are a type of medication used to help people to stop smoking. They help to reduce the withdrawal symptoms people experience when they stop smoking, like cravings and unpleasant mood changes. They also reduce the pleasure people usually experience when they smoke. The most widely‐available treatment in this drug type is varenicline. Cytisine is another, similar medication. They may cause unwanted effects such as feeling sick (nausea) and other stomach problems, difficulties sleeping, abnormal dreams, and headache. They may also lead to potentially serious unwanted effects, such as suicidal thoughts, heart problems and raised blood pressure. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out if using NRPAs can help people to quit smoking, and if they cause unwanted effects. We wanted to know: </p> <p>· how many people stopped smoking for at least 6 months; and</p> <p>· how many people had unwanted effects.</p> <p><b>What did we do?</b> </p> <p>We searched for studies that investigated NRPAs used to help people quit smoking. People in the studies had to be chosen at random to receive an NRPA, or another NRPA, placebo (medication like the NRPA but with no active ingredients) or no treatment. They had to be adult tobacco smokers who wanted to stop smoking. </p> <p><b>What did we find?</b> </p> <p>We found 75 studies that compared NRPAs with:</p> <p>· placebo or no medicine;</p> <p>· nicotine replacement therapy, such as patches or gum;</p> <p>· bupropion (another medicine to help people stop smoking);</p> <p>· another NRPA;</p> <p>· e‐cigarettes.</p> <p>The USA hosted the most studies (28 studies). Other studies took place in a range of countries across the world, some in several countries. </p> <p><b>Main results</b> </p> <p>People are more likely to stop smoking for at least six months using varenicline than using placebo (41 studies, 17,395 people), bupropion (9 studies, 7560 people), or just one type of nicotine replacement therapy, like patches alone (11 studies, 7572 people). They may be just as likely to quit as people using two or more kinds of nicotine replacement therapy, like patches and gum together (5 studies, 2344 people). </p> <p>Cytisine probably helps more people to stop smoking than placebo (4 studies, 4623 people) and may be just as effective as varenicline (2 studies, 2131 people). </p> <p>For every 100 people using varenicline to stop smoking, 21 to 25 might successfully stop, compared with only 18 of 100 people using bupropion, 18 of 100 people using a single form of nicotine‐replacement therapy, and 20 of 100 using two or more kinds of nicotine‐replacement therapy. For every 100 people using cytisine to stop smoking, 18 to 23 might successfully stop. </p> <p>The most common unwanted effect of varenicline is nausea, but this is mostly at mild or moderate levels and usually clears over time. People taking varenicline likely have an increased chance of a more serious unwanted effect that could result in going to hospital, however these are still rare (2.7% to 4% of people on varenicline, compared with 2.7% of people without) and may include many that are unrelated to varenicline. People taking cytisine may also have a slightly increased chance of serious unwanted effects compared with people not taking it, but this may be less likely compared with varenicline. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The evidence for some of our results is very reliable. We’re very confident that varenicline helps people to quit smoking better than many alternatives. We’re less sure of some other results because fewer or smaller studies provided evidence. </p> <p>Several results suggest one treatment is better or less harmful than another, but the opposite could still be true. </p> <p><b>How up to date is the evidence?</b> </p> <p>The evidence is up to date to 29 April 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006103-sec-0121" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006103-sec-0121"></div> <h3 class="title" id="CD006103-sec-0122">Implications for practice</h3> <section id="CD006103-sec-0122"> <p> <ul id="CD006103-list-0006"> <li> <p>Cytisine is likely to help more people to quit smoking than placebo or no medication.</p> </li> <li> <p>Varenicline at standard dosage (1.0 mg twice a day) increased the chances of successful long‐term smoking cessation by more than two‐fold compared with placebo. We did not find evidence that varenicline is less effective in any of the specific populations we investigated. </p> </li> <li> <p>Varenicline is more effective at helping people to quit smoking than bupropion, or a single form of nicotine replacement therapy, and may be as effective as or more effective than dual‐form nicotine replacement therapy. </p> </li> <li> <p>People taking varenicline are probably more likely to experience serious adverse events than those not taking it, and while there may be increased risk of cardiac serious adverse events and decreased risk of neuropsychiatric serious adverse events, evidence was compatible with both benefit and harm. </p> </li> <li> <p>Cytisine may lead to fewer people reporting serious adverse events than varenicline and may help a similar number of people to quit smoking. </p> </li> </ul> </p> </section> <h3 class="title" id="CD006103-sec-0123">Implications for research</h3> <section id="CD006103-sec-0123"> <p> <ul id="CD006103-list-0007"> <li> <p>Future trials should test the effectiveness and safety of cytisine compared with varenicline and other pharmacotherapies, and should also test variations in dose and duration. </p> </li> <li> <p>There is limited benefit to be gained from more trials testing the effect of standard dose varenicline compared with placebo for smoking cessation. </p> </li> <li> <p>Further varenicline trials should test the effect of variations in dose and duration and preloading varenicline before quitting, and may be useful in specific populations and settings where there is a plausible rationale that the effect may differ. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006103-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006103-sec-0008"></div> <div class="table" id="CD006103-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Varenicline versus placebo or no medication for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Varenicline versus placebo or no medication for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> smoking cessation clinics, hospitals, universities and other research centres<br/><b>Intervention:</b> varenicline<br/><b>Comparison:</b> placebo or no medication </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no medication</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with varenicline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> <p>(varenicline vs placebo)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>99 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b> </p> <p>(213 to 249)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.32</b> </p> <p>(2.15 to 2.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,395<br/>(41 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<sup>a</sup> </p> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> <p>(varenicline vs placebo or no medication)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> <p>(27 to 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> </p> <p>(1.01 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,356<br/>(26 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>b</sup> </p> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> <p>(varenicline vs placebo or no medication)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> <p>(7 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> </p> <p>(0.61 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7846<br/>(22 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>c</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> <p>(varenicline vs placebo or no medication)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> <p>(8 to 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> </p> <p>(0.79 to 1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7151<br/>(18 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>c</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Moderate heterogeneity detected, however all but three studies showed positive effect of varenicline, so we did not downgrade on this basis. </p> <p><sup>b</sup>Downgraded one level because of imprecision: CI incorporates no clinical difference as well as clinically significant harm. </p> <p><sup>c</sup>Downgraded two levels because of imprecision: CI incorporates clinically significant benefit and clinically significant harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006103-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cytisine versus placebo or no medication for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Cytisine versus placebo or no medication for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> smoking cessation clinics, hospitals, universities and other research centres<br/><b>Intervention:</b> cytisine<br/><b>Comparison:</b> placebo or no medication </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no medication</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with cytisine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> <p>(cytisine vs placebo)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>205 per 1000</b> </p> <p>(181 to 232)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.30</b> </p> <p>(1.15 to 1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4623<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>a</sup> </p> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> <p>(cytisine vs placebo or no medication)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> <p>(36 to 63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> </p> <p>(0.78 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3781<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>b</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> <p>(cytisine vs placebo or no medication)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> <p>(cytisine vs placebo or no medication)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of heterogeneity: I<sup>2</sup> = 83%.<br/><sup>b</sup>Downgraded two levels because of imprecision: CI incorporates clinically significant benefit and clinically significant harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006103-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Cytisine versus varenicline for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Cytisine versus varenicline for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> community, community pharmacy, participants' homes<br/><b>Intervention:</b> cytisine<br/><b>Comparison:</b> varenicline </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with varenicline</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with cytisine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>121 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b><br/>(95 to 152) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.79 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2131<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a,b</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> <p>(21 to 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.67</b> </p> <p>(0.44 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>c</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for heterogeneity: I<sup>2</sup> = 65% may be explained by the difference in duration of cytisine treatment (12 weeks of cytisine versus 12 weeks of varenicline in <a href="./references#CD006103-bbs2-0064" title="NCT02957786. Cytisine versus varenicline for smoking cessation. clinicaltrials.gov/show/NCT02957786 (first received 8 November 2016). WalkerN , SmithB , BarnesJ , VerbiestM , KurdzielT , ParagV , et al. Cytisine versus varenicline for smoking cessation for Maori (the indigenous people of New Zealand) and their extended family: protocol for a randomized non-inferiority trial. Addiction2019;114(2):344-52. WalkerN , SmithB , BarnesJ , VerbiestM , ParagV , PokhrelS , et al. Cytisine versus varenicline for smoking cessation in New Zealand indigenous Maori: a randomized controlled trial. Addiction2021;116(10):2847-58. ">Walker 2021</a>; 4 weeks of cytisine and 12 weeks of varenicline in <a href="./references#CD006103-bbs2-0014" title="ACTRN12616001654448. A non-inferiority trial of cytisine versus varenicline for smoking cessation. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12616001654448 (first received 30 November 2016). CourtneyRJ , McRobbieH , TutkaP , WeaverNA , PetrieD , MendelsohnCP , et al. Effect of cytisine vs varenicline on smoking cessation: a randomized clinical trial. JAMA2021;326(1):56-64. ThomasD , FarrellM , McRobbieH , TutkaP , PetrieD , WestR , et al. The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial. Addiction2019;114(5):923-33. ">Courtney 2021</a>).<br/><sup>b</sup>Downgraded two levels because of imprecision: CI incorporates clinically significant benefit and clinically significant harm.<br/><sup>c</sup>Downgraded two level because of imprecision: CI incorporates no difference as well as clinically significant benefit, and number of events in analysis very low (n = 82). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006103-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Cytisine versus nicotine replacement therapy for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Cytisine versus nicotine replacement therapy for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> participants' homes (participants were callers to a national Quitline)<br/><b>Intervention:</b> cytisine<br/><b>Comparison:</b> nicotine replacement therapy (NRT) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with NRT</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with cytisine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>218 per 1000</b> </p> <p>(173 to 275)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.43</b> </p> <p>(1.13 to 1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1310<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a,b</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> </p> <p>(45 to 104)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b> </p> <p>(0.76 to 1.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1310<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,c</sup> </p> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>NRT:</b> nicotine replacement therapy; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of risk of bias: sole study at high risk.<br/><sup>b</sup>Downgraded one level because of imprecision: fewer than 300 events in the analysis.<br/><sup>c</sup>Downgraded two levels because of imprecision: CI incorporates clinically significant benefit and clinically significant harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006103-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Varenicline versus bupropion for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Varenicline versus bupropion for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> smoking cessation clinics, hospitals, universities and other research centres<br/><b>Intervention:</b> varenicline<br/><b>Comparison:</b> bupropion </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with bupropion</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with varenicline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b> </p> <p>(222 to 264)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> </p> <p>(1.25 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7560<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> <p>(12 to 27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> </p> <p>(0.61 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5317<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> <p>(0 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> </p> <p>(0.16 to 7.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>866<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.17</b> </p> <p>(0.33 to 30.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>866<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels because of imprecision: CI incorporates clinically significant benefit and clinically significant harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006103-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Varenicline versus nicotine replacement therapy monotherapy for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Varenicline versus nicotine replacement therapy (NRT) monotherapy for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> smoking cessation clinics, hospitals, universities and other research centres<br/><b>Intervention:</b> varenicline<br/><b>Comparison:</b> n<b>i</b>cotine replacement therapy (NRT) monotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with NRT monotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with varenicline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>225 per 1000</b> </p> <p>(205 to 247)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> </p> <p>(1.14 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7572<br/>(11 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> <p>(5 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b> </p> <p>(0.50 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6535<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events in two studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>NRT:</b> nicotine replacement therapy; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels because of imprecision: fewer than 150 events in the analysis. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006103-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Varenicline versus combination nicotine replacement therapy for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Varenicline versus combination nicotine replacement therapy for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> smoking cessation clinics, hospitals, universities and other research centres<br/><b>Intervention:</b> varenicline<br/><b>Comparison:</b> combination nicotine replacement therapy (NRT) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with combination NRT</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with varenicline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>199 per 1000</b> </p> <p>(170 to 234)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> </p> <p>(0.87 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2344<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> <p>(1 to 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.15</b> </p> <p>(0.49 to 9.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1852<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>b</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.69</b> </p> <p>(0.23 to 96.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>764<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>b</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only one study reported any events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> <p>(0 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.32</b> </p> <p>(0.01 to 7.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>819<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>b</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only one study reported any events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>NRT:</b> nicotine replacement therapy; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels because of imprecision: confidence intervals include the potential for clinically significant benefit from either intervention.<br/><sup>b</sup>Downgraded two levels because of imprecision: CI incorporates clinically significant benefit and clinically significant harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006103-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Varenicline versus e‐cigarettes for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Varenicline versus e‐cigarettes for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who continued to smoke tobacco following acute coronary syndrome<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> varenicline<br/><b>Comparison:</b> e‐cigarettes </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with e‐cigarettes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with varenicline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>481 per 1000</p> <p>(179 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.25</p> <p>(1.21 to 8.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b</sup> </p> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels because of imprecision: fewer than 150 events in the analysis.<br/><sup>b</sup>Downgraded one level because of risk of bias: sole study at high risk. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006103-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006103-sec-0009"></div> <section id="CD006103-sec-0010"> <h3 class="title" id="CD006103-sec-0010">Description of the condition</h3> <p>Smoking is the main preventable cause of morbidity and premature death worldwide, killing more than 8 million people each year (<a href="./references#CD006103-bbs2-0244" title="World Health Organization. World Health Organization fact sheets: Tobacco. www.who.int/en/news-room/fact-sheets/detail/tobacco (accessed 16 November 2022).">WHO 2022</a>). It is also a leading cause of health inequalities (<a href="./references#CD006103-bbs2-0202" title="Actions on Smoking and Health (ASH). Briefing: Health inequalities and smoking. ash.org.uk/uploads/ASH-Briefing_Health-Inequalities.pdf2019.">ASH 2019</a>). Quitting tobacco smoking significantly reduces risk of tobacco‐related disease and death (<a href="./references#CD006103-bbs2-0240" title="US Department of Health and Human Services. Smoking cessation: a report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2020.">USDHHS 2020</a>). There are a range of interventions available to help people quit smoking, including different kinds of behavioural and pharmacological support, but even with the most effective interventions, long‐term quit rates remain relatively low (<a href="./references#CD006103-bbs2-0225" title="Livingstone-BanksJ , LindsonN , Hartmann-BoyceJ , AveyardP . Effects of interventions to combat tobacco addiction: Cochrane update of 2019 and 2020 reviews. Addiction2022;117(6):1573-88. [DOI: 10.1111/add.15769]">Livingstone‐Banks 2022a</a>; <a href="./references#CD006103-bbs2-0229" title="RigottiNA , KruseGR , Livingstone-BanksJ , Hartmann-BoyceJ . Treatment of tobacco smoking: a review. JAMA2022;327(6):566-77. [DOI: 10.1001/jama.2022.0395]">Rigotti 2022</a>). </p> </section> <section id="CD006103-sec-0011"> <h3 class="title" id="CD006103-sec-0011">Description of the intervention and how it might work</h3> <p>Nicotine receptor partial agonists are a family of drugs that aim to mitigate the addictiveness of tobacco by binding to the α4β2 nicotinic acetylcholine receptor (the receptor that mediates nicotine dependence through released dopamine). When bound to the receptor, a partial agonist prompts the receptor to release dopamine in the way nicotine would, and prevents nicotine from tobacco from binding to the receptor. This reduces nicotine withdrawal symptoms and reduces the rewarding effects of tobacco. There are two main nicotine receptor partial agonists: varenicline and cytisine. A third drug, dianicline, was developed but unfavourable results led to its withdrawal from further development (<a href="./references#CD006103-bbs2-0218" title="KirchhoffVD , NguyenHT , SoczynskaJK , WoldeyohannesH , McIntyreRS . Discontinued psychiatric drugs in 2008. Expert Opinion on Investigational Drugs2009;18(10):1431-43.">Kirchhoff 2009</a>). </p> <p>Varenicline was developed by Pfizer Inc in 1997 (<a href="./references#CD006103-bbs2-0204" title="CoeJW , BrooksPR , VetelinoMG , WirtzMC , ArnoldEP , HuangJ , et al. Varenicline: an alpha4beta2 nAChR nicotinic receptor partial agonist for smoking cessation. Journal of Medicinal Chemistry2005;48:3474-7.">Coe 2005</a>), and was approved as a prescription‐only aid to smoking cessation in 2006 by the American Food and Drug Administration under the trade name Chantix, and by the European Medicines Evaluation Agency under the trade name Champix. In July 2007 it was approved by the National Institute for Health and Clinical Excellence (NICE) for prescribing by the UK National Health Service (<a href="./references#CD006103-bbs2-0201" title="RawM , McNeillA , ArnottD . Varenicline: guidance for health professionals on a new prescription-only stop smoking medication. www.ash.org.uk/html/cessation/ASHVareniclineguidance.pdf (accessed November 2006).">ASH 2006</a>; <a href="./references#CD006103-bbs2-0228" title="National Institute for Health and Clinical Excellence. Varenicline for smoking cessation. www.nice.org.uk/nicemedia/pdf/TA123Guidance.pdf (accessed 14th April 2008)2007.">NICE 2007</a>). In 2021, the World Health Organization added varenicline to its Essential Medicines List (<a href="./references#CD006103-bbs2-0243" title="World Health Organization. Two new tobacco cessation medicines added to the WHO essential medicines list. www.who.int/news/item/05-11-2021-two-new-tobacco-cessation-medicines-added-to-the-who-essential-medicines-list (accessed 16 November 2022).">WHO 2021</a>). Post‐marketing surveillance raised subsequent concerns about possible links between varenicline and major health risks, including suicidal ideation and behaviour, depression, and serious adverse cardiovascular events (<a href="./references#CD006103-bbs2-0212" title="US Food and Drug Administration. FDA issues Public Health Advisory on Chantix. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116849.htm (accessed 3 September 2015).">FDA 2008</a>), which led to an FDA warning label in 2009. This warning was removed in 2016 after a large trial found no evidence to support the concerns (<a href="./references#CD006103-bbs2-0018" title="AnthenelliR , BenowitzN , WestR , St AubinL , McRaeT , LawrenceD , et al. Reports of suicidal ideation and behavior in the EAGLES trial. Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March2016;SYM5D:8. AnthenelliRM , BenowitzNL , WestR , St AubinL , McRaeT , LawrenceD , et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet2016;387(10037):2507-20. [DOI: dx.doi.org/10.1016/S0140-6736(16)30272-0]AnthenelliRM , GaffneyM , BenowitzNL , WestR , McRaeT , RussC , et al. Predictors of neuropsychiatric adverse events with smoking cessation medications in the randomized controlled EAGLES trial. Journal of General Internal Medicine2019;34(6):862-70. AyersCR , HeffnerJL , RussC , LawrenceD , McRaeT , EvinsAE , et al. Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: subgroup analysis of the randomized, active- and placebo-controlled EAGLES trial. Depression and Anxiety2020;37(3):247-60. BakerCL , PietriG . A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial. ClinicoEconomics and outcomes research2018;10:67-74. BeardE , JacksonSE , AnthenelliRM , BenowitzNL , AubinLS , McRaeT , et al. Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors. Addiction (Abingdon, England)2021;116(10):2816-24. BenowitzN , EvinsAE , WestR , St AubinL , McRaeT , LawrenceD , et al. EAGLES trial: study design and neuropsychiatric safety results. In: Society for Research on Nicotine and Tobacco, USA 3rd - 5th March. Vol. SYM5B. 2016:7. BenowitzNL , PipeA , WestR , HaysJT , TonstadS , McRaeT , et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Internal Medicine2018;178(5):622-31. CorreaJB , LawrenceD , McKennaBS , GaznickN , SacconePA , DubravaS , et al. Psychiatric co-morbidity and multi-morbidity in the EAGLES trial: descriptive correlates and associations with neuropsychiatric adverse events, treatment adherence, and smoking cessation. Nicotine &amp; Tobacco Research2021;23(10):1636-55. EbbertJ , Jimenez-RuizC , Dutro MP , FisherM , LiJ , Hays JT . Frequently reported adverse events with smoking cessation medications: post hoc analysis of a randomized trial. Mayo Clinic Proceedings2021;96(7):1801-11. EvinsAE , BenowitzNL , WestR , RussC , McRaeT , LawrenceD , et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, anxiety, and mood disorders in the EAGLES trial. Journal of Clinical Psychopharmacology2019;39(2):108-16. EvinsAE , WestR , BenowitzNL , RussC , LawrenceD , McRaeT , et al. Efficacy and safety of pharmacotherapeutic smoking cessation aids in schizophrenia spectrum disorders: subgroup analysis of EAGLES. Psychiatric Services (Washington, D.C.)2021;72(1):7-15. HeffnerJL , EvinsAE , RussC , LawrenceD , AyersCR , McRaeT , et al. Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: subgroup analysis of a randomized clinical trial. Journal of Affective Disorders2019;256:267-77. NCT01456936. A phase 4, randomized, double blind, active and placebo controlled multicenter study evaluating the neuropsychiatric safety and efficacy of 12 weeks varenicline tartrate 1mg BID and bupropion hydrochloride 150 mg BID for smoking cessation in subjects with and without a history of psychiatric disorders [EAGLES]. clinicaltrials.gov/ct2/show/NCT01456936 (first received 21 October 2011). NollenNL , AhluwaliaJS , Sanderson CoxL , OkuyemiK , LawrenceD , SamuelsL , et al. Assessment of racial differences in pharmacotherapy efficacy for smoking cessation: secondary analysis of the EAGLES randomized clinical trial. JAMA Network Open2021;4(1):e2032053. ProchaskaJ , BenowitzN , WestR , AnthenelliR . Evaluating adverse events in a global smoking cessation study (EAGLES): a randomized controlled trial comparing the safety and efficacy of the first-line smoking cessation aids in smokers with and without psychiatric disorders. Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March2016;SYM5:7. ProchaskaJ . Neuropsychiatric risk concerns in the context of smoking, quitting, and cessation pharmacotherapy use. Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March2016;SYM5A:7. WestR , BenowitzN , EvinsAE , St AubinL , McRaeT , LawrenceD , et al. Relative efficacy of varenicline, bupropion SR, and nicotine transdermal patch in aiding smoking cessation in the EAGLES trial. Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March2016;SYM5C:8. WestR , EvinsAE , BenowitzNL , RussC , McRaeT , LawrenceD , et al. Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. Addiction2018;113(8):1507-16. WilcoxC , OskooilarN , GuevarraK , Linh TongM , GroszD , MorrisseyJ , et al. A double-blind, active-and placebo-controlled evaluation of the neuropsychiatric safety and efficacy of varenicline and bupropion for smoking cessation in subjects with (pre-existing) psychiatric disorders: an objective blinded analysis. Neuropsychopharmacology2015;40:S260. ">EAGLES 2016</a>). In 2021, Pfizer announced a recall of varenicline because it exceeded acceptable intake limits of a nitrosamine impurity, called N‐nitroso‐varenicline. While this is believed to only be temporary, it has led to shortages at the time of writing. </p> <p>Cytisine was developed in Bulgaria in the 1960s, and is less widely available than varenicline (<a href="./references#CD006103-bbs2-0213" title="FouldsJ , BurkeM , SteinbergM , WilliamsJM , ZiedonisDM . Advances in pharmacotherapy for tobacco dependence. Expert Opinion on Emerging Drugs2004;9(1):39-53.">Foulds 2004</a>; <a href="./references#CD006103-bbs2-0236" title="TutkaP , ZatońskiW . Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacological Reports2005;58:777-98.">Tutka 2005</a>; <a href="./references#CD006103-bbs2-0237" title="TutkaP , MrózT , ZatońskiW . Cytisine - renaissance of well known alkaloid. Pharmacological aspects of efficacy in the treatment of tobacco dependence [Cytyzyna – renesans znanego alkaloidu. Aspekty farmakologiczne zastosowania w leczeniu uzależnienia od nikotyny]. Farmakoterapia w Psychiatrii i Neurologii2006;1:33-9.">Tutka 2006</a>). Its original manufacturer, Sopharma Pharmaceuticals, developed their phytoproduct from the plant <i>Cytisus Laburnum</i> L. (Golden Rain). Although cytisine is not licensed and available for use as a smoking cessation aid across most countries outside Eastern Europe, it works by the same mechanism as varenicline and it is available for substantially less cost (<a href="./references#CD006103-bbs2-0239" title="TutkaP , VinnikovD , CourtneyRJ , BenowitzNL . Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction2019;114(11):1951-69. [DOI: 10.1111/add.14721]">Tutka 2019</a>; <a href="./references#CD006103-bbs2-0214" title="GottiC , ClementiF . Cytisine and cytisine derivatives. More than smoking cessation aids. Pharmacological Research2021;170:105700. [DOI: 10.1016/j.phrs.2021.105700]">Gotti 2021</a>). An important difference between the treatments is that standard treatment with cytisine lasts 25 days, compared with 12 weeks for varenicline. </p> </section> <section id="CD006103-sec-0012"> <h3 class="title" id="CD006103-sec-0012">Why it is important to do this review</h3> <p>The scale of the impact on health from tobacco worldwide makes it imperative that we continue to develop our understanding of smoking cessation interventions. While the effectiveness of varenicline for smoking cessation is well established, substantial questions remain about different doses and durations of treatment, and what impact they have on how effective varenicline is at helping people to quit smoking. </p> <p>Varenicline is a front‐line smoking cessation medication in many countries, and its current shortage poses a substantial challenge for tobacco control strategies around the world. Learning more about how effective and safe cytisine is for smoking cessation may inform decisions about whether to licence it in countries that have historically relied on varenicline. </p> <p>This is an update of a Cochrane Review first published in 2007, and most recently updated in 2016. The previous update found high‐certainty evidence of a benefit from varenicline, but only included a limited number of studies testing cytisine for smoking cessation (<a href="./references#CD006103-bbs2-0249" title="CahillK , Lindson-HawleyN , ThomasKH , FanshaweTR , LancasterT . Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews2016, Issue 5. Art. No: CD006103. [DOI: 10.1002/14651858.CD006103.pub7]">Cahill 2016</a>). New evidence comparing cytisine with placebo and with varenicline warranted an update of this review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006103-sec-0013" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006103-sec-0013"></div> <p>To assess the effectiveness of nicotine receptor partial agonists, including varenicline and cytisine, for smoking cessation. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006103-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006103-sec-0014"></div> <section id="CD006103-sec-0015"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006103-sec-0016"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) and cluster‐RCTs. We did not include quasi‐randomised studies, in which the allocation sequence is not truly random, for example, studies where participant date of birth determines participant allocation. </p> </section> <section id="CD006103-sec-0017"> <h4 class="title">Types of participants</h4> <p>We included studies that recruited adult tobacco smokers. Studies testing nicotine receptor partial agonists to help smokeless tobacco users to quit, or as a relapse prevention intervention among people who are already abstinent from smoking tobacco, are covered in separate Cochrane Reviews (<a href="./references#CD006103-bbs2-0207" title="EbbertJO , MontoriVM , ErwinPJ , SteadLF . Interventions for smokeless tobacco use cessation. Cochrane Database of Systematic Reviews2011, Issue 2. Art. No: CD004306. [DOI: 10.1002/14651858.CD004306.pub4]">Ebbert 2011a</a>; <a href="./references#CD006103-bbs2-0224" title="Livingstone-BanksJ , NorrisE , Hartmann-BoyceJ , WestR , JarvisM , ChubbE , et al. Relapse prevention interventions for smoking cessation. Cochrane Database of Systematic Reviews2019, Issue 10. Art. No: CD003999. [DOI: 10.1002/14651858.CD003999.pub5]">Livingstone‐Banks 2019</a>; <a href="./references#CD006103-bbs2-0226" title="Livingstone-BanksJ , SiddiquiF , CroucherR , MehrotraR , VidyasagaranA , SiddiqiK . Interventions for smokeless tobacco use cessation. Cochrane Database of Systematic Reviews2022, Issue 1. Art. No: CD015314. [DOI: 10.1002/14651858.CD015314]">Livingstone‐Banks 2022b</a>). </p> </section> <section id="CD006103-sec-0018"> <h4 class="title">Types of interventions</h4> <p>Selective nicotine receptor partial agonists, including cytisine, dianicline and varenicline (or any other in this class of drug as they reach Phase 3 trial stage), compared with placebo, no medication, or another smoking cessation pharmacotherapy (including nicotine replacement therapy, bupropion, electronic cigarettes, and other nicotine receptor partial agonists). We also included studies that compared different doses and regimes of eligible treatments. Lobeline is covered in an earlier Cochrane Review (<a href="./references#CD006103-bbs2-0233" title="SteadLF , HughesJR . Lobeline for smoking cessation. Cochrane Database of Systematic Reviews2003, Issue 3. Art. No: CD000124. [DOI: 10.1002/14651858.CD000124]">Stead 2003</a>). We only included studies that tested the effect of nicotine receptor partial agonists for smoking cessation and not studies focused on harm reduction, which is covered in a separate Cochrane Review (<a href="./references#CD006103-bbs2-0223" title="Lindson-HawleyN , Hartmann-BoyceJ , FanshaweTR , BeghR , FarleyA , LancasterT . Interventions to reduce harm from continued tobacco use. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD005231. [DOI: 10.1002/14651858.CD005231.pub3]">Lindson‐Hawley 2016</a>). </p> </section> <section id="CD006103-sec-0019"> <h4 class="title">Types of outcome measures</h4> <section id="CD006103-sec-0020"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006103-list-0001"> <li> <p>Abstinence from smoked tobacco at longest follow‐up, at least six months from study baseline. We used the strictest definition of abstinence reported in each study (e.g. prolonged or continuous over point prevalence), and where available, we favoured biochemically validated over self‐reported abstinence. We only included studies that measured abstinence from tobacco smoking at six months or longer from baseline. </p> </li> <li> <p>Number of participants who experienced the following adverse events: nausea, insomnia, abnormal dreams, headache, depression, and suicidal ideation </p> </li> <li> <p>Number of participants who experienced serious adverse events as defined by the authors of included studies </p> </li> <li> <p>Number of participants who experienced neuropsychiatric serious adverse events</p> </li> <li> <p>Number of participants who experienced cardiac serious adverse events.</p> </li> </ul> </p> </section> </section> </section> <section id="CD006103-sec-0021"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006103-sec-0022"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Tobacco Addiction Group's Specialised Register for studies, using relevant terms (e.g. 'cytisine' or 'Tabex' or 'dianicline' or 'varenicline' or 'nicotine receptor partial agonist') in the title or abstract, or as keywords. This Register has been developed from electronic searching of the Cochrane Central Register of Controlled trials (CENTRAL), MEDLINE, Embase, and PsycINFO, together with handsearching of specialist journals, conference proceedings and reference lists of previous trials and overviews. The most recent search of the Register was on 29 April 2022, and included reports of trials indexed in CENTRAL, 2022, Issue 3; MEDLINE (via OVID) to update 20220405; Embase (via OVID) to week 202214; PsycINFO (via OVID) to update 20220404, all from inception. See the <a href="https://tobacco.cochrane.org/resources/cochrane-tag-specialised-register" target="_blank">Cochrane Tobacco Addiction Group Website</a> for details of the search strategies for these databases. The search strategy for this specific review is listed in <a href="./appendices#CD006103-sec-0127">Appendix 1</a>. We did not place any limits on our searches (e.g. by language, year of publication, or publication format). </p> </section> <section id="CD006103-sec-0023"> <h4 class="title">Searching other resources</h4> <p>Our search of the Cochrane Tobacco Addiction Group Specialised Register also covered ongoing and unpublished trials included in the following databases, as these are indexed in CENTRAL. </p> <p> <ul id="CD006103-list-0002"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>, searched via CENTRAL); and </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="https://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>, searched via CENTRAL). </p> </li> </ul> </p> <p>We also checked the reference lists of included studies for potentially eligible trials.</p> </section> </section> <section id="CD006103-sec-0024"> <h3 class="title" id="CD006103-sec-0024">Data collection and analysis</h3> <section id="CD006103-sec-0025"> <h4 class="title">Selection of studies</h4> <p>For this update we screened the search results in two stages using the software <a href="https://covidence.org/" target="_blank">Covidence</a>. Two review authors (of JL‐B, AT, AH and NL) independently screened the title and abstract of each study found in our searches. We then reviewed the full text of all potentially eligible reports in duplicate. At each stage, we resolved any disagreement through discussion and if needed by referring to a third review author. We noted the reasons for study exclusion at full‐text stage for our PRISMA diagram illustrating the flow of studies (<a href="./references#CD006103-bbs2-0221" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS One2009;6:e1000100.">Liberati 2009</a>). </p> </section> <section id="CD006103-sec-0026"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (of JL‐B, AT, AH, LH, TRF, and KT) independently extracted the following information about each included study in duplicate, using a prepiloted data extraction form. We resolved disagreement through discussion and if needed by referring to a third review author. </p> <p> <ul id="CD006103-list-0003"> <li> <p>Country and setting (e.g. primary care, community, hospital outpatient/inpatient)</p> </li> <li> <p>Method of recruiting participants</p> </li> <li> <p>Definition of smoker used</p> </li> <li> <p>Methods of randomisation and allocation, and blinding of study personnel, participants and assessors </p> </li> <li> <p>Demographic characteristics of participants (e.g. average age, sex, average cigarettes per day) </p> </li> <li> <p>Intervention and control description (dose, provider, duration, number of visits, etc.) </p> </li> <li> <p>Outcomes including definition of abstinence used, and biochemical validation of cessation</p> </li> <li> <p>Proportion of participants with follow‐up data</p> </li> <li> <p>Any adverse events</p> </li> <li> <p>Declarations of interest and sources of study funding</p> </li> </ul> </p> </section> <section id="CD006103-sec-0027"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed each included study using Cochrane's RoB 1 tool for the following domains of risk (<a href="./references#CD006103-bbs2-0216" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook.">Higgins 2011</a>). </p> <p> <ul id="CD006103-list-0004"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and study personnel and blinding/objectivity of outcome assessment (performance bias and detection bias) </p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective reporting (reporting bias)</p> </li> <li> <p>Other potential risks of bias. For this domain, we assessed and reported any forms of bias present in studies that did not fall under one of the above domains. Where no relevant form of other potential bias was found, we left this field blank. </p> </li> </ul> </p> <p>Two review authors (of JL‐B, AT, AH, LH, TRF, and KT) independently judged each study as at low, unclear, or high risk of bias for each domain, justifying judgements using information from the study report. We resolved disagreements in judgements through discussion and by referral to a third review author where needed. </p> </section> <section id="CD006103-sec-0028"> <h4 class="title">Measures of treatment effect</h4> <p>We present estimates of effects for individual studies using risk ratios (RRs), calculated as ((number of events in intervention condition/intervention denominator)/(number of events in control condition/control denominator)), with a 95% confidence interval (CI). An RR greater than one indicates a higher rate of outcome (either smoking abstinence or adverse events) in the intervention group than in the control group. </p> </section> <section id="CD006103-sec-0029"> <h4 class="title">Unit of analysis issues</h4> <p>As cluster‐randomised trials are eligible for inclusion in this review, there is the potential for unit of analysis issues. Where required, we adjusted for clustering using an intraclass correlation, either from the study in question or from a similar study. Where studies compared more than one eligible intervention arm with a non‐intervention control, we either pooled intervention arms together (assuming they did not differ in pharmacotherapy given) or added them separately to the meta‐analysis and split the control group data evenly between them, to avoid double‐counting any participants in the analysis. </p> </section> <section id="CD006103-sec-0030"> <h4 class="title">Dealing with missing data</h4> <p>We conducted our analyses on an intention‐to‐treat basis, including all participants in the study arms to which they were randomised, regardless of whether they received the intervention. We counted participants lost to follow‐up as continuing smoking, which is standard in the field (<a href="./references#CD006103-bbs2-0242" title="WestR , HajekP , SteadL , StapletonJ . Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction2005;100:299-303.">West 2005</a>). Where study reports lacked the information needed for our analyses, we tried to contact study authors to ask for this information. Attempts to contact study authors are recorded in the <a href="./references#CD006103-sec-0138" title="">Characteristics of included studies</a> tables. </p> </section> <section id="CD006103-sec-0031"> <h4 class="title">Assessment of heterogeneity</h4> <p>To investigate heterogeneity, we used the I<sup>2</sup> statistic, given by the formula [(Q ‐ df)/Q] × 100%, where Q is the Chi<sup>2</sup> statistic and df is its degrees of freedom (<a href="./references#CD006103-bbs2-0215" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;7414:557-60.">Higgins 2003</a>). This describes the percentage of variability in effect estimates that is due to heterogeneity rather than to sampling error (chance). We interpreted the I<sup>2</sup> result using the following overlapping bands (<a href="./references#CD006103-bbs2-0206" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>): </p> <p> <ul id="CD006103-list-0005"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ul> </p> <p>Where we found moderate to substantial heterogeneity, we investigated further using subgroup analyses based on study characteristics decided upon through review author consensus. In the event of considerable unexplained statistical heterogeneity (i.e. I<sup>2</sup> =75% or over), we evaluated whether it was still appropriate to report a pooled result (<a href="./references#CD006103-bbs2-0206" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). </p> </section> <section id="CD006103-sec-0032"> <h4 class="title">Assessment of reporting biases</h4> <p>For the two smoking cessation comparisons with 10 or more studies, we assessed the risk of reporting bias using a funnel plot. Regardless of the number of studies included, we considered the possibility of reporting bias in our discussion. </p> </section> <section id="CD006103-sec-0033"> <h4 class="title">Data synthesis</h4> <p>We conducted a narrative summary of the included studies and, where more than one study reported an outcome comparing an eligible intervention with placebo, no medication, another eligible intervention, or the same intervention delivered with a different dose or regime, we conducted meta‐analyses to pool data from sufficiently similar studies using a Mantel‐Haenszel fixed‐effect model to calculate pooled RRs with 95% CIs. </p> </section> <section id="CD006103-sec-0034"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where studies compared an intervention pharmacotherapy with either placebo or no medication and there was substantial heterogeneity, we considered subgrouping analyses based on comparator and using the I<sup>2</sup> statistic to test for difference between subgroups and decide whether to report an overall pooling or by subgroup only. </p> </section> <section id="CD006103-sec-0035"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses testing the effect of removing studies we judged to be at high risk of bias to see if those studies affected the overall result. In analyses where we pooled studies that compared an intervention with either placebo or no medication but did not subgroup, we conducted sensitivity analyses testing removing studies comparing against no medication. In our comparison of varenicline versus placebo we also conducted a further ad hoc sensitivity analysis to explore the high level of heterogeneity, removing studies that used an extended treatment course of 24 or 52 weeks rather than the 12 weeks of the other studies. </p> <p>Because we were primarily interested in whether there is evidence that varenicline works differently for disease‐specific populations and people in specific subgroups and healthcare settings, we conducted sensitivity analyses, treating studies in these populations and settings as subgroups of the main analyses and using the I<sup>2</sup> statistic to test for subgroup differences. </p> </section> <section id="CD006103-sec-0036"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Following standard Cochrane methods, we produced summary of findings tables for smoking abstinence at longest follow‐up and all of our serious adverse events outcomes for each comparison of varenicline or cytisine with placebo or another pharmacotherapy (<a href="./references#CD006103-bbs2-0231" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022</a>). Two review authors (JLB, NL) assessed the certainty of the evidence using the five GRADE considerations (risk of bias, inconsistency, imprecision, indirectness, and publication bias (<a href="./references#CD006103-bbs2-0230" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006103-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006103-sec-0037"></div> <section id="CD006103-sec-0038"> <h3 class="title">Description of studies</h3> <section id="CD006103-sec-0039"> <h4 class="title">Results of the search</h4> <p>Our literature searches for this update found 810 studies (from 885 records). After we removed duplicates, 682 studies remained for title and abstract screening. We ruled out 544 studies at this stage, leaving 138 studies for full‐text screening. From this, we identified 45 new included studies and 20 new ongoing studies, combined with studies from previous updates of this review, this resulted in a total of 75 included studies of 45,049 people and 28 ongoing studies. See <a href="#CD006103-fig-0001">Figure 1</a> for PRISMA diagram detailing study flow (<a href="./references#CD006103-bbs2-0221" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS One2009;6:e1000100.">Liberati 2009</a>). For this update, we contacted authors of four studies and received additional results data. </p> <div class="figure" id="CD006103-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram of searches for 2022 update" data-id="CD006103-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram of searches for 2022 update</p> </div> </div> </div> <p>For this update, we excluded 14 previously included studies because they focused on relapse prevention (these studies are covered in a separate review; <a href="./references#CD006103-bbs2-0224" title="Livingstone-BanksJ , NorrisE , Hartmann-BoyceJ , WestR , JarvisM , ChubbE , et al. Relapse prevention interventions for smoking cessation. Cochrane Database of Systematic Reviews2019, Issue 10. Art. No: CD003999. [DOI: 10.1002/14651858.CD003999.pub5]">Livingstone‐Banks 2019</a>), or had previously been included for data on harms but did not fully meet our inclusion criteria. </p> </section> <section id="CD006103-sec-0040"> <h4 class="title">Included studies</h4> <p>Full details of the included studies are given in the <a href="./references#CD006103-sec-0138" title="">Characteristics of included studies</a> tables. </p> <section id="CD006103-sec-0041"> <h5 class="title">Cytisine</h5> <p>Eight studies in just under 9000 people investigated cytisine as a smoking cessation drug. Four studies compared cytisine with placebo, two with varenicline, one with nicotine replacement therapy (NRT), and one with no medication. <a href="./references#CD006103-bbs2-0045" title="PastorinoU , LadisaV , TrussardoS , SabiaF , RolliL , ValsecchiC , et al. Cytisine therapy improved smoking cessation in the randomized SMILE lung cancer screening trial. Journal of Thoracic Oncology2022;17(11):1276-86. [DOI: 10.1016/j.jtho.2022.07.007.]">Pastorino 2022</a> also compared longer with shorter duration cytisine. Studies tested cytisine at a dose of 9 mg per day for 20 to 25 days, except for <a href="./references#CD006103-bbs2-0045" title="PastorinoU , LadisaV , TrussardoS , SabiaF , RolliL , ValsecchiC , et al. Cytisine therapy improved smoking cessation in the randomized SMILE lung cancer screening trial. Journal of Thoracic Oncology2022;17(11):1276-86. [DOI: 10.1016/j.jtho.2022.07.007.]">Pastorino 2022</a>, which gave cytisine for 40 and 84 days in different arms. </p> <p>Studies were conducted in Australia, Bangladesh and Pakistan, Italy, East Germany, Kyrgyzstan, New Zealand, and Poland. Two studies took place in smoking cessation clinics, and two in the community. <a href="./references#CD006103-bbs2-0063" title="WalkerN , HoweC , BullenC , McRobbieH , GloverM , ParagV , et al. Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. BMC Public Health2011;11(1):880. [CENTRAL: 814611] [EMBASE: 22104038] [6430] [PMID: 22104038]WalkerN , HoweC , GloverM , McRobbieH , BarnesJ , NosaV , et al. Cytisine versus nicotine for smoking cessation. New England Journal of Medicine2014;371(25):2353-62. [CENTRAL: 1037839] [EMBASE: 2014610901]">Walker 2014</a> recruited people who contacted a national smoking quitline. <a href="./references#CD006103-bbs2-0062" title="VinnikovD , BrimkulovN , BurjubaevaA . A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. Journal of Smoking Cessation2008;3(1):57-62. ">Vinnikov 2008</a> was set in a Kyrgyz mining company, and <a href="./references#CD006103-bbs2-0017" title="BoeckmannM , NohavovaI , DogarO , KralikovaE , PankovaA , ZvolskaK , et al. Protocol for the mixed-methods process and context evaluation of the TB &amp; Tobacco randomised controlled trial in Bangladesh and Pakistan: a hybrid effectiveness-implementation study. BMJ Open2018;8(3):e019878. DogarO , BaruaD , BoeckmannM , ElseyH , FatimaR , GabeR , et al. The safety, effectiveness and cost-effectiveness of cytisine in achieving six-month continuous smoking abstinence in tuberculosis patients—protocol for a double-blind, placebo-controlled randomized trial. Addiction2018;113(9):1716-27. DogarO , KedingA , GabeR , MarshallAM , HuqueR , BaruaD , et al. Cytisine for smoking cessation in patients with tuberculosis: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Global Health2020;8(11):e1408-17. ISRCTN43811467. Tuberculosis (TB) and tobacco. www.isrctn.com/ISRCTN43811467 (first received 23 March 2016). SiddiqiK , KedingA , MarshallAM , DogarO , LiJ , HuqueR , et al. Effect of quitting smoking on health outcomes during treatment for tuberculosis: secondary analysis of the TB &amp; Tobacco Trial. Thorax2021;7:74-8. ">Dogar 2020</a> took place in tuberculosis treatment centres. <a href="./references#CD006103-bbs2-0045" title="PastorinoU , LadisaV , TrussardoS , SabiaF , RolliL , ValsecchiC , et al. Cytisine therapy improved smoking cessation in the randomized SMILE lung cancer screening trial. Journal of Thoracic Oncology2022;17(11):1276-86. [DOI: 10.1016/j.jtho.2022.07.007.]">Pastorino 2022</a> recruited heavy smokers participating in a lung‐screening trial. </p> </section> <section id="CD006103-sec-0042"> <h5 class="title">Varenicline</h5> <p>Sixty‐eight studies of over 37,000 people tested varenicline for smoking cessation. This excludes two studies that compared varenicline with cytisine, which are described above. </p> <section id="CD006103-sec-0043"> <h6 class="title">Setting</h6> <p>Twenty‐eight studies were conducted in the USA, four in Canada, three in China, three in Japan, two in France, two in Greece, two in India, two in Turkey, one in Australia, one in Iran, one in Denmark, one in Finland, one in Israel, and one in Spain. Fifteen studies took place internationally, in between two and 15 countries. The studies were conducted in smoking cessation clinics, hospitals, universities and other research centres. </p> </section> <section id="CD006103-sec-0044"> <h6 class="title">Participants</h6> <p>Participants in the majority of trials were adult smokers, willing to make a quit attempt. Several trials were conducted in clinical subgroups, including hospital inpatients (<a href="./references#CD006103-bbs2-0009" title="BrinnM , DazielK , CarsonK , LabiszewskiN , EstermanA , SmithB . Cost effectiveness of an inpatient smoking cessation intervention for patients with tobacco related illnesses (Stop Trial): a multi-centre RCT [Abstract]. Respirology2013;18 Suppl 2:16 [O027]. [CENTRAL: 849080] [EMBASE: 71010964]CarsonK , BrinnM , PetersM , FitridgeR , KoblarS , JannesJ , et al. Superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 24-month randomised controlled trial for inpatients. Respirology2016;21 Suppl 2:45. CarsonK , SmithBJ , PetersMJ , VealeAJ , EstermanAJ . Superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: A 24-month randomized controlled trial for inpatients. Respirology2015;20 Suppl 3:115. CarsonK , SmithBJ , PetersMJ , VealeAJ , EstermanAJ . Superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 24-month randomized controlled trial for inpatients. Respirology2015;20:115. CarsonKV , BrinnMP , SmithBJ , GarsideCG , GoldsworthySJ , FitridgeRA . Varenicline tartrate and counselling versus counselling alone in a randomised controlled trial for inpatient smoking cessation: 3 month interim results [Abstract]. Respirology2010;15 Suppl 1:A30. CarsonKV , SmithBJ , BrinnMP , PetersMJ , FitridgeR , KoblarSA , et al. Safety of varenicline tartrate and counseling versus counseling alone for smoking cessation: a randomized controlled trial for inpatients (STOP study). Nicotine &amp; Tobacco Research2014;16(11):1495-502. [CENTRAL: 1036725] [EMBASE: 2014920189] [PMID: 25031315]Carson-ChahhoudKV , SmithBJ , PetersMJ , BrinnMP , AmeerF , SinghK , et al. Two-year efficacy of varenicline tartrate and counselling for inpatient smoking cessation (STOP study): a randomized controlled clinical trial. PloS One2020;15(4):e0231095. HninK , CarsonK , BrinnM , JannesJ , AmeerF , EstermanA , et al. Triggers resulting in relapse: cohort analysis from the smoking termination opportunity for inpatients (STOP) trial [Abstract]. Respirology2014;19 Suppl 2:40 [TO 076]. [CENTRAL: 996495] [EMBASE: 71605471]SmithB , CarsonK , DalzielK , BrinnM , MoayeriF , ClarkeP , et al. Cost effectiveness of inpatient initiated varenicline tartrate (VT) plus counselling compared to counselling alone: 2 year follow-up of the Smoking Termination Opportunity for inPatients (STOP) study. European respiratory journal. Conference: European Respiratory Society Annual Congress 2016. United Kingdom2016;48:PA4600. SmithBJ , CarsonKV , BrinnMP , LabiszewskiNA , PetersMJ , FitridgeR , et al. Smoking termination opportunity for in patients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial for inpatients. Thorax2013;68(5):485-6. [CENTRAL: 849081] [EMBASE: 2013242202] [NCT01141855/ClinicalTrials.gov] [PMID: 22993168]SmithBJ , PetersMJ , FitridgeRA , EstermanAJ , LittJC , HorowitzJD , et al. Varenicline tartrate and counselling versus counselling alone in a randomised controlled trial for inpatient smoking cessation: 6 month interim results. Conference: American Thoracic Society 2011 International Conference, May 13-182011. ">Carson‐Chahhoud 2020</a>; <a href="./references#CD006103-bbs2-0026" title="HongH , WangW , ChenL . Study on effect of 5A intervention method combined with varenicline for smoking cessation of COPD patients in stable stage. Chinese Nursing Research2015;29(2C):667-70. ">Hong 2015</a>; <a href="./references#CD006103-bbs2-0034" title="Le MaoR , TromeurC , PaleironN , SanchezO , GagnadouxF , JouneauS , et al. Effect of early initiation of varenicline on smoking cessation in COPD patients admitted for exacerbation: the save randomized clinical trial. COPD2020;17(1):7-14. NCT01694732. Efficacy of varenicline associated with intensive counselling versus placebo of varenicline associated with intensive counselling on smoking cessation at the acute phase of an exacerbation of chronic obstructive pulmonary disease (COPD). A multicenter randomized double-blind trial. ClinicalTrials.gov/show/NCT01694732 (first received 27 September 2012). TromeurC , Le MaoR , CouturandF . Effect of varenicline on smoking cessation in COPD patients recovering from exacerbation: a randomized trial. Fundamental &amp; Clinical Pharmacology2018;32 Suppl 1:32. ">Le Mao 2020</a>; <a href="./references#CD006103-bbs2-0054" title="SteinbergMB , RandallJ , GreenhausS , SchmelzerAC , RichardsonDL , CarsonJL . Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline. Addictive Behaviors2011;36(12):1127-32. ">Steinberg 2011</a>; <a href="./references#CD006103-bbs2-0070" title="DehghaniP , HabibB , WindleSB , RoyN , OldW , GrondinFR , et al. Smokers and postcessation weight gain after acute coronary syndrome. Journal of the American Heart Association2017;6(4):e004785. EisenbergMJ , WindleSB , RoyN , OldW , GrondinF , BataI , et al. Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. Circulation2016;133(1):21-30. NCT00794573. Evaluation of varenicline (Champix) in smoking cessation for patients post-acute coronary syndrome (EVITA) trial (EVITA). clinicaltrials.gov/ct2/show/NCT00794573 (first received 20 November 2008). WindleSB , BataI , MadanM , AbramsonBL , EisenbergMJ . A randomized controlled trial of the efficacy and safety of varenicline for smoking cessation after acute coronary syndrome: design and methods of the Evaluation of Varenicline in Smoking Cessation for Patients Post-Acute Coronary Syndrome trial. American Heart Journal2015;170(4):635-40. WindleSB , DehghaniP , RoyN , OldW , GrondinFR , BataI , et al. Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital. CMAJ : Canadian Medical Association Journal2018;190(12):E347-54. WindleSB , DehghaniP , RoyN , OldWD , GrondinFR , BataI , et al. Sustained smoking abstinence 12 months after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in hospitalized patients. Canadian Journal of Cardiology. Conference: 69th Annual Meeting of the Canadian Cardiovascular Society. Canada.2016;10 Suppl 1:S109-10. ">Windle 2018</a>; <a href="./references#CD006103-bbs2-0071" title="NCT00937508. Smoking cessation program in the pre-admission clinic. clinicaltrials.gov/ct2/show/NCT00937508 (first received 13 July 2009). WongJ , AbrishamiA , YangY , ZakiA , FriedmanZ , SelbyP , et al. A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial. Anesthesiology2012;117(4):755-64. [CENTRAL: 835869] [EMBASE: 2012567287] [PMID: 22890119]">Wong 2012</a>), and disease‐specific patient groups: cardiovascular disease (<a href="./references#CD006103-bbs2-0048" title="OckeneI , Salmoirago-BlotcherE . Varenicline for smoking cessation in patients with coronary heart disease [editorial]. Circulation2010;121(2):188-90. RigottiN , PipeA , BenowitzN , ArteagaC , GarzaD , TonstadS , et al. A randomized trial of varenicline for smoking cessation in patients with cardiovascular disease: analysis of efficacy by baseline characteristics. Circulation2010;Conference:2. RigottiNA , PipeAL , BenowitzNL , ArteagaC , GarzaD , TonstadS . Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease. Circulation2010;121(2):221-9. RigottiNA , PipeAL , BenowitzNL , ArteagaC , GarzaD , TonstadS . Response to letter regarding article, efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation2010;122(9):e446. ">Rigotti 2010</a>; <a href="./references#CD006103-bbs2-0070" title="DehghaniP , HabibB , WindleSB , RoyN , OldW , GrondinFR , et al. Smokers and postcessation weight gain after acute coronary syndrome. Journal of the American Heart Association2017;6(4):e004785. EisenbergMJ , WindleSB , RoyN , OldW , GrondinF , BataI , et al. Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. Circulation2016;133(1):21-30. NCT00794573. Evaluation of varenicline (Champix) in smoking cessation for patients post-acute coronary syndrome (EVITA) trial (EVITA). clinicaltrials.gov/ct2/show/NCT00794573 (first received 20 November 2008). WindleSB , BataI , MadanM , AbramsonBL , EisenbergMJ . A randomized controlled trial of the efficacy and safety of varenicline for smoking cessation after acute coronary syndrome: design and methods of the Evaluation of Varenicline in Smoking Cessation for Patients Post-Acute Coronary Syndrome trial. American Heart Journal2015;170(4):635-40. WindleSB , DehghaniP , RoyN , OldW , GrondinFR , BataI , et al. Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital. CMAJ : Canadian Medical Association Journal2018;190(12):E347-54. WindleSB , DehghaniP , RoyN , OldWD , GrondinFR , BataI , et al. Sustained smoking abstinence 12 months after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in hospitalized patients. Canadian Journal of Cardiology. Conference: 69th Annual Meeting of the Canadian Cardiovascular Society. Canada.2016;10 Suppl 1:S109-10. ">Windle 2018</a>); chronic obstructive pulmonary disease (<a href="./references#CD006103-bbs2-0026" title="HongH , WangW , ChenL . Study on effect of 5A intervention method combined with varenicline for smoking cessation of COPD patients in stable stage. Chinese Nursing Research2015;29(2C):667-70. ">Hong 2015</a>; <a href="./references#CD006103-bbs2-0034" title="Le MaoR , TromeurC , PaleironN , SanchezO , GagnadouxF , JouneauS , et al. Effect of early initiation of varenicline on smoking cessation in COPD patients admitted for exacerbation: the save randomized clinical trial. COPD2020;17(1):7-14. NCT01694732. Efficacy of varenicline associated with intensive counselling versus placebo of varenicline associated with intensive counselling on smoking cessation at the acute phase of an exacerbation of chronic obstructive pulmonary disease (COPD). A multicenter randomized double-blind trial. ClinicalTrials.gov/show/NCT01694732 (first received 27 September 2012). TromeurC , Le MaoR , CouturandF . Effect of varenicline on smoking cessation in COPD patients recovering from exacerbation: a randomized trial. Fundamental &amp; Clinical Pharmacology2018;32 Suppl 1:32. ">Le Mao 2020</a>; <a href="./references#CD006103-bbs2-0056" title="AntoniuSA , TroforAC . Varenicline for smoking cessation intervention in chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2011;12(16):2595-7. KotzD , Van SchayckOC . What justifies a placebo-controlled trial of varenicline for smoking cessation in patients with COPD? [comment]. Chest2011;139:968-9. TashkinDP , RennardS , HaysJT , MaW , LawrenceD , LeeTC . Effects of varenicline on smoking cessation in mild-to-moderate COPD: a randomized controlled trial. Chest2011;139:591-9. TashkinDP , RennardS , Taylor HaysJ , LawrenceD , MartonJP , LeeTC . Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine2011;105(11):1682-90. [CENTRAL: 811557] [6378] [PMID: 21621992]">Tashkin 2011</a>; <a href="./references#CD006103-bbs2-0072" title="YangDX , GuCJ , NiL , LiN , LiQY , ZhouJP . Assessment of efficacy of medication combined with WeChat platform for quitting smoking in patients with chronic obstructive pulmonary disease. Journal of Shanghai Jiaotong University (Medical Science)2016;36(3):385-9. ">Yang 2016</a>); HIV (<a href="./references#CD006103-bbs2-0002" title="AshareRL , ThompsonM , SerranoK , LeoneF , MetzgerD , FrankI , et al. Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV. Drug and Alcohol Dependence2019;200:26-33. AshareRL , WileytoEP , Logue-ChamberlainE , GrossR , TyndaleRF , LermanC , et al. Patterns of lapses and recoveries during a quit attempt using varenicline and behavioral counseling among smokers with and without HIV. Psychology of Addictive Behaviors2021;35(7):788-96. BauerAM , Hosie QuinnM , LubitzSF , FlitterA , AshareRL , LeoneFT , et al. Medication adherence and rate of nicotine metabolism are associated with response to treatment with varenicline among smokers with HIV. Addictive Behaviors2021;112:106638. LubitzSF , FlitterA , AshareRL , ThompsonM , LeoneF , GrossR , et al. Improved clinical outcomes among persons with HIV who quit smoking. AIDS Care2020;32(10):1217-23. NCT01710137. A placebo controlled trial of varenicline for smoking among those with HIV/AIDS. ClinicalTrials.gov/show/NCT01710137 (first received 6 October 2019). QuinnMH , BauerAM , FlitterA , LubitzSF , AshareRL , ThompsonM , et al. Correlates of varenicline adherence among smokers with HIV and its association with smoking cessation. Addictive Behaviors2020;102:106151. ThompsonM , SchnollR , SerranoK , LeoneF , GrossR , Collman RG , et al. The effect of varenicline on mood and cognition in smokers with HIV. Psychopharmacology2020;237(4):1223-31. ">Ashare 2019</a>; <a href="./references#CD006103-bbs2-0037" title="MercieP , ArsandauxJ , KatlamaC , FerretS , BeuscartA , SpadoneC , et al. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial. Lancet HIV2018;5(3):e126-35. MercieP , RoussillonC , KatlamaC , BeuscartA , FerretS , WirthN , et al. Varenicline vs placebo for smoking cessation: ANRS 144 Inter-ACTIV randomized trial. Topics in Antiviral Medicine2015;23:56-7. NCT00918307. Efficacy and safety of varenicline amongst HIV-infected patients (Inter-ACTIV). ClinicalTrials.gov/show/NCT00918307 (first received 11 June 2009). ">Mercie 2018</a>); asthma (<a href="./references#CD006103-bbs2-0067" title="WestergaardCG , PorsbjergC , BackerV . The effect of smoking cessation on airway inflammation in young asthma patients. Clinical &amp; Experimental Allergy2013;44:353-61. WestergaardCG , PorsbjergC , BackerV . The effect of varenicline on smoking cessation in a group of young asthma patients. American Journal of Respiratory and Critical Care Medicine2014;189:A1091. WestergaardCG , PorsbjergC , BackerV . The effect of varenicline on smoking cessation in a group of young asthma patients. Respiratory Medicine2015;109(11):1416-22. [DOI: 10.1016/j.rmed.2015.07.017]">Westergaard 2015</a>); substance use disorder (<a href="./references#CD006103-bbs2-0038" title="GriffinJL , SegalKS , NahviS . Barriers to telephone quitline use among methadone-maintained smokers. Nicotine &amp; Tobacco Research2015;17(8):931-6. NCT01027754. Smoking cessation treatment for methadone maintenance patients. clinicaltrials.gov/ct2/show/NCT01027754 (first received 9 December 2009). [ClinicalTrials.gov ID NCT01027754]NahviS , NingY , SegalKS , RichterKP , ArnstenJH . Varenicline efficacy and safety among methadone maintained smokers: a randomized placebo-controlled trial. Addiction2014;109(9):1554-63. [CENTRAL: 997902] [PMID: 24862167]">Nahvi 2014a</a>; <a href="./references#CD006103-bbs2-0053" title="De DiosMA , AndersonBJ , CavinessCM , SteinMD . Early quit days among methadone-maintained smokers in a smoking cessation trial. Nicotine &amp; Tobacco Research2014;16(11):1463-9. [CENTRAL: 1042497] NCT00790569. Varenicline versus nicotine replacement for methadone-maintained smokers. https://clinicaltrials.gov/ct2/show/NCT00790569 (first received 13 November 2008). SteinMD , CavinessCM , KurthME , AudetD , OlsonJ , AndersonBJ . Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. Drug and Alcohol Dependence2013;133(2):486-93. [CENTRAL: 870955] [EMBASE: 2013694276] [PMID: 23953658]">Stein 2013</a>); alcohol dependence (<a href="./references#CD006103-bbs2-0027" title="HurtRT , EbbertJO , CroghanIT , SchroederDR , HurtRD , HaysJT . Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: a randomized controlled trial. Drug and Alcohol Dependence2018;184:12-7. NCT01347112. Varenicline treatment for active alcoholic smokers. clinicaltrials.gov/ct2/show/NCT01347112 (first received 4 May 2011). ">Hurt 2018</a>; <a href="./references#CD006103-bbs2-0043" title="BoldKW , ZwebenA , FucitoLM , PiepmeierME , MuvvalaS , WuR , et al. Longitudinal findings from a randomized clinical trial of varenicline for alcohol use disorder with comorbid cigarette smoking. Alcoholism, Clinical and Experimental Research2019;43(5):937-44. NCT01553136. 1/2-multi-site study: varenicline treatment of alcohol dependent smokers. ClinicalTrials.gov/show/NCT01553136 (first received 13 March 2012). O'MalleySS , ZwebenA , FucitoLM , WuR , PiepmeierME , OckertDM , et al. Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: a randomized clinical trial. JAMA Psychiatry2018;75(2):129-38. ">O'Malley 2018</a>; <a href="./references#CD006103-bbs2-0073" title="NCT01286584. Varenicline in residential treatment (ViRT). clinicaltrials.gov/ct2/show/NCT01286584 (first received 31 January 2011). ZawertailoL , IvanovaA , NgG , Le FollB , SelbyP . Safety and efficacy of varenicline for smoking cessation in alcohol-dependent smokers in concurrent treatment for alcohol use disorder: a pilot, randomized placebo-controlled trial. Journal of Clinical Psychopharmacology2020;40(2):130-6. ">Zawertailo 2020</a>); depression (<a href="./references#CD006103-bbs2-0001" title="AnthenelliRM , MorrisC , RameyTS , DubravaSJ , TsilkosK , RussC , et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Annals of Internal Medicine2013;159(6):390-400. [CENTRAL: 921009] [EMBASE: 2013581859] [PMID: 24042367]DoranN , DubravaS , AnthenelliRM . Effects of varenicline, depressive symptoms, and region of enrollment on smoking cessation in depressed smokers. Nicotine &amp; Tobacco Research2018;21(2):156-62. NCT01078298. Safety and efficacy of 12 weeks of varenicline for smoking cessation in smokers with depression. clinicaltrials.gov/ct2/show/NCT01078298 (first received 2 March 2010). [ClinicalTrials.gov ID NCT01078298]">Anthenelli 2013</a>; <a href="./references#CD006103-bbs2-0013" title="CinciripiniPM , MinnixJA , GreenCE , RobinsonJD , EngelmannJM , VersaceF , et al. An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. Addiction2018;113(9):1673-82. NCT00943618. Combining varenicline and bupropion for smoking cessation. ClinicalTrials.gov/ct2/NCT00943618 (first received 22 July 2009). ">Cinciripini 2018</a>); and bipolar/schizophrenia, schizoaffective disorder (<a href="./references#CD006103-bbs2-0011" title="ChengappaKN , PerkinsKA , BrarJS , SchlichtPJ , TurkinSR , HetrickML , et al. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2014;75(7):765-72. [CENTRAL: 1014641] ChengappaKN . A randomized, double-blind, placebo-controlled clinical trial of varenicline in persons with bipolar disorder motivated to quit smoking. Bipolar Disorders2015;17:38. ForrestPE , BrinsonAJ , GannonJM , GeorgeTP , PerkinsKA , ChengappaKN . An association between the use of hypnotics and quit status in the treatment of nicotine dependence with varenicline in bipolar disorder. Journal of Clinical Psychopharmacology2015;35(2):199-200. NCT01010204. Varenicline treatment for smoking cessation in patients with bipolar disorder (BEST). clinicaltrials.gov/ct2/show/NCT01010204 (first received 9 November 2009). [ClinicalTrials.gov ID NCT01010204]">Chengappa 2014</a>; <a href="./references#CD006103-bbs2-0069" title="NCT00644969. Smoking cessation study for patients with schizophrenia or schizoaffective disorder. clinicaltrials.gov/ct2/show/NCT00644969 (first received 27 March 2008). WilliamsJM , AnthenelliRM , MorrisCD , TreadowJ , ThompsonJR , YunisC , et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry2012;73(5):654-60. [CENTRAL: 836870] [EMBASE: 2012321245] [PMID: 22697191]">Williams 2012</a>). <a href="./references#CD006103-bbs2-0018" title="AnthenelliR , BenowitzN , WestR , St AubinL , McRaeT , LawrenceD , et al. Reports of suicidal ideation and behavior in the EAGLES trial. Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March2016;SYM5D:8. AnthenelliRM , BenowitzNL , WestR , St AubinL , McRaeT , LawrenceD , et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet2016;387(10037):2507-20. [DOI: dx.doi.org/10.1016/S0140-6736(16)30272-0]AnthenelliRM , GaffneyM , BenowitzNL , WestR , McRaeT , RussC , et al. Predictors of neuropsychiatric adverse events with smoking cessation medications in the randomized controlled EAGLES trial. Journal of General Internal Medicine2019;34(6):862-70. AyersCR , HeffnerJL , RussC , LawrenceD , McRaeT , EvinsAE , et al. Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: subgroup analysis of the randomized, active- and placebo-controlled EAGLES trial. Depression and Anxiety2020;37(3):247-60. BakerCL , PietriG . A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial. ClinicoEconomics and outcomes research2018;10:67-74. BeardE , JacksonSE , AnthenelliRM , BenowitzNL , AubinLS , McRaeT , et al. Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors. Addiction (Abingdon, England)2021;116(10):2816-24. BenowitzN , EvinsAE , WestR , St AubinL , McRaeT , LawrenceD , et al. EAGLES trial: study design and neuropsychiatric safety results. In: Society for Research on Nicotine and Tobacco, USA 3rd - 5th March. Vol. SYM5B. 2016:7. BenowitzNL , PipeA , WestR , HaysJT , TonstadS , McRaeT , et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Internal Medicine2018;178(5):622-31. CorreaJB , LawrenceD , McKennaBS , GaznickN , SacconePA , DubravaS , et al. Psychiatric co-morbidity and multi-morbidity in the EAGLES trial: descriptive correlates and associations with neuropsychiatric adverse events, treatment adherence, and smoking cessation. Nicotine &amp; Tobacco Research2021;23(10):1636-55. EbbertJ , Jimenez-RuizC , Dutro MP , FisherM , LiJ , Hays JT . Frequently reported adverse events with smoking cessation medications: post hoc analysis of a randomized trial. Mayo Clinic Proceedings2021;96(7):1801-11. EvinsAE , BenowitzNL , WestR , RussC , McRaeT , LawrenceD , et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, anxiety, and mood disorders in the EAGLES trial. Journal of Clinical Psychopharmacology2019;39(2):108-16. EvinsAE , WestR , BenowitzNL , RussC , LawrenceD , McRaeT , et al. Efficacy and safety of pharmacotherapeutic smoking cessation aids in schizophrenia spectrum disorders: subgroup analysis of EAGLES. Psychiatric Services (Washington, D.C.)2021;72(1):7-15. HeffnerJL , EvinsAE , RussC , LawrenceD , AyersCR , McRaeT , et al. Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: subgroup analysis of a randomized clinical trial. Journal of Affective Disorders2019;256:267-77. NCT01456936. A phase 4, randomized, double blind, active and placebo controlled multicenter study evaluating the neuropsychiatric safety and efficacy of 12 weeks varenicline tartrate 1mg BID and bupropion hydrochloride 150 mg BID for smoking cessation in subjects with and without a history of psychiatric disorders [EAGLES]. clinicaltrials.gov/ct2/show/NCT01456936 (first received 21 October 2011). NollenNL , AhluwaliaJS , Sanderson CoxL , OkuyemiK , LawrenceD , SamuelsL , et al. Assessment of racial differences in pharmacotherapy efficacy for smoking cessation: secondary analysis of the EAGLES randomized clinical trial. JAMA Network Open2021;4(1):e2032053. ProchaskaJ , BenowitzN , WestR , AnthenelliR . Evaluating adverse events in a global smoking cessation study (EAGLES): a randomized controlled trial comparing the safety and efficacy of the first-line smoking cessation aids in smokers with and without psychiatric disorders. Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March2016;SYM5:7. ProchaskaJ . Neuropsychiatric risk concerns in the context of smoking, quitting, and cessation pharmacotherapy use. Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March2016;SYM5A:7. WestR , BenowitzN , EvinsAE , St AubinL , McRaeT , LawrenceD , et al. Relative efficacy of varenicline, bupropion SR, and nicotine transdermal patch in aiding smoking cessation in the EAGLES trial. Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March2016;SYM5C:8. WestR , EvinsAE , BenowitzNL , RussC , McRaeT , LawrenceD , et al. Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. Addiction2018;113(8):1507-16. WilcoxC , OskooilarN , GuevarraK , Linh TongM , GroszD , MorrisseyJ , et al. A double-blind, active-and placebo-controlled evaluation of the neuropsychiatric safety and efficacy of varenicline and bupropion for smoking cessation in subjects with (pre-existing) psychiatric disorders: an objective blinded analysis. Neuropsychopharmacology2015;40:S260. ">EAGLES 2016</a> enrolled two cohorts of adult smokers with and without histories of psychiatric disorders, including primary affective disorders (70%), anxiety disorders (19%), psychotic disorders (9.5%) and personality disorders (0.6%). <a href="./references#CD006103-bbs2-0023" title="GonzalesD , HajekP , PliammL , NackaertsK , Tseng L-J, McRaeTD , et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. Clinical Pharmacology and Therapeutics2014;96(3):390-6. [CENTRAL: 1014162] [EMBASE: 2014565570] [PMID: 24911368]NCT01244061. A multi-national study to assess how effective and safe the smoking cessation medicine varenicline is in smokers who have already tried varenicline in the past as a prescription medicine from their usual healthcare provider. clinicaltrials.gov/ct2/show/NCT01244061 (first received 19th November 2010). [ClinicalTrials.gov ID NCT01244061]">Gonzales 2014</a> recruited people who had previously used varenicline in an unsuccessful quit attempt. <a href="./references#CD006103-bbs2-0016" title="De DiosMA , AndersonBJ , StantonC , AudetDA , SteinM . Project Impact: a pharmacotherapy pilot trial investigating the abstinence and treatment adherence of Latino light smokers. Journal of Substance Abuse Treatment2012;43(3):322-30. [CENTRAL: 836798] [EMBASE: 2012562711] [PMID: 22377389]">De Dios 2012</a> and <a href="./references#CD006103-bbs2-0020" title="EbbertJO , CroghanIT , HurtRT , SchroederDR , HaysJT . Varenicline for smoking cessation in light smokers. Nicotine &amp; Tobacco Research2016;18(10):2031-5. ">Ebbert 2016</a> tested varenicline in light smokers. </p> </section> <section id="CD006103-sec-0045"> <h6 class="title">Interventions</h6> <p>Forty‐seven trials used the standard 12‐week regimen of varenicline, routinely titrating the first week up to the recommended daily dose of 1 mg twice a day. <a href="./references#CD006103-bbs2-0039" title="FagerströmK , NakamuraM , ChoH , TsaS , WangC , DaviesS , et al. Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries. Current Medical Research &amp; Opinion2010;26(9):2165-73. IgarashiA , TakumaH , FukadaT , TsutaniK . Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. Pharmacoeconomics2009;27(3):247-61. NakamuraM , OshimaA , FujimotoY , MaruyamaN , IshibashiT , ReevesKR . Efficacy and tolerability of nicotinic varenicline, an alpha4beta2 acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clinical Therapeutics2007;29(6):1040-56. [CENTRAL: 611262] [EMBASE: 2007380498] [PMID: 17692720]NakamuraM , OshimaA , OhkuraM , ArteagaC , SuwaK . Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in Japanese smokers. Clinical Therapeutics2014;36(6):918-27. [CENTRAL: 995377] [EMBASE: 2014542011]">Nakamura 2007</a>, <a href="./references#CD006103-bbs2-0042" title="NidesM , GloverED , ReusVI , ChristenAG , MakeBJ , BillingCB , et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. American Journal of Health Behavior2008;32(6):664-75. NidesM , OnckenC , GonzalezD , RennardS , WatskyEJ , AnzianoR , et al. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist. Archives of Internal Medicine2006;166:1561-8. OnckenC , WatskyE , ReevesK , AnzianoR . Varenicline is efficacious and well tolerated in promoting smoking cessation: results from a 7-week, randomized, placebo- and bupropion-controlled trial [POS1-047]. Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic2005. ">Nides 2006</a> and <a href="./references#CD006103-bbs2-0044" title="OnckenC , GonzalesD , NidesM , RennardS , WatskyE , BillingCB , et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine2006;166(15):1571-7. [CENTRAL: 567305] [EMBASE: 2006391945] [PMID: 16908789]OnckenC , WatskyE , ReevesK , AnzianoR . Smoking cessation with varenicline, a selective nicotinic receptor partial agonist: results from a phase 2 study [POS1-046]. Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic2005. ">Oncken 2006</a> tested 1 mg per day, and <a href="./references#CD006103-bbs2-0041" title="NiauraR , Taylor HaysJ , JorenbyDE , LeoneFT , PappasJE , ReevesKR , et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Current Medical Research and Opinion2008;24(7):1931-41. [clinicaltrials.gov ID: NCT00150228]">Niaura 2008</a> allowed participants to regulate their own dosage throughout the treatment phase. <a href="./references#CD006103-bbs2-0019" title="BastianH . Comment on Ebbert 2015 'Reduce to Quit' trial. www.ncbi.nlm.nih.gov/pubmed/?term=25688780 Feb 18 2015 (accessed 11 June 2015). EbbertJO , HughesJR , WestRJ , RennardSI , RussC , McRaeTD , et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA2015;313(7):687-94. [CENTRAL: 1050651] [PMID: 25688780]EbbertJO , HughesJR , WestRJ . Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. Journal of Vascular Surgery2015;313(7):687-94. NCT01370356. A study to evaluate the efficacy and safety of varenicline compared to placebo for smoking cessation through reduction. clinicaltrials.gov/ct2/show/NCT01370356 (first received 9 June 2011). [ClinicalTrials.gov ID NCT01370356]NakamuraM , AbeM , OhkuraM , TreadowJ , YuCR , ParkPW . Efficacy of varenicline for cigarette reduction before quitting in Japanese smokers: a subpopulation analysis of the reduce to quit trial. Clinical Therapeutics2017;39(4):863-72. WilcoxC , GroszD , Tong ML , MorrisseyJ , De FranciscoD , GuevarraK , et al. Smoking cessation through reduction: does it enhance or diminish successful quitting?Neuropsychopharmacology2014;39:S343-4. ">Ebbert 2015</a> and <a href="./references#CD006103-bbs2-0053" title="De DiosMA , AndersonBJ , CavinessCM , SteinMD . Early quit days among methadone-maintained smokers in a smoking cessation trial. Nicotine &amp; Tobacco Research2014;16(11):1463-9. [CENTRAL: 1042497] NCT00790569. Varenicline versus nicotine replacement for methadone-maintained smokers. https://clinicaltrials.gov/ct2/show/NCT00790569 (first received 13 November 2008). SteinMD , CavinessCM , KurthME , AudetD , OlsonJ , AndersonBJ . Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. Drug and Alcohol Dependence2013;133(2):486-93. [CENTRAL: 870955] [EMBASE: 2013694276] [PMID: 23953658]">Stein 2013</a> tested a 24‐week regimen, and <a href="./references#CD006103-bbs2-0068" title="ReevesK , WatskyE , WilliamsK , AzoulayS , BillingB , GongJ . The safety of varenicline taken for 52 weeks for smoking cessation [RPOS3-54]. Society for Research on Nicotine and Tobacco 12th Annual Conference Orlando Fla, USA2006. SpanglerJG , WilliamsKE , ReevesKR , BillingCB , PenningtonAM , GongJ . Comment and reply: a double-blind study evaluating the long-term safety of varenicline for smoking cessation. Current Medical Research and Opinion2008;24(2):577-9. WilliamsKE , ReevesKR , BillingCB , PenningtonAM , GongJ . A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Current Medical Research and Opinion2007;23(4):793-801. ">Williams 2007</a> tested 52 weeks. </p> </section> <section id="CD006103-sec-0046"> <h6 class="title">Comparators</h6> <p>Forty‐five studies compared varenicline with placebo and five with no medication. Of the 14 studies that compared varenicline with NRT, 12 randomised participants to receive single‐form NRT and five to a combination of two or more forms of NRT (3 studies tested varenicline against both NRT monotherapy and combination NRT). Ten studies compared varenicline with bupropion. </p> <p>Seven studies compared standard varenicline with either a lower dose (4 studies) or a longer duration (3 studies). </p> </section> <section id="CD006103-sec-0047"> <h6 class="title">Outcomes</h6> <p>All studies measured smoking cessation at least six months after study baseline. Follow‐up lengths ranged from six months to two years. Many studies biochemically validated abstinence using either exhaled carbon monoxide, or salivary or urinary cotinine. </p> <p>Thirty‐eight studies measured adverse events, including nausea, insomnia, abnormal dreams, headache, depression, and suicidal ideation. Twenty‐eight measured serious adverse events, neuropsychiatric serious adverse events and cardiac serious adverse events. </p> </section> </section> <section id="CD006103-sec-0048"> <h5 class="title">Dianicline</h5> <p>One trial investigated dianicline. It was set in 22 sites across six European countries (<a href="./references#CD006103-bbs2-0057" title="TonstadS , HolmeI , TønnesenP . Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial. Nicotine &amp; Tobacco Research2011;13(1):1-6. ">Tonstad 2011</a>). Dianicline was administered as a 40 mg tablet twice a day for seven weeks, with brief counselling at each contact. Final follow‐up of the participants was at 26 weeks, with self‐reported abstinence verified by expired carbon monoxide and by plasma cotinine samples. </p> </section> <section id="CD006103-sec-0049"> <h5 class="title">Study funding</h5> <p>Of the trials included in this review, 35 received funds from pharmaceutical companies with interests in the treatment being tested, 13 received free study medications, and four trials without pharmaceutical support had authors who had received funds for other work. Fifteen studies reported no conflicts, and two did not report study funding or author declarations of interests. This is significant because a recent analysis found that authors of opinion pieces on varenicline who reported financial ties to the pharmaceutical industry (as a conflict of interest or funding source) were more likely to minimise the cardiovascular and psychiatric risk of varenicline compared to those without conflicts of interest or industry funding (odds ratio 4.00, 95% CI 1.32 to 12.16 for cardiovascular risk; odds ratio 8.51, 95% CI 3.79 to 19.11 for psychiatric risk; <a href="./references#CD006103-bbs2-0211" title="FabbriA , NejstgaardCH , GrundyQ , BeroL , DunnAG , MohammadA , et al. Association between conflicts of interest and authors’ positions on harms of varenicline: a cross-sectional analysis. Journal of General Internal Medicine2022;37(2):290-7.">Fabbri 2022</a>). </p> </section> </section> <section id="CD006103-sec-0050"> <h4 class="title">Excluded studies</h4> <p>We list 95 potentially eligible but ultimately excluded studies, along with reasons for exclusion, in the <a href="./references#CD006103-sec-0139" title="">Characteristics of excluded studies</a> tables. Common reasons for exclusion were following up with participants for less than six months, not randomising participants, testing an eligible intervention for an ineligible purpose (smoking reduction or alcohol dependence), or testing another intervention as an adjunct to an eligible one. </p> <p>For this update we excluded 14 studies that were included in the previous version of the review. <a href="./references#CD006103-bbs2-0087" title="CatherC , HoeppnerS , PachasG , PrattS , AchtyesE , CieslakKM , et al. Improved depressive symptoms in adults with schizophrenia during a smoking cessation attempt with varenicline and behavioral therapy. Journal of Dual Diagnosis2017;13(3):168-78. EvinsAE , CatherC , PrattSA , PachasGN , HoeppnerSS , GoffDC , et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA2014;311(2):145-54. [CENTRAL: 921056] [EMBASE: 2014041619] [PMID: 24399553]EvinsAE . Extended duration pharmacotherapy with varenicline prevents relapse to smoking in adult smokers with schizophrenia. Neuropsychopharmacology2013;38:S63-4. [CENTRAL: 993941] [EMBASE: 71278012]NCT00621777. A study of varenicline for prevention of relapse to smoking in patients with schizophrenia. clinicaltrials.gov/ct2/show/NCT00621777 (first received 22 February 2008). PachasGN , CatherC , PrattSI , HoeppnerB , NinoJ , CarliniSV , et al. Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week open-label trial. Journal of Dual Diagnosis2012;8(2):117-25. ThorndikeAN , AchtyesED , CatherC , PrattS , PachasGN , HoeppnerSS , et al. Weight gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with serious mental illness: a subgroup analysis of a randomized trial. Journal of Clinical Psychiatry2016;77(3):e320-6. ThorndikeAN , HoeppnerSS , CatherC , PachasGN , AchtyesED , EvinsAE . Weight gain and cardiovascular risk reduction associated with tobacco abstinence in smokers with serious mental illness. Circulation2015;131:AP008. ">Evins 2014</a>, <a href="./references#CD006103-bbs2-0167" title="BolinK , Mörk A-C, WilsonK . Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. Journal of Evaluation in Clinical Practice2009;15:478-85. HajekP , TønnesonP , ArteagaC , RussC , TonstadS . Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment. Addiction2009;104:1597-602. KnightC , HowardP , BakerCL , MartonJP . The cost-effectiveness of an extended course (12 + 12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value in Health2010;13(2):209-14. KnightCJ , HowardPA , BakerCL . An evaluation of the cost-effectiveness of an extended course of varenicline in preventing smokers who have quit from relapsing [PSM3]. Value in Health2007;10(6):A472. LeeJH , JonesPG , BybeeK , O'KeefeJH . A longer course of varenicline therapy improves smoking cessation rates. Preventive Cardiology2008;11(4):210-4. O'BrienCP . Varenicline as maintenance therapy. Current Psychiatry Reports2007;9(5):348-8. TonstadS , TønnesenP , HajekP , WilliamsKE , BillingCB , ReevesKR . Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA2006;296(1):64-71. [clinicaltrials.gov ID: NCT00143286]">Tonstad 2006</a>, <a href="./references#CD006103-bbs2-0168" title="NCT00977249. Varenicline for long-term NRT users. clinicaltrials.gov/ct2/show/NCT00977249 (first received 15 September 2009). TønnesenP , MikkelsenK . Varenicline to stop long-term nicotine replacement use: a double-blind, randomized, placebo-controlled trial. Nicotine &amp; Tobacco Research2013;15(2):419-27. [CENTRAL: 861602] [EMBASE: 2013064611] [PMID: 23024246]">Tønnesen 2013</a>, and <a href="./references#CD006103-bbs2-0131" title="NCT00828113. Long-term varenicline treatment for smoking cessation. clinicaltrials.gov/ct2/show/NCT00828113 (first received 23 January 2009). ">NCT00828113</a> recruited already abstinent participants and tested varenicline for relapse prevention, a topic covered in a different Cochrane Review (<a href="./references#CD006103-bbs2-0224" title="Livingstone-BanksJ , NorrisE , Hartmann-BoyceJ , WestR , JarvisM , ChubbE , et al. Relapse prevention interventions for smoking cessation. Cochrane Database of Systematic Reviews2019, Issue 10. Art. No: CD003999. [DOI: 10.1002/14651858.CD003999.pub5]">Livingstone‐Banks 2019</a>). We excluded <a href="./references#CD006103-bbs2-0102" title="HajekP , McRobbieH , Myers SmithK , PhillipsA , CornwallD , DhanjiAR . Erratum: increasing varenicline dose in smokers WHO do not respond to the standard dosage: a randomized clinical trial (JAMA internal medicine (2015) 175: 2 (266-271)). JAMA Internal Medicine2016;176(1):143. HajekP , McRobbieH , Myers SmithK , PhillipsA , CornwallD , DhanjiAR . Increasing varenicline dose in smokers who do not respond to the standard dosage: a randomized clinical trial. JAMA Internal Medicine2015;175(2):266-71. [CENTRAL: 1047635] [EMBASE: 2015718793] [PMID: 25545858]">Hajek 2015</a> because follow‐up was under six months. <a href="./references#CD006103-bbs2-0076" title="BrandonTH , DrobesDJ , UnrodM , HeckmanBW , OliverJA , RoetzheimRC , et al. Varenicline effects on craving, cue reactivity, and smoking reward. Psychopharmacology2011;218(2):391-403. ">Brandon 2011</a>, <a href="./references#CD006103-bbs2-0085" title="EbbertJO , CroghanIT , NorthF , SchroederDR . A pilot study to assess smokeless tobacco use reduction with varenicline. Nicotine &amp; Tobacco Research2011;13(9):820-6. ">Ebbert 2011b</a>, <a href="./references#CD006103-bbs2-0088" title="FaesselH , RavvaP , WilliamsK . Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics2009;31:177-89. [clinicaltrials.gov ID: NCT00463918]">Faessel 2009</a>, <a href="./references#CD006103-bbs2-0089" title="FagerströmK , GilljamH , MetcalfeM , TonstadS , MessigM . Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ2010;341:c6549. [DOI: 10.1136/bmjc6549]">Fagerström 2010</a>, <a href="./references#CD006103-bbs2-0097" title="GarzaD , MurphyM , Tseng L-J, RiordanHJ , ChatterjeeA . A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biological Psychiatry2011;69:1075-82. ">Garza 2011</a>, <a href="./references#CD006103-bbs2-0109" title="HughesJR , RennardSI , FingarJR , TalbotSK , CallasPW , FagerströmKO . Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial. Nicotine &amp; Tobacco Research2011;13(10):955-64. NCT00595868. Efficacy of varenicline in ambivalent smokers. ClinicalTrials.gov/ct2/show/NCT00595868 2007 (accessed 2 January 2016). ">Hughes 2011</a>, <a href="./references#CD006103-bbs2-0118" title="McClureEA , VandreyRG , JohnsonMW , StitzerML . Effects of varenicline on abstinence and smoking reward following a programmed lapse. Nicotine &amp; Tobacco Research2013;15(1):139-48. [CENTRAL: 873078] [EMBASE: 2012756138] [PMID: 22573730]NCT00944554. Varenicline for relapse prevention. ClinicalTrials.gov/ct2/ 2009 (accessed 2 November 2010). ">McClure 2013</a>, <a href="./references#CD006103-bbs2-0121" title="MeszarosZS , Abdul-MalakY , DimmockJA , WangD , AjagbeTO , BatkiSL . Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. Journal of Clinical Psychopharmacology2013;33(2):243-7. [CENTRAL: 908808] [EMBASE: 2013155799] [PMID: 23422399]MeszarosZS , Abdul-MalakY , DimmockJA , WangD , BatkiSL . Varenicline treatment of alcohol and nicotine dependence in schizophrenia: problems encountered in a pilot trial. American Journal on Addictions / American Academy of Psychiatrists in Alcoholism and Addictions2012;21(4):393-4. [CENTRAL: 834600] [EMBASE: 70815316]NCT00727103. Varenicline treatment in alcohol and nicotine dependent patients with schizophrenia. clinicaltrials.gov/ct2/show/NCT00727103 (first received 1 August 2008). ">Meszaros 2013</a> and <a href="./references#CD006103-bbs2-0123" title="MitchellJM , TeagueCH , KayserAS , BartlettSE , FieldsHL . Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology2012;223(3):299-306. [CENTRAL: 845347] [PMID: 22547331]">Mitchell 2012</a> were previously included for data on harms only but did not meet all of our prespecified inclusion criteria. </p> <p>We did not find sufficient information to include or exclude two studies. These are listed in <a href="./references#CD006103-sec-0140" title="">Characteristics of studies awaiting classification</a>. </p> </section> <section id="CD006103-sec-0051"> <h4 class="title">Ongoing studies</h4> <p>We found 28 eligible ongoing studies, some with multiple relevant comparisons. Studies that tested varenicline compared it with placebo (11 studies), no medication (two studies), bupropion (one study), NRT (seven studies), e‐cigarettes (one study), and different doses or regimes of varenicline (six studies). Studies that tested cytisine compared it with placebo (two studies), varenicline (two studies), NRT (one study), and e‐cigarettes (one study). </p> <p>Studies were set in various populations and setting, including HIV (three studies), hospital and perioperative patients (three studies), cardiovascular disease (three studies), substance abuse (two studies), mental health (two studies), and single studies in lung cancer, diabetes, chronic obstructive pulmonary disease, adolescents, and e‐cigarette users who smoke. </p> <p>Further details of the ongoing studies are given in the <a href="./references#CD006103-sec-0141" title="">Characteristics of ongoing studies</a> tables. </p> </section> </section> <section id="CD006103-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, we judged 22 studies to be at low risk of bias (low risk of bias across all domains), 18 at high risk of bias (high risk of bias in at least one domain), and the remaining 35 at unclear risk of bias. Our judgements on the risks of bias of all the included studies are summarised in <a href="#CD006103-fig-0002">Figure 2</a> and <a href="#CD006103-fig-0003">Figure 3</a>, and reasons for the judgements are detailed in the <a href="./references#CD006103-sec-0138" title="">Characteristics of included studies</a> tables. </p> <div class="figure" id="CD006103-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD006103-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD006103-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD006103-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD006103-sec-0053"> <h4 class="title">Allocation</h4> <p>We separately assessed allocation bias resulting from randomisation sequence generation and from allocation concealment. We judged 29 studies to be at unclear risk of allocation bias as a result of insufficient information about randomisation sequence generation. The remaining studies were judged at low risk, with none deemed to be at high risk. </p> <p>We judged one study to be at high risk of allocation bias as a result of inadequate concealment of randomisation because that study's participant allocation was unblinded. We judged 34 studies to be at unclear risk because there was insufficient information to make a judgement. We judged the remaining studies to be at low risk. </p> </section> <section id="CD006103-sec-0054"> <h4 class="title">Blinding</h4> <p>We judged 10 studies to be at high risk of performance or detection bias because they were open‐label studies without blinding of participant allocation. We judged 13 studies to be at unclear risk because there was insufficient information to make a judgement. The remaining studies were deemed at low risk. </p> </section> <section id="CD006103-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>We judged five studies to be at high risk of attrition bias, four because of either high levels of attrition or highly differential attrition rates between study arms, and one that did not provide a baseline number of participants, and reported only those followed up at 12 months as a denominator (<a href="./references#CD006103-bbs2-0006" title="BenliAR , ErturhanS , OrucMA , KalpakciP , SunayD , DemirelY . A comparison of the efficacy of varenicline and bupropion and an evaluation of the effect of the medications in the context of the smoking cessation programme. Tobacco Induced Diseases2017;15(10):1-8. [DOI: 10.1186/s12971-017-0116-0]">Benli 2017</a>). We judged 20 studies to be at unclear risk because of insufficient reporting of follow‐up rates for us to make a judgement. The remaining studies were deemed at low risk. </p> </section> <section id="CD006103-sec-0056"> <h4 class="title">Selective reporting</h4> <p>We judged two studies to be at high risk of reporting bias. In <a href="./references#CD006103-bbs2-0039" title="FagerströmK , NakamuraM , ChoH , TsaS , WangC , DaviesS , et al. Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries. Current Medical Research &amp; Opinion2010;26(9):2165-73. IgarashiA , TakumaH , FukadaT , TsutaniK . Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. Pharmacoeconomics2009;27(3):247-61. NakamuraM , OshimaA , FujimotoY , MaruyamaN , IshibashiT , ReevesKR . Efficacy and tolerability of nicotinic varenicline, an alpha4beta2 acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clinical Therapeutics2007;29(6):1040-56. [CENTRAL: 611262] [EMBASE: 2007380498] [PMID: 17692720]NakamuraM , OshimaA , OhkuraM , ArteagaC , SuwaK . Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in Japanese smokers. Clinical Therapeutics2014;36(6):918-27. [CENTRAL: 995377] [EMBASE: 2014542011]">Nakamura 2007</a>, continuous abstinence rates for all participants were reported, but demographics, withdrawal and craving measures, and point‐prevalence abstinence were reported for the nicotine‐dependent subset of participants only. The trial registry entry for <a href="./references#CD006103-bbs2-0060" title="NCT01531049. Smoking cessation in young adults in Northern Finland. ClinicalTrials.gov/show/NCT01531049 (first received 10 February 2012). TuiskuA , SalmelaM , NieminenP , ToljamoT . Varenicline and nicotine patch therapies in young adults motivated to quit smoking: a randomized, placebo-controlled, prospective study. Basic &amp; Clinical Pharmacology &amp; Toxicology2016;119(1):78-84. ">Tuisku 2016</a> planned a 12‐month follow‐up, which was not reported in their results paper. However, it is possible that this may be reported in a subsequent paper. We judged 18 studies to be at unclear risk because there was insufficient information to make a judgement; typically because no protocol or trial registry entry was available. We judged the remaining studies to be at low risk. </p> </section> <section id="CD006103-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>We judged two studies to be at high risk of bias for other reasons. For <a href="./references#CD006103-bbs2-0029" title="IoakeimidisN , VlachopoulosC , GeorgakopoulosC , AbdelrasoulM , SklirosN , KatsiV , et al. Smoking cessation rates with varenicline and electronic cigarettes in relapsed smokers with a history of acute coronary syndrome. European Heart Journal2018;Suppl 1: European Society of Cardiology Congress, ESC 2018. Germany. 39:242. ">Ioakeimidis 2018</a>, we found only an abstract and poster, which reported different quit rates in the e‐cigarette arm. <a href="./references#CD006103-bbs2-0075" title="ZincirSB , ZincirS , KaymakE , SunbulEA . Comparison of the effectiveness of varenicline, extended-release bupropion and nicotine replacement therapy on the success and the maintenance of a smoking cessation program. Bulletin of Clinical Psychopharmacology2013;23(3):224-30. [CENTRAL: 914104] [EMBASE: 2013628205]">Zincir 2013</a> reported that no participants experienced adverse events, which is unlikely given standard definitions of adverse events. </p> <p>We judged five studies to be at unclear risk of bias from other sources. In <a href="./references#CD006103-bbs2-0050" title="NCT00894166. Evaluation of a tailored smoking cessation treatment algorithm based on initial treatment response and genotype (ConNIC3). clinicaltrials.gov/ct2/show/NCT00894166 (first received 6 May 2009). RoseJE , BehmFM . Adapting smoking cessation treatment according to initial response to precessation nicotine patch. American Journal of Psychiatry2013;170(8):860-7. [CENTRAL: 873084] [EMBASE: 2013550171] [PMID: 23640009]UhlGR , WaltherD , MusciR , FisherC , AnthonyJC , StorrCL , et al. Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances. Molecular Psychiatry2014;19(1):50-4. [PMID: 23128154]">Rose 2013</a>, there was a minor unexplained reporting disparity, with different denominators given for the varenicline arm. <a href="./references#CD006103-bbs2-0063" title="WalkerN , HoweC , BullenC , McRobbieH , GloverM , ParagV , et al. Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. BMC Public Health2011;11(1):880. [CENTRAL: 814611] [EMBASE: 22104038] [6430] [PMID: 22104038]WalkerN , HoweC , GloverM , McRobbieH , BarnesJ , NosaV , et al. Cytisine versus nicotine for smoking cessation. New England Journal of Medicine2014;371(25):2353-62. [CENTRAL: 1037839] [EMBASE: 2014610901]">Walker 2014</a> supplied cytisine for free, while NRT users had to pay a nominal charge (NZD 3 for an 8‐week course of each NRT item). <a href="./references#CD006103-bbs2-0034" title="Le MaoR , TromeurC , PaleironN , SanchezO , GagnadouxF , JouneauS , et al. Effect of early initiation of varenicline on smoking cessation in COPD patients admitted for exacerbation: the save randomized clinical trial. COPD2020;17(1):7-14. NCT01694732. Efficacy of varenicline associated with intensive counselling versus placebo of varenicline associated with intensive counselling on smoking cessation at the acute phase of an exacerbation of chronic obstructive pulmonary disease (COPD). A multicenter randomized double-blind trial. ClinicalTrials.gov/show/NCT01694732 (first received 27 September 2012). TromeurC , Le MaoR , CouturandF . Effect of varenicline on smoking cessation in COPD patients recovering from exacerbation: a randomized trial. Fundamental &amp; Clinical Pharmacology2018;32 Suppl 1:32. ">Le Mao 2020</a> reported that their small sample size was because of premature interruption of pharmaceutical funding. <a href="./references#CD006103-bbs2-0012" title="CinciripiniPM , GreenCE , RobinsonJD , Karam-HageM , EngelmannJM , MinnixJA , et al. Benefits of varenicline vs. bupropion for smoking cessation: a Bayesian analysis of the interaction of reward sensitivity and treatment. Psychopharmacology2017;234(11):1769-79. CinciripiniPM , Karam-HageM . Randomised controlled trial: study suggests varenicline safe and effective among adults with stable depression. Evidence-Based Medicine2014;19(3):92. [EMBASE: 2014382469] [PMID: 24482150]CinciripiniPM , RobinsonJD , Karam-HageM , MinnixJA , LamC , VersaceF , et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry2013;70(5):522-33. [CENTRAL: 863881] [EMBASE: 2013278203] [PMID: 23536105]CuiY , Engelmann JM , XianJ , Minnix JA , Lam CY , Karam-HageM , et al. Pharmacological intervention and abstinence in smokers undergoing cessation treatment: a psychophysiological study. International Journal of Psychophysiology2018;123:25-34. HaysJT . Varenicline may reduce negative effect while aiding smoking cessation. Evidence-Based Medicine2014;19(1):23. [PMID: 23990527]NCT00507728. Pharmacogenetics, emotional reactivity and smoking. ClinicalTrials.gov/ct2/NCT00507728 (first received 26 July 207). [ClinicalTrials.gov ID NCT00507728]">Cinciripini 2013</a> began comparing nortriptyline with bupropion, but after three months nortriptyline was changed to varenicline. In <a href="./references#CD006103-bbs2-0011" title="ChengappaKN , PerkinsKA , BrarJS , SchlichtPJ , TurkinSR , HetrickML , et al. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2014;75(7):765-72. [CENTRAL: 1014641] ChengappaKN . A randomized, double-blind, placebo-controlled clinical trial of varenicline in persons with bipolar disorder motivated to quit smoking. Bipolar Disorders2015;17:38. ForrestPE , BrinsonAJ , GannonJM , GeorgeTP , PerkinsKA , ChengappaKN . An association between the use of hypnotics and quit status in the treatment of nicotine dependence with varenicline in bipolar disorder. Journal of Clinical Psychopharmacology2015;35(2):199-200. NCT01010204. Varenicline treatment for smoking cessation in patients with bipolar disorder (BEST). clinicaltrials.gov/ct2/show/NCT01010204 (first received 9 November 2009). [ClinicalTrials.gov ID NCT01010204]">Chengappa 2014</a>, four participants in each arm received bupropion for depression. Three out of 15 varenicline quitters and one out of three placebo quitters were on long‐term bupropion. </p> </section> </section> <section id="CD006103-sec-0058"> <h3 class="title" id="CD006103-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD006103-tbl-0001"><b>Summary of findings 1</b> Varenicline versus placebo or no medication for smoking cessation</a>; <a href="./full#CD006103-tbl-0002"><b>Summary of findings 2</b> Cytisine versus placebo or no medication for smoking cessation</a>; <a href="./full#CD006103-tbl-0003"><b>Summary of findings 3</b> Cytisine versus varenicline for smoking cessation</a>; <a href="./full#CD006103-tbl-0004"><b>Summary of findings 4</b> Cytisine versus nicotine replacement therapy for smoking cessation</a>; <a href="./full#CD006103-tbl-0005"><b>Summary of findings 5</b> Varenicline versus bupropion for smoking cessation</a>; <a href="./full#CD006103-tbl-0006"><b>Summary of findings 6</b> Varenicline versus nicotine replacement therapy monotherapy for smoking cessation</a>; <a href="./full#CD006103-tbl-0007"><b>Summary of findings 7</b> Varenicline versus combination nicotine replacement therapy for smoking cessation</a>; <a href="./full#CD006103-tbl-0008"><b>Summary of findings 8</b> Varenicline versus e‐cigarettes for smoking cessation</a> </p> <p>See summary of findings tables (<a href="./full#CD006103-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD006103-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD006103-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD006103-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD006103-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD006103-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD006103-tbl-0007">summary of findings Table 7</a>; <a href="./full#CD006103-tbl-0008">summary of findings Table 8</a>). </p> <section id="CD006103-sec-0059"> <h4 class="title">Cytisine versus placebo or no medication</h4> <section id="CD006103-sec-0060"> <h5 class="title">Smoking cessation</h5> <p>We pooled five studies that compared cytisine to either placebo or no medication, subgrouping by comparator type (placebo versus no medication). We found evidence of a substantial subgroup difference (I<sup>2</sup> = 97.3%; <a href="./references#CD006103-fig-0006" title="">Analysis 1.1</a>) and so present the subgroup effects separately here. Four studies, including 4623 participants, compared standard dose cytisine (9 mg per day) with placebo. More people successfully quit smoking in the cytisine arm (RR 1.30, 95% CI 1.15 to 1.47; moderate‐certainty evidence; <a href="./references#CD006103-fig-0006" title="">Analysis 1.1</a>.1), but there was a high level of heterogeneity (I<sup>2</sup> = 83%). We present the pooled estimate despite this heterogeneity as all point estimates suggested a benefit from cytisine. <a href="./references#CD006103-bbs2-0045" title="PastorinoU , LadisaV , TrussardoS , SabiaF , RolliL , ValsecchiC , et al. Cytisine therapy improved smoking cessation in the randomized SMILE lung cancer screening trial. Journal of Thoracic Oncology2022;17(11):1276-86. [DOI: 10.1016/j.jtho.2022.07.007.]">Pastorino 2022</a> compared standard‐dose cytisine with no medication. This three‐arm trial tested different durations of cytisine (40 days and 84 days), so we split the control arm. More people randomised to receive cytisine successfully quit than in the no‐medication arm (RR 4.44, 95% CI 3.06 to 6.46; I<sup>2</sup> = 0%; 869 participants; <a href="./references#CD006103-fig-0006" title="">Analysis 1.1</a>.2). </p> <p>We were unable to conduct our planned sensitivity analysis removing studies at high risk of bias because we judged all studies comparing with placebo to be at low or unclear risk and the sole study comparing with no medication to be at high risk. </p> </section> <section id="CD006103-sec-0061"> <h5 class="title">Adverse events</h5> <p>None of the studies in this comparison measured our prespecified adverse events outcomes, so we pooled all non‐serious adverse events. Results from four studies of 4052 participants showed that more people randomised to receive cytisine reported experiencing non‐serious adverse events than those randomised to receive placebo or no medication (RR 1.22, 95% CI 1.07 to 1.39; I<sup>2</sup> = 0%; <a href="./references#CD006103-fig-0007" title="">Analysis 1.2</a>). However, a sensitivity analysis removing one study comparing cytisine with no medication resulted in a confidence interval that crossed the null (RR 1.19, 95% CI 0.97 to 1.46; I<sup>2</sup> = 0%; 3 studies, 3183 participants). </p> </section> <section id="CD006103-sec-0062"> <h5 class="title">Serious adverse events</h5> <p>Results from three studies of 3781 participants comparing cytisine with placebo or no medication showed no evidence of difference in the number who experienced serious adverse events (RR 1.04, 95% CI 0.78 to 1.37; I<sup>2</sup> = 0%; low‐certainty evidence; <a href="./references#CD006103-fig-0008" title="">Analysis 1.3</a>). A sensitivity analysis removing one study comparing cytisine with no medication did not affect the interpretation of this result (RR 1.15, 95% CI 0.79 to 1.67; I<sup>2</sup> = 0%; 2 studies, 3012 participants). None of the studies measured neuropsychiatric or cardiac serious adverse events. </p> </section> </section> <section id="CD006103-sec-0063"> <h4 class="title">Cytisine: variations in usage</h4> <p><a href="./references#CD006103-bbs2-0045" title="PastorinoU , LadisaV , TrussardoS , SabiaF , RolliL , ValsecchiC , et al. Cytisine therapy improved smoking cessation in the randomized SMILE lung cancer screening trial. Journal of Thoracic Oncology2022;17(11):1276-86. [DOI: 10.1016/j.jtho.2022.07.007.]">Pastorino 2022</a> compared 40 days and 84 days of cytisine, and found that more people successfully quit on the longer treatment, although confidence intervals did cross the null, indicating the potential for no difference in the effects (RR 1.28, 95% CI 0.98 to 1.67; 480 participants; <a href="./references#CD006103-fig-0009" title="">Analysis 2.1</a>). </p> </section> <section id="CD006103-sec-0064"> <h4 class="title">Cytisine versus varenicline</h4> <section id="CD006103-sec-0065"> <h5 class="title">Smoking cessation</h5> <p>Two studies including 2131 people compared standard‐dose cytisine (9 mg per day) with standard‐dose varenicline (2 mg per day), and did not detect evidence of a clear difference in the number of people who quit smoking. However, confidence intervals indicate imprecision (RR 1.00, 95% CI 0.79 to 1.26; I<sup>2</sup> = 65%; low‐certainty evidence; <a href="./references#CD006103-fig-0010" title="">Analysis 3.1</a>). There was substantial statistical heterogeneity (I<sup>2</sup> =65%), which may be explained by the difference in duration of cytisine treatment (12 weeks of cytisine versus 12 weeks of varenicline in <a href="./references#CD006103-bbs2-0064" title="NCT02957786. Cytisine versus varenicline for smoking cessation. clinicaltrials.gov/show/NCT02957786 (first received 8 November 2016). WalkerN , SmithB , BarnesJ , VerbiestM , KurdzielT , ParagV , et al. Cytisine versus varenicline for smoking cessation for Maori (the indigenous people of New Zealand) and their extended family: protocol for a randomized non-inferiority trial. Addiction2019;114(2):344-52. WalkerN , SmithB , BarnesJ , VerbiestM , ParagV , PokhrelS , et al. Cytisine versus varenicline for smoking cessation in New Zealand indigenous Maori: a randomized controlled trial. Addiction2021;116(10):2847-58. ">Walker 2021</a>; 4 weeks of cytisine and 12 weeks of varenicline in <a href="./references#CD006103-bbs2-0014" title="ACTRN12616001654448. A non-inferiority trial of cytisine versus varenicline for smoking cessation. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12616001654448 (first received 30 November 2016). CourtneyRJ , McRobbieH , TutkaP , WeaverNA , PetrieD , MendelsohnCP , et al. Effect of cytisine vs varenicline on smoking cessation: a randomized clinical trial. JAMA2021;326(1):56-64. ThomasD , FarrellM , McRobbieH , TutkaP , PetrieD , WestR , et al. The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial. Addiction2019;114(5):923-33. ">Courtney 2021</a>). </p> </section> <section id="CD006103-sec-0066"> <h5 class="title">Adverse events</h5> <p>Two studies of 2017 participants found that people randomised to receive cytisine were less likely to report experiencing nausea (RR 0.41, 95% CI 0.33 to 0.50; I<sup>2</sup> = 0%; <a href="./references#CD006103-fig-0011" title="">Analysis 3.2</a>) and abnormal dreams (RR 0.60, 95% CI 0.50 to 0.73; I<sup>2</sup> = 58%; <a href="./references#CD006103-fig-0012" title="">Analysis 3.3</a>) than those in the varenicline arm. </p> <p>The same two studies of 2017 participants, found no evidence of clear differences between the cytisine and varenicline arms in the number of people experiencing insomnia (RR 0.90, 95% CI 0.73 to 1.10; I<sup>2</sup> = 68%; <a href="./references#CD006103-fig-0013" title="">Analysis 3.4</a>), headaches (RR 1.02, 95% CI 0.79 to 1.33; I<sup>2</sup> = 0%; <a href="./references#CD006103-fig-0014" title="">Analysis 3.5</a>), and suicidal ideation (RR 0.33, 95% CI 0.01 to 8.02; I<sup>2</sup> not estimable as events only in 1 study; <a href="./references#CD006103-fig-0016" title="">Analysis 3.7</a>). However, in all cases confidence intervals indicated imprecision, and the potential for more adverse events when using either treatment. </p> <p>One study of 679 participants did not find evidence of a clear difference between cytisine and varenicline arms in the number of people experiencing depression (RR 3.04, 95% CI 0.12 to 74.47; <a href="./references#CD006103-fig-0015" title="">Analysis 3.6</a>); however, this result should also be treated with caution because of substantial imprecision. </p> </section> <section id="CD006103-sec-0067"> <h5 class="title">Serious adverse events</h5> <p>Two studies of 2017 participants compared the number of people in cytisine and varenicline arms reporting experiencing serious adverse events. The point estimate showed that fewer people in the cytisine arm reported serious adverse events (RR 0.67, 95% CI 0.44 to 1.03; I<sup>2</sup> = 45%; low‐certainty evidence; point estimate favours cytisine; <a href="./references#CD006103-fig-0017" title="">Analysis 3.8</a>), but confidence intervals did incorporate the potential for no difference. Neither study measured neuropsychiatric or cardiac serious adverse events. </p> </section> </section> <section id="CD006103-sec-0068"> <h4 class="title">Cytisine versus nicotine replacement therapy</h4> <section id="CD006103-sec-0069"> <h5 class="title">Smoking cessation</h5> <p><a href="./references#CD006103-bbs2-0063" title="WalkerN , HoweC , BullenC , McRobbieH , GloverM , ParagV , et al. Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. BMC Public Health2011;11(1):880. [CENTRAL: 814611] [EMBASE: 22104038] [6430] [PMID: 22104038]WalkerN , HoweC , GloverM , McRobbieH , BarnesJ , NosaV , et al. Cytisine versus nicotine for smoking cessation. New England Journal of Medicine2014;371(25):2353-62. [CENTRAL: 1037839] [EMBASE: 2014610901]">Walker 2014</a> provided participants with cytisine, compared with an eight‐week course of NRT, supplied in the form of vouchers that required redemption by participants. Participants in the cytisine arm also received vouchers for NRT to use after their initial 25‐day course of cytisine, and study authors reported that at week one 26 participants were using NRT obtained through the vouchers; only 19 participants used NRT and cytisine concomitantly. This study found that more people in the cytisine arm successfully quit than in the NRT arm (RR 1.43, 95% CI 1.13 to 1.80; 1310 participants; low‐certainty evidence; <a href="./references#CD006103-fig-0018" title="">Analysis 4.1</a>). </p> </section> <section id="CD006103-sec-0070"> <h5 class="title">Adverse events</h5> <p>Nausea was the only one of our adverse event outcomes measured. <a href="./references#CD006103-bbs2-0063" title="WalkerN , HoweC , BullenC , McRobbieH , GloverM , ParagV , et al. Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. BMC Public Health2011;11(1):880. [CENTRAL: 814611] [EMBASE: 22104038] [6430] [PMID: 22104038]WalkerN , HoweC , GloverM , McRobbieH , BarnesJ , NosaV , et al. Cytisine versus nicotine for smoking cessation. New England Journal of Medicine2014;371(25):2353-62. [CENTRAL: 1037839] [EMBASE: 2014610901]">Walker 2014</a> reported that, compared with people randomised to receive NRT, those in the cytisine arm were more likely to report experiencing nausea (RR 15.00, 95% CI 3.60 to 62.51; 1310 participants; <a href="./references#CD006103-fig-0019" title="">Analysis 4.2</a>). </p> </section> <section id="CD006103-sec-0071"> <h5 class="title">Serious adverse events</h5> <p><a href="./references#CD006103-bbs2-0063" title="WalkerN , HoweC , BullenC , McRobbieH , GloverM , ParagV , et al. Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. BMC Public Health2011;11(1):880. [CENTRAL: 814611] [EMBASE: 22104038] [6430] [PMID: 22104038]WalkerN , HoweC , GloverM , McRobbieH , BarnesJ , NosaV , et al. Cytisine versus nicotine for smoking cessation. New England Journal of Medicine2014;371(25):2353-62. [CENTRAL: 1037839] [EMBASE: 2014610901]">Walker 2014</a> did not find evidence of a difference in the rate of serious adverse events between those randomised to receive cytisine or NRT (RR 1.15, 95% CI 0.76 to 1.75; 1310 participants; very low‐certainty evidence; <a href="./references#CD006103-fig-0020" title="">Analysis 4.3</a>). <a href="./references#CD006103-bbs2-0063" title="WalkerN , HoweC , BullenC , McRobbieH , GloverM , ParagV , et al. Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. BMC Public Health2011;11(1):880. [CENTRAL: 814611] [EMBASE: 22104038] [6430] [PMID: 22104038]WalkerN , HoweC , GloverM , McRobbieH , BarnesJ , NosaV , et al. Cytisine versus nicotine for smoking cessation. New England Journal of Medicine2014;371(25):2353-62. [CENTRAL: 1037839] [EMBASE: 2014610901]">Walker 2014</a> did not measure neuropsychiatric or cardiac serious adverse events. </p> </section> </section> <section id="CD006103-sec-0072"> <h4 class="title">Varenicline versus placebo or no medication</h4> <section id="CD006103-sec-0073"> <h5 class="title">Smoking cessation</h5> <p>We pooled studies that compared varenicline to either placebo or no medication, subgrouping by comparator type (placebo or no medication). We found evidence of a substantial subgroup difference (I<sup>2</sup> = 95.8%; <a href="./references#CD006103-fig-0021" title="">Analysis 5.1</a>) and so present the subgroup effects separately here. Forty‐six studies compared standard‐dose varenicline (2 mg per day) with either placebo or no medication. Our meta‐analysis found that more people successfully quit smoking when randomised to receive varenicline compared with placebo (RR 2.32, 95% CI 2.15 to 2.51; I<sup>2</sup> = 60%, 41 studies, 17,395 participants; high‐certainty evidence; <a href="./references#CD006103-fig-0021" title="">Analysis 5.1</a>.1) or with no medication (RR 1.57, 95% CI 1.37 to 1.80; I<sup>2</sup> = 95%; 5 studies, 1050 participants; <a href="./references#CD006103-fig-0021" title="">Analysis 5.1</a>.2). Despite the substantial heterogeneity in the latter subgroup we present the pooled estimate as all the individual study point estimates suggested a benefit of varenicline. </p> <p>A sensitivity analysis removing studies at high risk of bias did not reduce the heterogeneity found in the varenicline versus placebo analysis or the interpretation of the effect. However, removing three studies that used an extended treatment course of 24 or 52 weeks rather than the 12 weeks of the other studies, resulted in a minor impact, reducing the I<sup>2</sup> statistic to 53%. We were unable to conduct a sensitivity analysis removing high risk of bias studies for the varenicline versus no medication analysis, as we judged all studies to be at high risk. </p> <p><a href="./references#CD006103-bbs2-0033" title="KingA , VenaA , deWitH , GrantJE , CaoD . Effect of combination treatment with varenicline and nicotine patch on smoking cessation among smokers who drink heavily: a randomized clinical trial. JAMA Network Open2022;5(3):e220951. NCT02859142. Varenicline augmentation of patch outcomes in heavy drinkers' smoking cessation. clinicaltrials.gov/show/NCT02859142 (first received 8 August 2016). ">King 2022</a> tested varenicline combined with NRT patch against NRT patch with a varenicline placebo. We did not include this study in our analysis, but it showed no clear evidence of a difference in quit rates as a result of adding varenicline (RR 0.94, 95% CI 0.51 to 1.72; 122 participants). However, confidence intervals incorporated the possibilities of both an increased and a decreased quit rate, as well as no difference. </p> </section> <section id="CD006103-sec-0074"> <h5 class="title">Adverse events</h5> <p>Studies comparing varenicline with placebo or no medication found that people randomised to receive varenicline were more likely to report experiencing nausea (RR 2.61, 95% CI 2.44 to 2.80; I<sup>2</sup> = 79%; 36 studies, 17,080 participants; <a href="./references#CD006103-fig-0022" title="">Analysis 5.2</a>), insomnia (RR 1.37, 95% CI 1.27 to 1.47; I<sup>2</sup> = 29%; 35 studies, 16,803 participants; <a href="./references#CD006103-fig-0023" title="">Analysis 5.3</a>), abnormal dreams (RR 1.82, 95% CI 1.67 to 1.97; I<sup>2</sup> = 70%; 32 studies, 16,211 participants; <a href="./references#CD006103-fig-0024" title="">Analysis 5.4</a>), and headaches (RR 1.11, 95% CI 1.03 to 1.19; I<sup>2</sup> = 30%; 31 studies, 16,326 participants; <a href="./references#CD006103-fig-0025" title="">Analysis 5.5</a>). Statistical heterogeneity was substantial in our analyses for nausea and abnormal dreams, but we decided to present the pooled estimate because the point estimates of individuals studies were almost entirely in the same direction. </p> <p>Studies comparing varenicline with placebo or no medication did not find clear evidence of difference in the numbers of participants who reported experiencing depression (RR 1.05, 95% CI 0.91 to 1.20; I<sup>2</sup> = 0%; 32 studies, 15,922 participants; <a href="./references#CD006103-fig-0026" title="">Analysis 5.6</a>), and found fewer people reporting suicidal ideation in the varenicline arm (RR 0.69, 95% CI 0.44 to 1.08; I<sup>2</sup> = 0%; 22 studies, 12,343 participants; <a href="./references#CD006103-fig-0027" title="">Analysis 5.7</a>). However, confidence intervals indicated imprecision, and included the potential for harm as well as no difference. </p> <p>We conducted sensitivity analyses removing studies comparing varenicline with no medication rather than placebo, but this had no substantial impact on heterogeneity or results. </p> </section> <section id="CD006103-sec-0075"> <h5 class="title">Serious adverse event</h5> <section id="CD006103-sec-0076"> <h6 class="title">Serious adverse events</h6> <p>Twenty‐six studies of 14,356 participants found that more people randomised to receive varenicline reported experiencing serious adverse events than those randomised to receive placebo or no medication (RR 1.23, 95% CI 1.01 to 1.48; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD006103-fig-0028" title="">Analysis 5.8</a>). Absolute rates for serious adverse events were 3.3% and 2.7% in varenicline and control arms respectively. <a href="./references#CD006103-bbs2-0033" title="KingA , VenaA , deWitH , GrantJE , CaoD . Effect of combination treatment with varenicline and nicotine patch on smoking cessation among smokers who drink heavily: a randomized clinical trial. JAMA Network Open2022;5(3):e220951. NCT02859142. Varenicline augmentation of patch outcomes in heavy drinkers' smoking cessation. clinicaltrials.gov/show/NCT02859142 (first received 8 August 2016). ">King 2022</a> tested varenicline combined with NRT patch against NRT patch with a varenicline placebo. We did not include this study in our analysis, but it reported two participants with serious adverse events in the varenicline arm and none in the NRT‐alone arm. A sensitivity analysis removing one study comparing varenicline with no medication had no substantial impact on this result. </p> </section> <section id="CD006103-sec-0077"> <h6 class="title">Neuropsychiatric serious adverse events</h6> <p>The point estimate from pooling 22 studies of 7846 people showed that fewer people reported experiencing neuropsychiatric serious adverse events in the varenicline arm compared with placebo or no medication (RR 0.89, 95% CI 0.61 to 1.29; I<sup>2</sup> = 0%; low‐certainty evidence; <a href="./references#CD006103-fig-0029" title="">Analysis 5.9</a>). However confidence intervals demonstrated imprecision, also encompassing the possibility of more neuropsychiatric serious adverse events in the varenicline arm. A sensitivity analysis removing one study comparing varenicline with no medication had no substantial impact on this result. </p> </section> <section id="CD006103-sec-0078"> <h6 class="title">Cardiac serious adverse events</h6> <p>The point estimate from pooling 18 studies of 7151 people showed that more people reported experiencing cardiac serious adverse events in the varenicline arm compared with placebo or no medication (RR 1.20, 95% CI 0.79 to 1.84; I<sup>2</sup> = 0%; low‐certainty evidence; <a href="./references#CD006103-fig-0030" title="">Analysis 5.10</a>). However confidence intervals demonstrated imprecision, also encompassing the possibility of no difference or fewer serious adverse events in the varenicline arm. A sensitivity analysis removing one study comparing varenicline with no medication had no substantial impact on this result. </p> </section> </section> </section> <section id="CD006103-sec-0079"> <h4 class="title">Varenicline: variations in usage</h4> <section id="CD006103-sec-0080"> <h5 class="title">Low‐dose varenicline versus placebo</h5> <p>Four studies tested varenicline at doses lower than standard (under 2 mg per day). Three studies tested 1 mg per day compared with placebo and still found that more people quit in the varenicline arm (RR 1.87, 95% CI 1.35 to 2.60; 906 participants; <a href="./references#CD006103-fig-0031" title="">Analysis 6.1</a>.1). There was substantial heterogeneity (I<sup>2</sup> = 71%), however in all cases point estimates favoured varenicline. </p> <p><a href="./references#CD006103-bbs2-0041" title="NiauraR , Taylor HaysJ , JorenbyDE , LeoneFT , PappasJE , ReevesKR , et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Current Medical Research and Opinion2008;24(7):1931-41. [clinicaltrials.gov ID: NCT00150228]">Niaura 2008</a> allowed participants to choose their own dose of varenicline, ranging between 0.5 mg and 2.0 mg daily, and found more people in the varenicline arm quit than in the placebo arm (RR 2.92, 95% CI 1.57 to 5.41; 320 participants; <a href="./references#CD006103-fig-0031" title="">Analysis 6.1</a>.2). </p> </section> <section id="CD006103-sec-0081"> <h5 class="title">Higher‐dose varenicline versus lower‐dose varenicline</h5> <p>Four studies compared varenicline at 2 mg per day with 1 mg per day and did not provide clear evidence of a difference in how many people quit (RR 1.12, 95% CI 0.97 to 1.30; 1563 participants; I<sup>2</sup> = 44%; <a href="./references#CD006103-fig-0032" title="">Analysis 6.2</a>.1); however confidence intervals encompassed potential benefit and a slight disadvantage of the higher dose. <a href="./references#CD006103-bbs2-0042" title="NidesM , GloverED , ReusVI , ChristenAG , MakeBJ , BillingCB , et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. American Journal of Health Behavior2008;32(6):664-75. NidesM , OnckenC , GonzalezD , RennardS , WatskyEJ , AnzianoR , et al. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist. Archives of Internal Medicine2006;166:1561-8. OnckenC , WatskyE , ReevesK , AnzianoR . Varenicline is efficacious and well tolerated in promoting smoking cessation: results from a 7-week, randomized, placebo- and bupropion-controlled trial [POS1-047]. Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic2005. ">Nides 2006</a> also compared other dosages and also did not find clear evidence of a difference in quit rates among participants randomised to receive 2 mg compared with 0.3 mg per day (RR 1.84 95% CI 0.89 to 3.84; 253 participants; <a href="./references#CD006103-fig-0032" title="">Analysis 6.2</a>.2) or 1 mg compared with 0.3 mg per day (RR 0.71, 95% CI 0.28 to 1.81; 254 participants; <a href="./references#CD006103-fig-0032" title="">Analysis 6.2</a>.3). However, in both cases confidence intervals were wide and may indicate benefit and harm of higher doses. </p> </section> <section id="CD006103-sec-0082"> <h5 class="title">Longer‐duration varenicline versus standard‐duration varenicline</h5> <p>Three studies tested extended durations of varenicline compared with standard duration of varenicline (12 weeks). We found no clear evidence of a difference as a result of extending varenicline treatment to 24 weeks (RR 0.97, 95% CI 0.77 to 1.23; I<sup>2</sup> = 17%; 2 studies, 1458 participants; <a href="./references#CD006103-fig-0033" title="">Analysis 6.3</a>.1) or 52 weeks (RR 1.30, 95% CI 0.70 to 2.43; 1 study; 107 participants; <a href="./references#CD006103-fig-0033" title="">Analysis 6.3</a>.2). However, the confidence intervals indicate imprecision and uncertainty in the point estimates. </p> </section> <section id="CD006103-sec-0083"> <h5 class="title">Six weeks versus one week of varenicline preloading</h5> <p><a href="./references#CD006103-bbs2-0007" title="BohadanaA , Freier-DrorY , PelesV , BabaiP , IzbickiG . Extending varenicline preloading to 6 weeks facilitates smoking cessation: a single-site, randomised controlled trial: six-week varenicline preloading for smoking cessation. eClinicalMedicine2020;19(100228):1-10. IzbickiG , Freier DrorY , BohadanaA . Extended, 6 weeks, varenicline preloading: does it facilitate smoking reduction and cessation? a randomized double-blind, placebo-controlled study. American Journal of Respiratory and Critical Care Medicine Conference: 2019 International Conference of the American Thoracic Society2019;199(9):A2378. NCT02634281. Extended (6-Week) varenicline preloading: does it facilitate smoking reduction and cessation?https://clinicaltrials.gov/show/NCT02634281 (first received 18 December 2015). ">Bohadana 2020</a> tested varenicline with a preloading period of six weeks before quit date against the standard one week of preloading and found that more people in the six‐week preloading arm quit than in the one‐week arm (RR 5.60, 95% CI 2.24 to 14.02; 242 participants). </p> </section> </section> <section id="CD006103-sec-0084"> <h4 class="title">Varenicline in specific patient groups</h4> <p>Studies testing varenicline against placebo or no medication in specific patient populations did not find any clear evidence of varenicline working differently in these groups than in the general population. </p> <p>Analyses found more people successfully quitting in the varenicline arm than in control in studies of people with cardiovascular disease (RR 1.88, 95% CI 1.44 to 2.47; I<sup>2</sup> = 81%; 2 studies, 1006 participants; <a href="./references#CD006103-fig-0035" title="">Analysis 7.1</a>); schizophrenia, bipolar disorder, or another psychiatric disorder (RR 2.26, 95% CI 1.78 to 2.86; I<sup>2</sup> = 0%; 3 studies, 2245 participants; <a href="./references#CD006103-fig-0038" title="">Analysis 7.4</a>); depression (RR 2.17, 95% CI 1.45 to 3.24; I<sup>2</sup> = 0%; 2 studies, 745 participants; <a href="./references#CD006103-fig-0039" title="">Analysis 7.5</a>); HIV (RR 1.96, 95% CI 1.06 to 3.63; I<sup>2</sup> = 0%; 2 studies, 427 participants; <a href="./references#CD006103-fig-0042" title="">Analysis 7.8</a>); and chronic obstructive pulmonary disease (RR 1.47, 95% CI 1.28 to 1.69; I<sup>2</sup> = 94%; 4 studies of 860 participants; <a href="./references#CD006103-fig-0036" title="">Analysis 7.2</a>). </p> <p>Treating these trials as a subgroup of the main analysis (<a href="./references#CD006103-fig-0021" title="">Analysis 5.1</a>), testing for subgroup differences showed no evidence that varenicline works differently from in the general population: cardiovascular disease, P = 0.24, I<sup>2</sup> = 26.2%; psychiatric disorders, P = 0.40, I<sup>2</sup> = 0%; depression, P = 0.92, I<sup>2</sup> = 0%; HIV, P = 0.69, I<sup>2</sup> = 0%). Testing the COPD result for subgroup difference initially showed evidence that varenicline may work differently, with lower effectiveness, in this population (P &lt; 0.00001, I<sup>2</sup> = 96.8%), however this difference disappeared when we performed a sensitivity analysis removing studies comparing varenicline with no medication rather than placebo (P = 1.00, I<sup>2</sup> = 0%). </p> <p>Analyses presented inconclusive evidence for three patient populations: asthma (RR 1.25, 95% CI 0.38 to 4.14; 1 study; 52 participants; <a href="./references#CD006103-fig-0037" title="">Analysis 7.3</a>), substance use disorder (RR 3.72, 95% CI 0.50 to 27.59; I<sup>2</sup> = 0%; 2 studies, 294 participants; <a href="./references#CD006103-fig-0040" title="">Analysis 7.6</a>), and alcohol dependence (RR 3.01, 95% CI 0.92 to 9.92; I<sup>2</sup> = 54%; 3 studies, 195 participants; <a href="./references#CD006103-fig-0041" title="">Analysis 7.7</a>). However, point estimates all favoured varenicline, and wide confidence intervals were likely the result of very low numbers of events. Treating the trials as a subgroup of the main analysis (<a href="./references#CD006103-fig-0021" title="">Analysis 5.1</a>) and testing for subgroup differences showed no evidence that varenicline works differently in these populations (asthma: P = 0.76, I<sup>2</sup> = 0.4%; substance use disorder: P = 0.61, I<sup>2</sup> = 0%; alcohol dependence: P = 0.70, I<sup>2</sup> = 0.4%). </p> </section> <section id="CD006103-sec-0085"> <h4 class="title">Varenicline in specific settings or subgroups</h4> <p>Six studies of 1324 participants tested varenicline against placebo or no medication among hospital inpatients and perioperative patients and found that more people successfully quit in the varenicline arm (RR 1.27, 95% CI 1.12 to 1.43; I<sup>2</sup> = 58%; <a href="./references#CD006103-fig-0043" title="">Analysis 8.1</a>). Treating these trials as a subgroup of the main analysis (<a href="./references#CD006103-fig-0021" title="">Analysis 5.1</a>), which includes studies conducted in both clinical and community settings such as cessation clinics and university campuses, and testing for subgroup differences did show evidence of subgroup difference, with lower effectiveness (P &lt; 0.00001; I<sup>2</sup> = 98.6%). Heterogeneity remained when we performed a sensitivity analysis removing studies comparing varenicline with no medication rather than placebo (P &lt; 0.00001; I<sup>2</sup> = 96%). </p> <p><a href="./references#CD006103-bbs2-0023" title="GonzalesD , HajekP , PliammL , NackaertsK , Tseng L-J, McRaeTD , et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. Clinical Pharmacology and Therapeutics2014;96(3):390-6. [CENTRAL: 1014162] [EMBASE: 2014565570] [PMID: 24911368]NCT01244061. A multi-national study to assess how effective and safe the smoking cessation medicine varenicline is in smokers who have already tried varenicline in the past as a prescription medicine from their usual healthcare provider. clinicaltrials.gov/ct2/show/NCT01244061 (first received 19th November 2010). [ClinicalTrials.gov ID NCT01244061]">Gonzales 2014</a> tested varenicline against placebo among people who had previously used varenicline for two weeks or more, at least three months prior to admission to the study, and had not successfully quit but were motivated to try again. This single study found that more people successfully quit in the varenicline arm (RR 6.15, 95% CI 2.98 to 12.70; 494 participants; <a href="./references#CD006103-fig-0044" title="">Analysis 8.2</a>). </p> <p>Two studies of 114 participants tested varenicline against placebo among light smokers and found that more people successfully quit in the varenicline arm (RR 4.16, 95% CI 1.58 to 10.97; I<sup>2</sup> = 0%; <a href="./references#CD006103-fig-0045" title="">Analysis 8.3</a>). Treating these trials as a subgroup of the main analysis (<a href="./references#CD006103-fig-0021" title="">Analysis 5.1</a>) and testing for subgroup differences showed no evidence that varenicline works differently in this population (P = 0.20, I<sup>2</sup> = 39.3%). </p> </section> <section id="CD006103-sec-0086"> <h4 class="title">Varenicline versus bupropion</h4> <section id="CD006103-sec-0087"> <h5 class="title">Smoking cessation</h5> <p>Nine studies of 7560 participants compared varenicline with bupropion and found that more people quit smoking when using varenicline (RR 1.36, 95% CI 1.25 to 1.49; I<sup>2</sup> = 0%; high‐certainty evidence; <a href="./references#CD006103-fig-0046" title="">Analysis 9.1</a>). </p> <p><a href="./references#CD006103-bbs2-0031" title="JohnsDA . The efficacy of combination therapy with varenicline and bupropion for smoking cessation. Annals of Oncology2017;Suppl 2: 7th European Lung Cancer Conference, ELCC 2017. Switzerland. 28:iii6-7. ">Johns 2017b</a> randomised 300 participants to receive varenicline, bupropion, or both. They did not provide any useable results data but reported that more people quit in the combined varenicline and bupropion arm compared with the bupropion‐ or varenicline‐alone arms. However, only an abstract was available for this study, and without further information, this result should be treated with caution. </p> </section> <section id="CD006103-sec-0088"> <h5 class="title">Adverse events</h5> <p>Studies comparing varenicline with bupropion found that people randomised to receive varenicline were more likely to report experiencing nausea (RR 2.46, 95% CI 2.20 to 2.75; I<sup>2</sup> = 0%; 4 studies, 5808 participants; <a href="./references#CD006103-fig-0047" title="">Analysis 9.2</a>), abnormal dreams (RR 1.56, 95% CI 1.39 to 1.76; I<sup>2</sup> = 0%; 4 studies, 5808 participants; <a href="./references#CD006103-fig-0049" title="">Analysis 9.4</a>), and headache (RR 1.24, 95% CI 1.06 to 1.45; I<sup>2</sup> = 13%; 3 studies, 4888 participants; <a href="./references#CD006103-fig-0050" title="">Analysis 9.5</a>). However, people randomised to receive varenicline were less likely to report experiencing insomnia (RR 0.84, 95% CI 0.75 to 0.93; I<sup>2</sup> = 75%; 6 studies, 6789 participants; <a href="./references#CD006103-fig-0048" title="">Analysis 9.3</a>). </p> <p>Two studies of 4210 people did not find evidence a difference between those randomised to receive varenicline or bupropion in reported rates of depression (RR 0.90, 95% CI 0.35 to 2.35; I<sup>2</sup> = 0%; <a href="./references#CD006103-fig-0051" title="">Analysis 9.6</a>) or suicidal ideation (RR 1.99, 95% CI 0.18 to 21.93; I<sup>2</sup> not estimable as events only in 1 study; <a href="./references#CD006103-fig-0052" title="">Analysis 9.7</a>). </p> </section> <section id="CD006103-sec-0089"> <h5 class="title">Serious adverse events</h5> <section id="CD006103-sec-0090"> <h6 class="title">Serious adverse events</h6> <p>Five studies of 5317 people did not find evidence of a clear difference in the number of people reporting experiencing serious adverse events (RR 0.89, 95% CI 0.61 to 1.31; I<sup>2</sup> = 0%; low‐certainty evidence; <a href="./references#CD006103-fig-0053" title="">Analysis 9.8</a>). </p> </section> <section id="CD006103-sec-0091"> <h6 class="title">Neuropsychiatric serious adverse events</h6> <p>Two studies of 866 people did not find evidence of a clear difference in the number of people reporting experiencing neuropsychiatric serious adverse events (RR 1.05, 95% CI 0.16 to 7.04; I<sup>2</sup> = 10%; low‐certainty evidence; <a href="./references#CD006103-fig-0054" title="">Analysis 9.9</a>), though confidence intervals were very wide. </p> </section> <section id="CD006103-sec-0092"> <h6 class="title">Cardiac serious adverse events</h6> <p>Two studies of 866 people did not find evidence of a clear difference in the number of people reporting experiencing cardiac serious adverse events (RR 3.17, 95% CI 0.33 to 30.18; I<sup>2</sup> = 0%; low‐certainty evidence; <a href="./references#CD006103-fig-0055" title="">Analysis 9.10</a>), though confidence intervals were very wide. </p> </section> </section> </section> <section id="CD006103-sec-0093"> <h4 class="title">Varenicline versus nicotine replacement therapy (NRT) monotherapy</h4> <section id="CD006103-sec-0094"> <h5 class="title">Smoking cessation</h5> <p>Eleven studies of 7572 participants compared varenicline with NRT monotherapy and found that more people quit smoking in the varenicline arm (RR 1.25, 95% CI 1.14 to 1.37; I<sup>2</sup> = 28%; high‐certainty evidence; <a href="./references#CD006103-fig-0056" title="">Analysis 10.1</a>). </p> </section> <section id="CD006103-sec-0095"> <h5 class="title">Adverse events</h5> <p>Studies comparing varenicline with NRT monotherapy found that people randomised to receive varenicline were more likely to report experiencing nausea (RR 2.69, 95% CI 2.41 to 3.01; I<sup>2</sup> = 59%; 6 studies, 6500 participants; <a href="./references#CD006103-fig-0057" title="">Analysis 10.2</a>) and headache (RR 1.14, 95% CI 1.01 to 1.28; I<sup>2</sup> = 69%; 4 studies, 6287 participants; <a href="./references#CD006103-fig-0060" title="">Analysis 10.5</a>). However, they did not find evidence of a clear difference in the number of people reporting experiencing insomnia (RR 1.08, 95% CI 0.96 to 1.21; I<sup>2</sup> = 42%; 5 studies, 6319 participants; <a href="./references#CD006103-fig-0058" title="">Analysis 10.3</a>), abnormal dreams (RR 0.93, 95% CI 0.83 to 1.05; I<sup>2</sup> = 67%; 4 studies, 5803 participants; <a href="./references#CD006103-fig-0059" title="">Analysis 10.4</a>), or depression (RR 0.94, 95% CI 0.76 to 1.16; I<sup>2</sup> = 0%; 3 studies, 5541 participants; <a href="./references#CD006103-fig-0061" title="">Analysis 10.6</a>). The pooled point estimate from two studies found a higher rate of suicidal ideation among participants in the varenicline arm (RR 5.00, 95% CI 0.87 to 28.77; I<sup>2</sup> = 0%; 2 studies, 4876 participants; <a href="./references#CD006103-fig-0062" title="">Analysis 10.7</a>), but confidence intervals were very wide and incorporated the potential for no difference or reduced harm. Statistical heterogeneity was substantial in several analyses, but we decided to present the pooled estimate because the point estimates of individuals studies were almost entirely in the same direction in each analysis. </p> </section> <section id="CD006103-sec-0096"> <h5 class="title">Serious adverse events</h5> <section id="CD006103-sec-0097"> <h6 class="title">Serious adverse events</h6> <p>Six studies of 6535 people comparing varenicline with NRT monotherapy found that people randomised to receive varenicline were less likely to report experiencing serious adverse events (RR 0.70, 95% CI 0.50 to 0.99; I<sup>2</sup> = 24%; low‐certainty evidence; <a href="./references#CD006103-fig-0063" title="">Analysis 10.8</a>). </p> </section> <section id="CD006103-sec-0098"> <h6 class="title">Neuropsychiatric serious adverse events</h6> <p>Only one study measured neuropsychiatric serious adverse events, and reported no events in either arm (<a href="./references#CD006103-bbs2-0049" title="MartinRA , RohsenowDJ , TideyJW . Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement. Journal of Substance Abuse Treatment2019;104:22-7. NCT00756275. Varenicline and motivational advice for smokers with substance use disorders. ClinicalTrials.gov/ct2/show/NCT00756275 (first received 22 September 2008). [ClinicalTrials.gov ID NCT00756275]RohsenowD , TideyJW , MartinRA , ColbyS , MontiPM . Varenicline versus nicotine patch plus brief advice for sober smokers in substance treatment. Drug and Alcohol Dependence2015;156:e191-2. RohsenowDJ , TideyJW , MartinRA , ColbySM , MontiPM . Varenicline helps smokers with SUD stop smoking without harming recovery (POS5-63). Society for Research on Nicotine and Tobacco 21st Annual Meeting February 25-28 Philadelphia2015. RohsenowDJ , TideyJW , MartinRA , ColbySM , SwiftRM , LeggioL , et al. Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms. Addiction2017;112(10):1808-20. ">Rohsenow 2017</a>; 137 participants). </p> </section> <section id="CD006103-sec-0099"> <h6 class="title">Cardiac serious adverse events</h6> <p>Only one study measured cardiac serious adverse events, and reported no events in either arm (<a href="./references#CD006103-bbs2-0049" title="MartinRA , RohsenowDJ , TideyJW . Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement. Journal of Substance Abuse Treatment2019;104:22-7. NCT00756275. Varenicline and motivational advice for smokers with substance use disorders. ClinicalTrials.gov/ct2/show/NCT00756275 (first received 22 September 2008). [ClinicalTrials.gov ID NCT00756275]RohsenowD , TideyJW , MartinRA , ColbyS , MontiPM . Varenicline versus nicotine patch plus brief advice for sober smokers in substance treatment. Drug and Alcohol Dependence2015;156:e191-2. RohsenowDJ , TideyJW , MartinRA , ColbySM , MontiPM . Varenicline helps smokers with SUD stop smoking without harming recovery (POS5-63). Society for Research on Nicotine and Tobacco 21st Annual Meeting February 25-28 Philadelphia2015. RohsenowDJ , TideyJW , MartinRA , ColbySM , SwiftRM , LeggioL , et al. Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms. Addiction2017;112(10):1808-20. ">Rohsenow 2017</a>; 137 participants). </p> </section> </section> </section> <section id="CD006103-sec-0100"> <h4 class="title">Varenicline versus combination NRT</h4> <section id="CD006103-sec-0101"> <h5 class="title">Smoking cessation</h5> <p>Five studies of 2344 participants compared varenicline with combination NRT and did not detect evidence of a clear difference in the number of people who quit smoking, although confidence intervals indicate imprecision, which reduces our certainty in the effect (RR 1.02, 95% CI 0.87 to 1.20; I<sup>2</sup> = 0%; low‐certainty evidence; <a href="./references#CD006103-fig-0066" title="">Analysis 11.1</a>). </p> </section> <section id="CD006103-sec-0102"> <h5 class="title">Adverse events</h5> <p>Studies comparing varenicline with combination NRT found that people randomised to receive varenicline were more likely to report experiencing nausea (RR 1.76, 95% CI 1.45 to 2.15; I<sup>2</sup> = 47%; 3 studies, 1609 participants; <a href="./references#CD006103-fig-0067" title="">Analysis 11.2</a>), insomnia (RR 1.40, 95% CI 1.15 to 1.70; I<sup>2</sup> = 82%; 3 studies, 1609 participants; <a href="./references#CD006103-fig-0068" title="">Analysis 11.3</a>), and abnormal dreams (RR 1.59, 95% CI 1.22 to 2.08; 1 study; 549 participants; <a href="./references#CD006103-fig-0069" title="">Analysis 11.4</a>). However, they did not find evidence of a clear difference in the number of people reporting experiencing headache (RR 0.98, 95% CI 0.78 to 1.23; I<sup>2</sup> = 0%; 3 studies, 1609 participants; <a href="./references#CD006103-fig-0070" title="">Analysis 11.5</a>), depression (RR 1.08, 95% CI 0.83 to 1.40; I<sup>2</sup> = 82%; 3 studies, 1609 participants; <a href="./references#CD006103-fig-0071" title="">Analysis 11.6</a>), or suicidal ideation (RR 0.94, 95% CI 0.06 to 14.79; I<sup>2</sup> not estimable as events only in 1 study; 2 studies, 764 participants; <a href="./references#CD006103-fig-0072" title="">Analysis 11.7</a>). Statistical heterogeneity was substantial in several analyses, but we decided to present the pooled estimate because the point estimates of individual studies were almost entirely in the same direction. </p> </section> <section id="CD006103-sec-0103"> <h5 class="title">Serious adverse events</h5> <section id="CD006103-sec-0104"> <h6 class="title">Serious adverse events</h6> <p>Pooled data from four studies of 1852 people showed more people in the varenicline arm reporting serious adverse events compared with combination NRT (RR 2.15, 95% CI 0.49 to 9.46; I<sup>2</sup> = 0%; low‐certainty evidence; <a href="./references#CD006103-fig-0073" title="">Analysis 11.8</a>). However, confidence intervals were very wide and included the potential for no difference or reduced risk. </p> </section> <section id="CD006103-sec-0105"> <h6 class="title">Neuropsychiatric serious adverse events</h6> <p>Two studies of 764 people reported the number of people reporting neuropsychiatric serious adverse events. While the point estimate suggested participants receiving varenicline were more likely to report experiencing neuropsychiatric serious adverse events, confidence intervals were extremely wide, and incorporated both benefit and harm (RR 4.69, 95% CI 0.23 to 96.50; I<sup>2</sup> not estimable as events only in 1 study; low‐certainty evidence; <a href="./references#CD006103-fig-0074" title="">Analysis 11.9</a>). </p> </section> <section id="CD006103-sec-0106"> <h6 class="title">Cardiac serious adverse events</h6> <p>Two studies of 819 people reported the number of people reporting cardiac serious adverse events. While the point estimate suggested that participants receiving varenicline were less likely to report experiencing cardiac serious adverse events, confidence intervals were very wide, and incorporated both benefit and harm (RR 0.32, 95% CI 0.01 to 7.88; I<sup>2</sup> not estimable as events only in 1 study; low‐certainty evidence; <a href="./references#CD006103-fig-0075" title="">Analysis 11.10</a>). </p> </section> </section> </section> <section id="CD006103-sec-0107"> <h4 class="title">Varenicline versus e‐cigarettes</h4> <section id="CD006103-sec-0108"> <h5 class="title">Smoking cessation</h5> <p>One study of 54 participants compared varenicline with e‐cigarettes and found that more people quit smoking in the varenicline arm (RR 3.25, 95% CI 1.21 to 8.71; very low‐certainty evidence; <a href="./references#CD006103-fig-0076" title="">Analysis 12.1</a>). </p> </section> <section id="CD006103-sec-0109"> <h5 class="title">Adverse events</h5> <p>The only one of our adverse event outcomes reported by this study was nausea. While the point estimate suggested that participants receiving varenicline were more likely to report experiencing nausea, confidence intervals were extremely wide, and incorporated both benefit and harm (RR 3.00, 95% CI 0.33 to 27.06; <a href="./references#CD006103-fig-0077" title="">Analysis 12.2</a>). </p> </section> <section id="CD006103-sec-0110"> <h5 class="title">Serious adverse events</h5> <p>While the study reported serious adverse events, neuropsychiatric serious adverse events, and cardiac serious adverse events as outcomes, they reported no events among study participants in either arm. </p> </section> </section> <section id="CD006103-sec-0111"> <h4 class="title">Dianicline versus placebo</h4> <section id="CD006103-sec-0112"> <h5 class="title">Smoking cessation</h5> <p><a href="./references#CD006103-bbs2-0057" title="TonstadS , HolmeI , TønnesenP . Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial. Nicotine &amp; Tobacco Research2011;13(1):1-6. ">Tonstad 2011</a> (602 participants) compared dianicline with placebo and did not detect evidence of a clear difference in the number of people who quit smoking (RR 1.20, 95% CI 0.82 to 1.75; <a href="./references#CD006103-fig-0081" title="">Analysis 13.1</a>), however, results were imprecise and confidence intervals encompass the possibility of benefit and harm of dianicline. </p> </section> <section id="CD006103-sec-0113"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD006103-bbs2-0057" title="TonstadS , HolmeI , TønnesenP . Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial. Nicotine &amp; Tobacco Research2011;13(1):1-6. ">Tonstad 2011</a> reported that more people randomised to receive dianicline reported experiencing nausea (RR 2.83, 95% CI 1.88 to 4.27; 602 participants; <a href="./references#CD006103-fig-0082" title="">Analysis 13.2</a>) and depression (RR 8.05, 95% CI 1.01 to 63.99; 602 participants; <a href="./references#CD006103-fig-0084" title="">Analysis 13.4</a>) than those in the placebo arm. They did not detect a difference in the number of people reporting experiencing headaches (RR 1.23, 95% CI 0.82 to 1.85; 602 participants; <a href="./references#CD006103-fig-0083" title="">Analysis 13.3</a>). The study did not measure our other adverse event outcomes. </p> </section> <section id="CD006103-sec-0114"> <h5 class="title">Serious adverse events</h5> <p><a href="./references#CD006103-bbs2-0057" title="TonstadS , HolmeI , TønnesenP . Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial. Nicotine &amp; Tobacco Research2011;13(1):1-6. ">Tonstad 2011</a> did not detect a difference in rates of serious adverse events (RR 1.01, 95% CI 0.20 to 4.95; 602 participants; <a href="./references#CD006103-fig-0085" title="">Analysis 13.5</a>) or cardiac serious adverse events (RR 1.01, 95% CI 0.06 to 16.02; 602 participants; <a href="./references#CD006103-fig-0086" title="">Analysis 13.6</a>) between participants in the dianicline and placebo study arms. However, in both instances confidence intervals were very wide and included the potential for both harm and benefit. The study did not measure neuropsychiatric serious adverse events. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006103-sec-0115" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006103-sec-0115"></div> <section id="CD006103-sec-0116"> <h3 class="title" id="CD006103-sec-0116">Summary of main results</h3> <p>This review includes eight studies that investigated cytisine use in just under 9000 people, 68 studies that investigated varenicline use in over 37,000 people, and one study that investigated dianicline use in 602 people. Forty‐five of these studies are new to this update. </p> <p>We found moderate‐certainty evidence that cytisine probably helps more people to quit smoking than placebo. While people randomised to receive cytisine were more likely to experience adverse events than those in the placebo arm, low‐certainty evidence gave no clear indication of an increased risk of serious adverse events. We found no data on neuropsychiatric or cardiac serious adverse events. </p> <p>Our analysis did not find evidence of a clear difference in cessation rates between cytisine and varenicline, although this low‐certainty evidence is subject to imprecision and may change as more evidence becomes available. A component network meta‐analysis that is currently underway may reveal a more certain result by also employing data from indirect comparisons (<a href="./references#CD006103-bbs2-0222" title="LindsonN , TheodoulouA , Livingstone-BanksJ , AveyardP , FanshaweTR , Ordóñez-MenaJM , et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015226. [DOI: 10.1002/14651858.CD015226]">Lindson 2022</a>). Although the point estimates in the separate analyses comparing varenicline with placebo and cytisine with placebo did differ (with the varenicline analysis producing a higher risk ratio) the issue with this type of indirect comparison is it does not adjust for potential differences in baseline event rates. In our analysis, <a href="./references#CD006103-bbs2-0017" title="BoeckmannM , NohavovaI , DogarO , KralikovaE , PankovaA , ZvolskaK , et al. Protocol for the mixed-methods process and context evaluation of the TB &amp; Tobacco randomised controlled trial in Bangladesh and Pakistan: a hybrid effectiveness-implementation study. BMJ Open2018;8(3):e019878. DogarO , BaruaD , BoeckmannM , ElseyH , FatimaR , GabeR , et al. The safety, effectiveness and cost-effectiveness of cytisine in achieving six-month continuous smoking abstinence in tuberculosis patients—protocol for a double-blind, placebo-controlled randomized trial. Addiction2018;113(9):1716-27. DogarO , KedingA , GabeR , MarshallAM , HuqueR , BaruaD , et al. Cytisine for smoking cessation in patients with tuberculosis: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Global Health2020;8(11):e1408-17. ISRCTN43811467. Tuberculosis (TB) and tobacco. www.isrctn.com/ISRCTN43811467 (first received 23 March 2016). SiddiqiK , KedingA , MarshallAM , DogarO , LiJ , HuqueR , et al. Effect of quitting smoking on health outcomes during treatment for tuberculosis: secondary analysis of the TB &amp; Tobacco Trial. Thorax2021;7:74-8. ">Dogar 2020</a> was the largest study that compared cytisine with placebo. It recruited people diagnosed with pulmonary tuberculosis who, as part of the behavioural aspect of the intervention, were informed of the dangers of continued tobacco use in people with tuberculosis. This made for a highly motivated population, who also happened to smoke fewer cigarettes per day than in other cytisine trials. These two characteristics may have contributed to the higher placebo arm quit rates in the cytisine studies and minimised the benefit gained from pharmacotherapy. These factors may also explain why the results from <a href="./references#CD006103-bbs2-0017" title="BoeckmannM , NohavovaI , DogarO , KralikovaE , PankovaA , ZvolskaK , et al. Protocol for the mixed-methods process and context evaluation of the TB &amp; Tobacco randomised controlled trial in Bangladesh and Pakistan: a hybrid effectiveness-implementation study. BMJ Open2018;8(3):e019878. DogarO , BaruaD , BoeckmannM , ElseyH , FatimaR , GabeR , et al. The safety, effectiveness and cost-effectiveness of cytisine in achieving six-month continuous smoking abstinence in tuberculosis patients—protocol for a double-blind, placebo-controlled randomized trial. Addiction2018;113(9):1716-27. DogarO , KedingA , GabeR , MarshallAM , HuqueR , BaruaD , et al. Cytisine for smoking cessation in patients with tuberculosis: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Global Health2020;8(11):e1408-17. ISRCTN43811467. Tuberculosis (TB) and tobacco. www.isrctn.com/ISRCTN43811467 (first received 23 March 2016). SiddiqiK , KedingA , MarshallAM , DogarO , LiJ , HuqueR , et al. Effect of quitting smoking on health outcomes during treatment for tuberculosis: secondary analysis of the TB &amp; Tobacco Trial. Thorax2021;7:74-8. ">Dogar 2020</a> are less compelling than those of the other studies, and may also account for the statistical heterogeneity in the cytisine versus placebo analysis (I<sup>2</sup> = 83%). </p> <p>Participants in the cytisine arm were less likely to experience nausea or abnormal dreams than those in the varenicline arm, and there was no evidence of a difference in rates of insomnia, headache, depression, or suicidal ideation. The same studies provided low‐certainty evidence of fewer people experiencing serious adverse events in the cytisine arm compared with varenicline. However, in all cases, confidence intervals indicated imprecision, and the potential for more adverse events when using either treatment. We found no data on neuropsychiatric or cardiac serious adverse events. </p> <p>Low‐certainty evidence suggested that cytisine may help more people to quit than NRT monotherapy (<a href="./references#CD006103-bbs2-0063" title="WalkerN , HoweC , BullenC , McRobbieH , GloverM , ParagV , et al. Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. BMC Public Health2011;11(1):880. [CENTRAL: 814611] [EMBASE: 22104038] [6430] [PMID: 22104038]WalkerN , HoweC , GloverM , McRobbieH , BarnesJ , NosaV , et al. Cytisine versus nicotine for smoking cessation. New England Journal of Medicine2014;371(25):2353-62. [CENTRAL: 1037839] [EMBASE: 2014610901]">Walker 2014</a>). However, after the initial 25‐day course, participants in the cytisine arm also received vouchers for NRT. This may distort the results as some participants in the cytisine arm may have in fact received two pharmacotherapies, but study authors reported that few participants in the cytisine arm used their NRT vouchers. Low‐certainty evidence did not show a difference in the number of people reporting serious adverse events. We found no data on neuropsychiatric or cardiac serious adverse events. </p> <p>Evidence on the effect of different lengths of cytisine treatment was sparse and inconclusive.</p> <p>There is high‐certainty evidence that varenicline increases the chances of successful smoking cessation by more than two‐fold compared with placebo. Since the previous version of this review was published (<a href="./references#CD006103-bbs2-0249" title="CahillK , Lindson-HawleyN , ThomasKH , FanshaweTR , LancasterT . Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews2016, Issue 5. Art. No: CD006103. [DOI: 10.1002/14651858.CD006103.pub7]">Cahill 2016</a>), this estimate has remained stable, despite the growing inclusion of pragmatic trials in real‐world settings and those conducted in particular groups of smokers previously excluded from clinical trials, such as those in lower‐ and middle‐income countries, and in disease‐specific populations. </p> <p>We also found high‐certainty evidence that varenicline helped more people to quit than bupropion, or NRT monotherapy, with no clear evidence of difference between varenicline and bupropion in rates of serious adverse events, neuropsychiatric serious adverse events, or cardiac serious adverse events (all low‐certainty evidence), and low‐certainty evidence suggesting reduced risk of serious adverse events compared with NRT. We found no data comparing varenicline with NRT monotherapy for neuropsychiatric or cardiac serious adverse events. </p> <p>Low‐certainty evidence did not show a difference in quit rates compared with combination NRT, and while low‐certainty evidence suggested potentially increased risk of serious adverse events and neuropsychiatric serious adverse events, and reduced risk of cardiac serious adverse events, in all cases confidence intervals were very wide, encompassing both substantial harm and benefit. </p> <p>One small study of 54 people provided very‐low certainty evidence of more people quitting with varenicline than with e‐cigarettes (<a href="./references#CD006103-bbs2-0029" title="IoakeimidisN , VlachopoulosC , GeorgakopoulosC , AbdelrasoulM , SklirosN , KatsiV , et al. Smoking cessation rates with varenicline and electronic cigarettes in relapsed smokers with a history of acute coronary syndrome. European Heart Journal2018;Suppl 1: European Society of Cardiology Congress, ESC 2018. Germany. 39:242. ">Ioakeimidis 2018</a>); however this study was at high risk of bias and imprecise due to few events, and while they reported serious adverse events, neuropsychiatric serious adverse events, and cardiac serious adverse events as outcomes, they reported no events among study participants in either arm. Studies that tested varenicline versus placebo in specific populations and settings did not demonstrate varenicline working differently than it does in the general population in disease‐specific groups of patients (e.g. cardiovascular, chronic obstructive pulmonary disease, HIV, schizophrenia and psychiatric disorders, depression, alcohol dependence), or in specific subgroups or settings (e.g. hospital inpatients, light‐smokers, smokers who failed to quit on varenicline previously). </p> <p>Analyses found evidence of increased rates of adverse events such as nausea, insomnia, abnormal dreams, and headache among people randomised to receive varenicline compared with placebo. However, we found no clear evidence of increased rates of depression or suicidal ideation, although confidence intervals indicated imprecision, and the potential for more or fewer adverse events when using varenicline compared with control. Moderate‐certainty serious adverse event data suggest there may be a 23% increased risk of such events among the varenicline groups compared with the controls. However, serious adverse events were still rare (2.7% to 4% of people on varenicline, compared with 2.7% of people without) and this finding is based on simple counts across the trials of participants reporting one or more such events, thus not distinguishing between events attributed and those unrelated to treatment. We did not find evidence of an increased risk of neuropsychiatric serious adverse events, but pooled results did suggest a potential increased risk of cardiac serious adverse events, although again these results were subject to imprecision, and we deemed this evidence to be low certainty because of its compatibility with both increased and decreased risk of harm. </p> <p>One trial compared dianicline with placebo for smoking cessation and the results were inconclusive (<a href="./references#CD006103-bbs2-0057" title="TonstadS , HolmeI , TønnesenP . Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial. Nicotine &amp; Tobacco Research2011;13(1):1-6. ">Tonstad 2011</a>). </p> </section> <section id="CD006103-sec-0117"> <h3 class="title" id="CD006103-sec-0117">Overall completeness and applicability of evidence</h3> <p>We conducted systematic searches of multiple online databases, including clinical trials registries and followed Cochrane methods for screening. We therefore expect that any published trials we have missed will be through chance rather than systematic error. We were able to assess publication bias for two comparisons by constructing funnel plots: varenicline versus placebo (<a href="#CD006103-fig-0004">Figure 4</a>), and varenicline versus NRT monotherapy (<a href="#CD006103-fig-0005">Figure 5</a>). <a href="#CD006103-fig-0005">Figure 5</a> appears to show a small amount of asymmetry that may suggest a lack of smaller trials with negative findings. However, the number of studies is still very low with few smaller studies, and so we cannot treat this as definitive evidence of publication bias. These were the only cessation comparisons with enough studies to construct a funnel plot, so we were unable to assess publication bias for other comparisons. As such, we cannot ignore the possibility of publication bias for some comparisons in this review. </p> <div class="figure" id="CD006103-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison 5: varenicline (1.0 mg 2/d) vs placebo, outcome: 5.1 abstinence at longest follow‐up" data-id="CD006103-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison 5: varenicline (1.0 mg 2/d) vs placebo, outcome: 5.1 abstinence at longest follow‐up </p> </div> </div> </div> <div class="figure" id="CD006103-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison 10: varenicline vs nicotine replacement therapy monotherapy, outcome: 10.1 abstinence at longest follow‐up" data-id="CD006103-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison 10: varenicline vs nicotine replacement therapy monotherapy, outcome: 10.1 abstinence at longest follow‐up </p> </div> </div> </div> <p>The benefits of varenicline for smoking cessation is now well established, with the point estimate remaining unchanged as more studies (including non‐manufacturer‐ (Pfizer) funded trials) accumulate. Trials are now being conducted and reported in areas where the evidence is less comprehensive, such as testing cytisine (against placebo and varenicline), and testing varenicline in specific populations and settings, and in variations of treatment dose or duration. </p> </section> <section id="CD006103-sec-0118"> <h3 class="title" id="CD006103-sec-0118">Quality of the evidence</h3> <p>We judged the evidence comparing varenicline with placebo for smoking cessation to be of high certainty. While we detected moderate heterogeneity (I<sup>2</sup> = 60%), all but three studies had a point estimate that favoured varenicline over placebo, so we did not downgrade on this basis. The effectiveness of varenicline for smoking cessation has remained constant through several updates of this review, and we think it is unlikely to change with further evidence. We judged the evidence on serious adverse events to be of moderate certainty, downgraded because of imprecision. For cardiac and neuropsychiatric serious adverse events, we downgraded evidence to low because of imprecision. Despite respectable numbers of studies and participants in each analysis, because of the rarity of these kinds of adverse events, there were very few events in the analyses, with some studies reporting no events at all. </p> <p>We judged the evidence comparing cytisine with placebo to be of moderate certainty for smoking cessation and low certainty for serious adverse events, downgraded due to substantial unexplained heterogeneity and imprecision, respectively. We judged the evidence comparing cytisine with varenicline for smoking cessation and serious adverse events to be of low certainty, respectively, downgraded for imprecision in both cases. </p> <p>We judged the evidence comparing varenicline with bupropion and NRT monotherapy for smoking cessation to be of high certainty, and with combination NRT to be of low certainty, limited by imprecision. Only one small study compared varenicline with e‐cigarettes for smoking cessation, and we graded this evidence as of very low certainty because of imprecision and risk of bias. </p> </section> <section id="CD006103-sec-0119"> <h3 class="title" id="CD006103-sec-0119">Potential biases in the review process</h3> <p>We have followed standard Cochrane methodology, which endeavours to minimise biases in the review process, so we are confident that any errors in our data will be through chance rather than systematic error. However, it is impossible to rule out individual errors in the review process. </p> <p>A potential limitation to our review is that for data on harms we relied on adverse events and serious adverse events as defined by papers reporting included studies. This does not take into account whether those events were genuinely attributable to the tested interventions. Further, we only considered the number of participants reporting these events, which does not account for people who experienced more than one event. </p> <p>Another potential limitation is that the majority of varenicline trials reported in this review received either funding or study medication from Pfizer Inc, the manufacturers of varenicline. Evidence from systematic reviews suggests that industry‐funded trials, although conducted to a high standard, are more likely to have outcomes favourable to the product sponsor than studies with other sponsors (<a href="./references#CD006103-bbs2-0209" title="EtterJF , BurriM , StapletonJ . The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis. Addiction2007;102(5):815-22.">Etter 2007</a>; <a href="./references#CD006103-bbs2-0241" title="WalshRA . Australia's experience with varenicline: usage, costs and adverse reactions [letter]. Addiction2011;106:449-52.">Walsh 2011</a>). However, we deem the provision of study medication less likely to amount to the kind of sponsorship that may bias results, and modern trials increasingly report funders and medication providers as having no involvement in trial conduct or decision making. </p> </section> <section id="CD006103-sec-0120"> <h3 class="title" id="CD006103-sec-0120">Agreements and disagreements with other studies or reviews</h3> <p>Reviews of controlled studies of cytisine have focused upon its potential as an established and affordable aid to smoking cessation (<a href="./references#CD006103-bbs2-0208" title="Etter J-F. Cytisine for smoking cessation: a literature review and a meta-analysis. Archives of Internal Medicine2006;166:1-7.">Etter 2006</a>; <a href="./references#CD006103-bbs2-0210" title="EtterJF , LukasRJ , BenowitzNL , WestR , DreslerCM . Cytisine for smoking cessation: a research agenda. Drug and Alcohol Dependence2008;92(1-3):3-8.">Etter 2008</a>; <a href="./references#CD006103-bbs2-0236" title="TutkaP , ZatońskiW . Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacological Reports2005;58:777-98.">Tutka 2005</a>; <a href="./references#CD006103-bbs2-0237" title="TutkaP , MrózT , ZatońskiW . Cytisine - renaissance of well known alkaloid. Pharmacological aspects of efficacy in the treatment of tobacco dependence [Cytyzyna – renesans znanego alkaloidu. Aspekty farmakologiczne zastosowania w leczeniu uzależnienia od nikotyny]. Farmakoterapia w Psychiatrii i Neurologii2006;1:33-9.">Tutka 2006</a>; <a href="./references#CD006103-bbs2-0238" title="TutkaP . Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation. Expert Opinion on Investigational Drugs2008;17(10):1473-85.">Tutka 2008</a>). Many of the early cytisine studies excluded from this review are discussed and evaluated in <a href="./references#CD006103-bbs2-0208" title="Etter J-F. Cytisine for smoking cessation: a literature review and a meta-analysis. Archives of Internal Medicine2006;166:1-7.">Etter 2006</a>, who concluded that cytisine may be effective for smoking cessation. A systematic review and network meta‐analysis (<a href="./references#CD006103-bbs2-0219" title="LeavissJ , SullivanW , RenS , Everson-HockE , StevensonM , StevensJW , et al. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? a systematic review and economic evaluation. Health Technology Assessment2014;18(33):1-120.">Leaviss 2014</a>), compared the benefits and cost‐effectiveness of cytisine (2 trials: <a href="./references#CD006103-bbs2-0062" title="VinnikovD , BrimkulovN , BurjubaevaA . A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. Journal of Smoking Cessation2008;3(1):57-62. ">Vinnikov 2008</a>; <a href="./references#CD006103-bbs2-0066" title="WestR , ZatonskiW , CedzynskaM , LewandowskaD , PazikJ , AveyardPA , et al. Placebo-controlled trial of cytisine for smoking cessation. New England Journal of Medicine2011;365:1193-200. [Current Controlled Trials ID: ISRCTN37568749]WestR , ZatonskiW . Cytisine increased smoking cessation in adults. Annals of Internal Medicine2012;156(2):JC1-6. [CENTRAL: 897954] [EMBASE: 2012033460]">West 2011</a>), with varenicline (21 trials). While the analysis found both treatments to be effective for smoking cessation, cytisine delivered more quality‐adjusted life‐years at a lower cost than varenicline. Cytisine was also associated with lower rates of headache and nausea than varenicline. Our analyses on harms, using direct evidence, found lower rates of nausea, but did not find evidence of difference in rates of headache. A recent review of cytisine found similar results to ours, though with a slightly higher point estimate for smoking cessation (<a href="./references#CD006103-bbs2-0239" title="TutkaP , VinnikovD , CourtneyRJ , BenowitzNL . Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction2019;114(11):1951-69. [DOI: 10.1111/add.14721]">Tutka 2019</a>). This is likely because they had broader inclusion criteria than our review, and included studies with shorter follow‐up periods. </p> <p>A Cochrane overview and network meta‐analysis of a number of pharmacological interventions for smoking cessation assessed 12 Cochrane Reviews published to November 2012 (<a href="./references#CD006103-bbs2-0203" title="CahillK , StevensS , PereraR , LancasterT . Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database of Systematic Reviews2013, Issue 5. Art. No: CD009329. [DOI: 10.1002/14651858.CD009329.pub2]">Cahill 2013</a>), and therefore drew on the previous version of this review. Comparisons between varenicline, bupropion and single‐treatment NRT found varenicline to be superior to both treatments (OR 1.59, 95% credible interval 1.29 to 1.96 and OR 1.57, 95% credible interval 1.29 to 1.91, respectively). Varenicline demonstrated comparable benefits for smoking cessation to combination NRT (OR 1.06, 95% credible interval 0.75 to 1.48), but the number of NRT trials informing this comparison was low (9 trials). This review is currently being updated (<a href="./references#CD006103-bbs2-0222" title="LindsonN , TheodoulouA , Livingstone-BanksJ , AveyardP , FanshaweTR , Ordóñez-MenaJM , et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015226. [DOI: 10.1002/14651858.CD015226]">Lindson 2022</a>). A 2012 network meta‐analysis (<a href="./references#CD006103-bbs2-0227" title="MillsEJ , WuP , LockhartI , ThorlundK , PuhanM , EbbertJO . Comparisons of high-dose and combination nicotine replacement therapy, varenicline and bupropion for smoking cessation: a systematic review and multiple-treatment meta-analysis. Annals of Medicine2012;44(6):588-97.">Mills 2012</a>), comparing high‐dose and combination NRT versus varenicline and versus bupropion across 146 RCTs, found varenicline (11 trials) to be superior to placebo and to bupropion at all time points, and similar in benefits for smoking cessation to standard and to high‐dose NRT, in line with our findings. A more recent systematic review with network meta‐analysis reported similar findings to ours, reporting a benefit from varenicline compared with placebo (OR 2.69, 95% CI 2.27 to 3.19), bupropion (OR 1.46, 95% CI 1.18 to 1.81), and standard‐dose NRT (OR 1.32, 95% CI 1.05 to 1.65; <a href="./references#CD006103-bbs2-0235" title="Thomas, KH, Dalili, MN, López-López, JA, Keeney, E, Phillippo, DM, Munafò, MR, et al. Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials. Addiction2020;117:861-76. [DOI: 10.1111/add.15675]">Thomas 2020</a>). However, they did not find evidence of increased rates of serious adverse events amongst those randomised to receive varenicline compared with placebo (OR 1.09, 95% CI 0.91 to 1.34), contrary to the increased risk we detected. This may be due to their choice of a random‐effects rather than fixed‐effect model for their analysis. They did not find clear evidence of a difference in cardiac serious adverse events (OR 0.76, 95% CI 0.41 to 1.25) and neuropsychiatric serious adverse events (OR 0.96, 95% CI 0.76 to 1.21), which is in line with our findings. </p> <p>An earlier systematic review and meta‐analysis of 39 RCTs (10,761 participants) by the same team assessed the risk of neuropsychiatric adverse events among users of varenicline (<a href="./references#CD006103-bbs2-0234" title="ThomasKH , MartinRM , KnipeDW , HigginsJP , GunnellD . Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ2015;350:h1109. [PROSPERO 2014:CRD42014009224]">Thomas 2015</a>). In line with our findings, the authors found no clear evidence of an increased risk of suicide or attempted suicide (Peto odds ratio (OR) 1.67, 95% CI 0.33 to 8.57), suicidal ideation (Peto OR 0.58, 95% CI 0.28 to 1.20), depression (Peto OR 0.96, 95% CI 0.75 to 1.22) or death (Peto OR 1.05, 95% CI 0.47 to 2.38) associated with varenicline. <a href="./references#CD006103-bbs2-0220" title="SterlingLH , WindleSB , FilionKB , ToumaL , EisenbergMJ . Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. Journal of the American Heart Association2016;5:e002849. [DOI: 10.1161/JAHA.115.002849]">Lee 2016</a> compared cardiovascular serious adverse event rates between people randomised to receive varenicline or placebo. They did not find evidence of increased risk of cardiovascular serious adverse events (RR 1.03, 95% CI 0.72 to 1.49) in 38 trials of 12,706 people. This result was consistent among cardiovascular (RR 1.04, 95% CI 0.57 to 1.89) and non‐cardiovascular patients (RR 1.03, 95% CI 0.64 to 1.64). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006103-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram of searches for 2022 update" data-id="CD006103-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram of searches for 2022 update</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD006103-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD006103-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison 5: varenicline (1.0 mg 2/d) vs placebo, outcome: 5.1 abstinence at longest follow‐up" data-id="CD006103-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison 5: varenicline (1.0 mg 2/d) vs placebo, outcome: 5.1 abstinence at longest follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison 10: varenicline vs nicotine replacement therapy monotherapy, outcome: 10.1 abstinence at longest follow‐up" data-id="CD006103-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison 10: varenicline vs nicotine replacement therapy monotherapy, outcome: 10.1 abstinence at longest follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cytisine vs placebo or no medication, Outcome 1: Abstinence at longest follow‐up" data-id="CD006103-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Cytisine vs placebo or no medication, Outcome 1: Abstinence at longest follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cytisine vs placebo or no medication, Outcome 2: Adverse events" data-id="CD006103-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Cytisine vs placebo or no medication, Outcome 2: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cytisine vs placebo or no medication, Outcome 3: Serious adverse events" data-id="CD006103-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Cytisine vs placebo or no medication, Outcome 3: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Cytisine: longer vs shorter duration, Outcome 1: Abstinence at longest follow‐up" data-id="CD006103-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Cytisine: longer vs shorter duration, Outcome 1: Abstinence at longest follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Cytisine vs varenicline, Outcome 1: Abstinence at longest follow‐up" data-id="CD006103-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Cytisine vs varenicline, Outcome 1: Abstinence at longest follow‐up</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Cytisine vs varenicline, Outcome 2: Nausea" data-id="CD006103-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Cytisine vs varenicline, Outcome 2: Nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Cytisine vs varenicline, Outcome 3: Abnormal dreams" data-id="CD006103-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Cytisine vs varenicline, Outcome 3: Abnormal dreams</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Cytisine vs varenicline, Outcome 4: Insomnia" data-id="CD006103-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Cytisine vs varenicline, Outcome 4: Insomnia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Cytisine vs varenicline, Outcome 5: Headache" data-id="CD006103-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Cytisine vs varenicline, Outcome 5: Headache</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Cytisine vs varenicline, Outcome 6: Depression" data-id="CD006103-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Cytisine vs varenicline, Outcome 6: Depression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Cytisine vs varenicline, Outcome 7: Suicidal ideation" data-id="CD006103-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Cytisine vs varenicline, Outcome 7: Suicidal ideation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Cytisine vs varenicline, Outcome 8: SAEs" data-id="CD006103-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Cytisine vs varenicline, Outcome 8: SAEs</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cytisine vs NRT, Outcome 1: Abstinence at longest follow‐up" data-id="CD006103-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Cytisine vs NRT, Outcome 1: Abstinence at longest follow‐up</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cytisine vs NRT, Outcome 2: Nausea" data-id="CD006103-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Cytisine vs NRT, Outcome 2: Nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cytisine vs NRT, Outcome 3: SAEs" data-id="CD006103-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Cytisine vs NRT, Outcome 3: SAEs</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 1: Abstinence at longest follow‐up" data-id="CD006103-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 1: Abstinence at longest follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 2: Nausea" data-id="CD006103-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 2: Nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 3: Insomnia" data-id="CD006103-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 3: Insomnia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 4: Abnormal dreams" data-id="CD006103-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 4: Abnormal dreams </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 5: Headache" data-id="CD006103-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 5: Headache</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 6: Depression" data-id="CD006103-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 6: Depression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 7: Suicidal ideation" data-id="CD006103-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 7: Suicidal ideation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 8: SAEs" data-id="CD006103-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 8: SAEs</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 9: Neuropsychiatric SAEs (not deaths)" data-id="CD006103-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 9: Neuropsychiatric SAEs (not deaths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 10: Cardiac SAEs, including deaths" data-id="CD006103-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Varenicline 2 mg per day vs placebo or no medication, Outcome 10: Cardiac SAEs, including deaths </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Varenicline: variations in usage, Outcome 1: Low‐dose varenicline vs placebo" data-id="CD006103-fig-0031" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Varenicline: variations in usage, Outcome 1: Low‐dose varenicline vs placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Varenicline: variations in usage, Outcome 2: Higher‐dose varenicline versus lower‐dose varenicline" data-id="CD006103-fig-0032" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Varenicline: variations in usage, Outcome 2: Higher‐dose varenicline versus lower‐dose varenicline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Varenicline: variations in usage, Outcome 3: Longer vs standard duration varenicline" data-id="CD006103-fig-0033" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Varenicline: variations in usage, Outcome 3: Longer vs standard duration varenicline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Varenicline: variations in usage, Outcome 4: 6 week vs 1 week preloading" data-id="CD006103-fig-0034" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Varenicline: variations in usage, Outcome 4: 6 week vs 1 week preloading</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 1: Cardiovascular disease" data-id="CD006103-fig-0035" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 1: Cardiovascular disease </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 2: COPD" data-id="CD006103-fig-0036" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 2: COPD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 3: Asthma" data-id="CD006103-fig-0037" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 3: Asthma </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 4: Schizophrenia/bipolar/psychiatric disorder" data-id="CD006103-fig-0038" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 4: Schizophrenia/bipolar/psychiatric disorder </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 5: Depression" data-id="CD006103-fig-0039" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 5: Depression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 6: Substance use disorder/ methadone‐maintained at 24 weeks" data-id="CD006103-fig-0040" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 6: Substance use disorder/ methadone‐maintained at 24 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 7: Alcohol‐dependence" data-id="CD006103-fig-0041" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 7: Alcohol‐dependence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 8: HIV" data-id="CD006103-fig-0042" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Varenicline (vs placebo or no medication) in specific patient groups, Outcome 8: HIV </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Varenicline in specific settings/subgroups, Outcome 1: Hospital inpatients/perioperative patients" data-id="CD006103-fig-0043" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Varenicline in specific settings/subgroups, Outcome 1: Hospital inpatients/perioperative patients </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Varenicline in specific settings/subgroups, Outcome 2: Smokers with a previous quit attempt on varenicline" data-id="CD006103-fig-0044" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Varenicline in specific settings/subgroups, Outcome 2: Smokers with a previous quit attempt on varenicline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Varenicline in specific settings/subgroups, Outcome 3: Light or heavy smokers" data-id="CD006103-fig-0045" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Varenicline in specific settings/subgroups, Outcome 3: Light or heavy smokers </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Varenicline vs bupropion, Outcome 1: Abstinence at longest follow‐up" data-id="CD006103-fig-0046" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Varenicline vs bupropion, Outcome 1: Abstinence at longest follow‐up</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Varenicline vs bupropion, Outcome 2: Nausea" data-id="CD006103-fig-0047" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Varenicline vs bupropion, Outcome 2: Nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Varenicline vs bupropion, Outcome 3: Insomnia" data-id="CD006103-fig-0048" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Varenicline vs bupropion, Outcome 3: Insomnia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Varenicline vs bupropion, Outcome 4: Abnormal dreams" data-id="CD006103-fig-0049" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Varenicline vs bupropion, Outcome 4: Abnormal dreams</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Varenicline vs bupropion, Outcome 5: Headache" data-id="CD006103-fig-0050" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Varenicline vs bupropion, Outcome 5: Headache</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-009.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Varenicline vs bupropion, Outcome 6: Depression" data-id="CD006103-fig-0051" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-009.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9: Varenicline vs bupropion, Outcome 6: Depression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-009.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Varenicline vs bupropion, Outcome 7: Suicidal ideation" data-id="CD006103-fig-0052" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-009.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9: Varenicline vs bupropion, Outcome 7: Suicidal ideation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-009.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Varenicline vs bupropion, Outcome 8: SAEs" data-id="CD006103-fig-0053" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-009.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9: Varenicline vs bupropion, Outcome 8: SAEs</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-009.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Varenicline vs bupropion, Outcome 9: Neuropsychiatric SAEs (not deaths)" data-id="CD006103-fig-0054" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-009.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9: Varenicline vs bupropion, Outcome 9: Neuropsychiatric SAEs (not deaths)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-009.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Varenicline vs bupropion, Outcome 10: Cardiac SAEs, including deaths" data-id="CD006103-fig-0055" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-009.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9: Varenicline vs bupropion, Outcome 10: Cardiac SAEs, including deaths</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-009.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Varenicline vs NRT monotherapy, Outcome 1: Abstinence at longest follow‐up" data-id="CD006103-fig-0056" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Varenicline vs NRT monotherapy, Outcome 1: Abstinence at longest follow‐up</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Varenicline vs NRT monotherapy, Outcome 2: Nausea" data-id="CD006103-fig-0057" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Varenicline vs NRT monotherapy, Outcome 2: Nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Varenicline vs NRT monotherapy, Outcome 3: Insomnia" data-id="CD006103-fig-0058" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Varenicline vs NRT monotherapy, Outcome 3: Insomnia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Varenicline vs NRT monotherapy, Outcome 4: Abnormal dreams" data-id="CD006103-fig-0059" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: Varenicline vs NRT monotherapy, Outcome 4: Abnormal dreams</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-010.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Varenicline vs NRT monotherapy, Outcome 5: Headache" data-id="CD006103-fig-0060" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-010.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: Varenicline vs NRT monotherapy, Outcome 5: Headache</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-010.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Varenicline vs NRT monotherapy, Outcome 6: Depression" data-id="CD006103-fig-0061" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-010.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10: Varenicline vs NRT monotherapy, Outcome 6: Depression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-010.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Varenicline vs NRT monotherapy, Outcome 7: Suicidal ideation" data-id="CD006103-fig-0062" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-010.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.7</div> <div class="figure-caption"> <p>Comparison 10: Varenicline vs NRT monotherapy, Outcome 7: Suicidal ideation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-010.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Varenicline vs NRT monotherapy, Outcome 8: SAEs" data-id="CD006103-fig-0063" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-010.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.8</div> <div class="figure-caption"> <p>Comparison 10: Varenicline vs NRT monotherapy, Outcome 8: SAEs</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-010.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Varenicline vs NRT monotherapy, Outcome 9: Neuropsychiatric SAEs (not deaths)" data-id="CD006103-fig-0064" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-010.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.9</div> <div class="figure-caption"> <p>Comparison 10: Varenicline vs NRT monotherapy, Outcome 9: Neuropsychiatric SAEs (not deaths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-010.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Varenicline vs NRT monotherapy, Outcome 10: Cardiac SAEs, including deaths" data-id="CD006103-fig-0065" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-010.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.10</div> <div class="figure-caption"> <p>Comparison 10: Varenicline vs NRT monotherapy, Outcome 10: Cardiac SAEs, including deaths </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-010.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Varenicline vs combination NRT, Outcome 1: Abstinence at longest follow‐up" data-id="CD006103-fig-0066" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Varenicline vs combination NRT, Outcome 1: Abstinence at longest follow‐up</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Varenicline vs combination NRT, Outcome 2: Nausea" data-id="CD006103-fig-0067" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Varenicline vs combination NRT, Outcome 2: Nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Varenicline vs combination NRT, Outcome 3: Insomnia" data-id="CD006103-fig-0068" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Varenicline vs combination NRT, Outcome 3: Insomnia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-011.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Varenicline vs combination NRT, Outcome 4: Abnormal dreams" data-id="CD006103-fig-0069" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-011.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: Varenicline vs combination NRT, Outcome 4: Abnormal dreams</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-011.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Varenicline vs combination NRT, Outcome 5: Headache" data-id="CD006103-fig-0070" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-011.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11: Varenicline vs combination NRT, Outcome 5: Headache</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-011.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Varenicline vs combination NRT, Outcome 6: Depression" data-id="CD006103-fig-0071" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-011.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11: Varenicline vs combination NRT, Outcome 6: Depression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-011.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Varenicline vs combination NRT, Outcome 7: Suicidal ideation" data-id="CD006103-fig-0072" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-011.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11: Varenicline vs combination NRT, Outcome 7: Suicidal ideation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-011.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Varenicline vs combination NRT, Outcome 8: SAEs" data-id="CD006103-fig-0073" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-011.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.8</div> <div class="figure-caption"> <p>Comparison 11: Varenicline vs combination NRT, Outcome 8: SAEs</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-011.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Varenicline vs combination NRT, Outcome 9: Neuropsychiatric SAEs (not deaths)" data-id="CD006103-fig-0074" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-011.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.9</div> <div class="figure-caption"> <p>Comparison 11: Varenicline vs combination NRT, Outcome 9: Neuropsychiatric SAEs (not deaths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-011.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Varenicline vs combination NRT, Outcome 10: Cardiac SAEs, including deaths" data-id="CD006103-fig-0075" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-011.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.10</div> <div class="figure-caption"> <p>Comparison 11: Varenicline vs combination NRT, Outcome 10: Cardiac SAEs, including deaths </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-011.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Varenicline vs e‐cigarettes, Outcome 1: Abstinence at longest follow‐up" data-id="CD006103-fig-0076" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Varenicline vs e‐cigarettes, Outcome 1: Abstinence at longest follow‐up</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Varenicline vs e‐cigarettes, Outcome 2: Nausea" data-id="CD006103-fig-0077" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Varenicline vs e‐cigarettes, Outcome 2: Nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Varenicline vs e‐cigarettes, Outcome 3: SAEs" data-id="CD006103-fig-0078" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Varenicline vs e‐cigarettes, Outcome 3: SAEs</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Varenicline vs e‐cigarettes, Outcome 4: Neuropsychiatric SAEs (not deaths)" data-id="CD006103-fig-0079" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: Varenicline vs e‐cigarettes, Outcome 4: Neuropsychiatric SAEs (not deaths) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-012.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Varenicline vs e‐cigarettes, Outcome 5: Cardiac SAEs, including deaths" data-id="CD006103-fig-0080" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-012.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-012.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12: Varenicline vs e‐cigarettes, Outcome 5: Cardiac SAEs, including deaths</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-012.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Dianicline vs placebo, Outcome 1: Abstinence at longest follow‐up" data-id="CD006103-fig-0081" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Dianicline vs placebo, Outcome 1: Abstinence at longest follow‐up</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Dianicline vs placebo, Outcome 2: Nausea" data-id="CD006103-fig-0082" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Dianicline vs placebo, Outcome 2: Nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Dianicline vs placebo, Outcome 3: Headache" data-id="CD006103-fig-0083" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Dianicline vs placebo, Outcome 3: Headache</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Dianicline vs placebo, Outcome 4: Depression" data-id="CD006103-fig-0084" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Dianicline vs placebo, Outcome 4: Depression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-013.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Dianicline vs placebo, Outcome 5: Serious adverse events" data-id="CD006103-fig-0085" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-013.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-013.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13: Dianicline vs placebo, Outcome 5: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-013.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006103-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/urn:x-wiley:14651858:media:CD006103:CD006103-CMP-013.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Dianicline vs placebo, Outcome 6: Cardiac SAEs, including deaths" data-id="CD006103-fig-0086" src="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-013.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_t/tCD006103-CMP-013.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.6</div> <div class="figure-caption"> <p>Comparison 13: Dianicline vs placebo, Outcome 6: Cardiac SAEs, including deaths</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/media/CDSR/CD006103/image_n/nCD006103-CMP-013.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006103-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Varenicline versus placebo or no medication for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Varenicline versus placebo or no medication for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> smoking cessation clinics, hospitals, universities and other research centres<br/><b>Intervention:</b> varenicline<br/><b>Comparison:</b> placebo or no medication </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no medication</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with varenicline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> <p>(varenicline vs placebo)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>99 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b> </p> <p>(213 to 249)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.32</b> </p> <p>(2.15 to 2.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,395<br/>(41 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<sup>a</sup> </p> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> <p>(varenicline vs placebo or no medication)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> <p>(27 to 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> </p> <p>(1.01 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,356<br/>(26 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>b</sup> </p> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> <p>(varenicline vs placebo or no medication)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> <p>(7 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> </p> <p>(0.61 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7846<br/>(22 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>c</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> <p>(varenicline vs placebo or no medication)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> <p>(8 to 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> </p> <p>(0.79 to 1.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7151<br/>(18 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>c</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Moderate heterogeneity detected, however all but three studies showed positive effect of varenicline, so we did not downgrade on this basis. </p> <p><sup>b</sup>Downgraded one level because of imprecision: CI incorporates no clinical difference as well as clinically significant harm. </p> <p><sup>c</sup>Downgraded two levels because of imprecision: CI incorporates clinically significant benefit and clinically significant harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Varenicline versus placebo or no medication for smoking cessation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006103-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cytisine versus placebo or no medication for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Cytisine versus placebo or no medication for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> smoking cessation clinics, hospitals, universities and other research centres<br/><b>Intervention:</b> cytisine<br/><b>Comparison:</b> placebo or no medication </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no medication</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with cytisine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> <p>(cytisine vs placebo)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>205 per 1000</b> </p> <p>(181 to 232)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.30</b> </p> <p>(1.15 to 1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4623<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>a</sup> </p> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> <p>(cytisine vs placebo or no medication)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> <p>(36 to 63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> </p> <p>(0.78 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3781<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>b</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> <p>(cytisine vs placebo or no medication)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> <p>(cytisine vs placebo or no medication)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of heterogeneity: I<sup>2</sup> = 83%.<br/><sup>b</sup>Downgraded two levels because of imprecision: CI incorporates clinically significant benefit and clinically significant harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Cytisine versus placebo or no medication for smoking cessation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006103-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Cytisine versus varenicline for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Cytisine versus varenicline for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> community, community pharmacy, participants' homes<br/><b>Intervention:</b> cytisine<br/><b>Comparison:</b> varenicline </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with varenicline</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with cytisine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>121 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b><br/>(95 to 152) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> </p> <p>(0.79 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2131<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a,b</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> <p>(21 to 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.67</b> </p> <p>(0.44 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2017<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>c</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for heterogeneity: I<sup>2</sup> = 65% may be explained by the difference in duration of cytisine treatment (12 weeks of cytisine versus 12 weeks of varenicline in <a href="./references#CD006103-bbs2-0064" title="NCT02957786. Cytisine versus varenicline for smoking cessation. clinicaltrials.gov/show/NCT02957786 (first received 8 November 2016). WalkerN , SmithB , BarnesJ , VerbiestM , KurdzielT , ParagV , et al. Cytisine versus varenicline for smoking cessation for Maori (the indigenous people of New Zealand) and their extended family: protocol for a randomized non-inferiority trial. Addiction2019;114(2):344-52. WalkerN , SmithB , BarnesJ , VerbiestM , ParagV , PokhrelS , et al. Cytisine versus varenicline for smoking cessation in New Zealand indigenous Maori: a randomized controlled trial. Addiction2021;116(10):2847-58. ">Walker 2021</a>; 4 weeks of cytisine and 12 weeks of varenicline in <a href="./references#CD006103-bbs2-0014" title="ACTRN12616001654448. A non-inferiority trial of cytisine versus varenicline for smoking cessation. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12616001654448 (first received 30 November 2016). CourtneyRJ , McRobbieH , TutkaP , WeaverNA , PetrieD , MendelsohnCP , et al. Effect of cytisine vs varenicline on smoking cessation: a randomized clinical trial. JAMA2021;326(1):56-64. ThomasD , FarrellM , McRobbieH , TutkaP , PetrieD , WestR , et al. The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial. Addiction2019;114(5):923-33. ">Courtney 2021</a>).<br/><sup>b</sup>Downgraded two levels because of imprecision: CI incorporates clinically significant benefit and clinically significant harm.<br/><sup>c</sup>Downgraded two level because of imprecision: CI incorporates no difference as well as clinically significant benefit, and number of events in analysis very low (n = 82). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Cytisine versus varenicline for smoking cessation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006103-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Cytisine versus nicotine replacement therapy for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Cytisine versus nicotine replacement therapy for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> participants' homes (participants were callers to a national Quitline)<br/><b>Intervention:</b> cytisine<br/><b>Comparison:</b> nicotine replacement therapy (NRT) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with NRT</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with cytisine</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>218 per 1000</b> </p> <p>(173 to 275)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.43</b> </p> <p>(1.13 to 1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1310<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a,b</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b> </p> <p>(45 to 104)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b> </p> <p>(0.76 to 1.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1310<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,c</sup> </p> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>NRT:</b> nicotine replacement therapy; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of risk of bias: sole study at high risk.<br/><sup>b</sup>Downgraded one level because of imprecision: fewer than 300 events in the analysis.<br/><sup>c</sup>Downgraded two levels because of imprecision: CI incorporates clinically significant benefit and clinically significant harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Cytisine versus nicotine replacement therapy for smoking cessation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006103-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Varenicline versus bupropion for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Varenicline versus bupropion for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> smoking cessation clinics, hospitals, universities and other research centres<br/><b>Intervention:</b> varenicline<br/><b>Comparison:</b> bupropion </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with bupropion</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with varenicline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b> </p> <p>(222 to 264)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> </p> <p>(1.25 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7560<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> <p>(12 to 27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> </p> <p>(0.61 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5317<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> <p>(0 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b> </p> <p>(0.16 to 7.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>866<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.17</b> </p> <p>(0.33 to 30.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>866<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels because of imprecision: CI incorporates clinically significant benefit and clinically significant harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Varenicline versus bupropion for smoking cessation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006103-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Varenicline versus nicotine replacement therapy monotherapy for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Varenicline versus nicotine replacement therapy (NRT) monotherapy for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> smoking cessation clinics, hospitals, universities and other research centres<br/><b>Intervention:</b> varenicline<br/><b>Comparison:</b> n<b>i</b>cotine replacement therapy (NRT) monotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with NRT monotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with varenicline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>225 per 1000</b> </p> <p>(205 to 247)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> </p> <p>(1.14 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7572<br/>(11 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> <p>(5 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b> </p> <p>(0.50 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6535<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events in two studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>NRT:</b> nicotine replacement therapy; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels because of imprecision: fewer than 150 events in the analysis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Varenicline versus nicotine replacement therapy monotherapy for smoking cessation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006103-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Varenicline versus combination nicotine replacement therapy for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Varenicline versus combination nicotine replacement therapy for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke tobacco<br/><b>Setting:</b> smoking cessation clinics, hospitals, universities and other research centres<br/><b>Intervention:</b> varenicline<br/><b>Comparison:</b> combination nicotine replacement therapy (NRT) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with combination NRT</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with varenicline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>199 per 1000</b> </p> <p>(170 to 234)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.02</b> </p> <p>(0.87 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2344<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>a</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> <p>(1 to 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.15</b> </p> <p>(0.49 to 9.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1852<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>b</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> <p>(0 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.69</b> </p> <p>(0.23 to 96.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>764<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>b</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only one study reported any events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> <p>(0 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.32</b> </p> <p>(0.01 to 7.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>819<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>b</sup> </p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only one study reported any events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>NRT:</b> nicotine replacement therapy; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels because of imprecision: confidence intervals include the potential for clinically significant benefit from either intervention.<br/><sup>b</sup>Downgraded two levels because of imprecision: CI incorporates clinically significant benefit and clinically significant harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Varenicline versus combination nicotine replacement therapy for smoking cessation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006103-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Varenicline versus e‐cigarettes for smoking cessation</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Varenicline versus e‐cigarettes for smoking cessation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who continued to smoke tobacco following acute coronary syndrome<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> varenicline<br/><b>Comparison:</b> e‐cigarettes </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with e‐cigarettes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with varenicline</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Smoking abstinence at longest follow‐up</b> (6+ months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>148 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>481 per 1000</p> <p>(179 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.25</p> <p>(1.21 to 8.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a,b</sup> </p> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropsychiatric SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiac SAEs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> <p>(no events in analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk in the comparison group is calculated as the median risk in control groups.<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAE</b>: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels because of imprecision: fewer than 150 events in the analysis.<br/><sup>b</sup>Downgraded one level because of risk of bias: sole study at high risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Varenicline versus e‐cigarettes for smoking cessation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/full#CD006103-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006103-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cytisine vs placebo or no medication</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Cytisine vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.15, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Cytisine vs no medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.44 [3.06, 6.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.07, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.78, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cytisine vs placebo or no medication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006103-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Cytisine: longer vs shorter duration</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.98, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 84 days vs 40 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.98, 1.67]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Cytisine: longer vs shorter duration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006103-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Cytisine vs varenicline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.79, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.33, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Abnormal dreams <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.50, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.73, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.79, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [0.12, 74.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Suicidal ideation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 SAEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.44, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Cytisine vs varenicline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006103-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Cytisine vs NRT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.13, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.00 [3.60, 62.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 SAEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.76, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Cytisine vs NRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006103-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Varenicline 2 mg per day vs placebo or no medication</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Varenicline vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [2.15, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Varenicline vs no medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.37, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.61 [2.44, 2.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.27, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Abnormal dreams <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.67, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [1.03, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.91, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Suicidal ideation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.44, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 SAEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.01, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Neuropsychiatric SAEs (not deaths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.61, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Cardiac SAEs, including deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.79, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Varenicline 2 mg per day vs placebo or no medication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006103-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Varenicline: variations in usage</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Low‐dose varenicline vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 1 mg per day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>946</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.35, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 As desired</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [1.57, 5.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Higher‐dose varenicline versus lower‐dose varenicline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 2 mg per day vs 1 mg per day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.97, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 2 mg per day vs 0.3 mg per day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [0.89, 3.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.3 1 mg per day vs 0.3 mg per day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.28, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Longer vs standard duration varenicline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 24 weeks vs 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.77, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 52 weeks vs 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.70, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 6 week vs 1 week preloading <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.60 [2.24, 14.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Varenicline: variations in usage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006103-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Varenicline (vs placebo or no medication) in specific patient groups</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Cardiovascular disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.44, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 COPD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.28, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Asthma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.38, 4.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Schizophrenia/bipolar/psychiatric disorder <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [1.78, 2.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [1.45, 3.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Substance use disorder/ methadone‐maintained at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.72 [0.50, 27.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Alcohol‐dependence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.01 [0.92, 9.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 HIV <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.06, 3.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Varenicline (vs placebo or no medication) in specific patient groups</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006103-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Varenicline in specific settings/subgroups</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Hospital inpatients/perioperative patients <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.12, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Smokers with a previous quit attempt on varenicline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Light or heavy smokers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 Light smokers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.16 [1.58, 10.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Varenicline in specific settings/subgroups</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006103-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Varenicline vs bupropion</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.25, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [2.20, 2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.75, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Abnormal dreams <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.39, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.06, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.6 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.35, 2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.7 Suicidal ideation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.18, 21.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.8 SAEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.61, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.9 Neuropsychiatric SAEs (not deaths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>866</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.16, 7.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.10 Cardiac SAEs, including deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>866</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.17 [0.33, 30.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Varenicline vs bupropion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006103-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Varenicline vs NRT monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.14, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [2.41, 3.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.96, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Abnormal dreams <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.01, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.6 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.76, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.7 Suicidal ideation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.87, 28.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.8 SAEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.50, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.9 Neuropsychiatric SAEs (not deaths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.10 Cardiac SAEs, including deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Varenicline vs NRT monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006103-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Varenicline vs combination NRT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.87, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.45, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.15, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 Abnormal dreams <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.22, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.5 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.78, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.6 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.83, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.7 Suicidal ideation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.06, 14.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.8 SAEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.49, 9.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.9 Neuropsychiatric SAEs (not deaths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.69 [0.23, 96.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.10 Cardiac SAEs, including deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Varenicline vs combination NRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006103-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Varenicline vs e‐cigarettes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.25 [1.21, 8.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.33, 27.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 SAEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Neuropsychiatric SAEs (not deaths) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.5 Cardiac SAEs, including deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Varenicline vs e‐cigarettes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006103-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Dianicline vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.82, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [1.88, 4.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.82, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.05 [1.01, 63.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.20, 4.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.6 Cardiac SAEs, including deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.06, 16.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Dianicline vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006103.pub9/references#CD006103-tbl-0021">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006103.pub9&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD006103-note-0012">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD006103-note-0019">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006103-note-0024">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006103-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD006103-note-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD006103-note-0018">Magyar</a> </li> <li class="section-language"> <a class="" href="ja#CD006103-note-0023">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD006103-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD006103-note-0025">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD006103-note-0014">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD006103-note-0013">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD006103-note-0022">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006103-note-0020">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD006103-note-0021">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006103\x2epub9"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006103\x2epub9"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006103\x2epub9"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006103\x2epub9\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006103\x2epub9"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006103.pub9&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006103.pub9';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006103.pub9/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006103.pub9/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006103.pub9%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729717437"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006103.pub9/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729717441"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006103.pub9/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee3b19dd99377',t:'MTc0MDcyOTcxNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 